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SUMMARY
ANNUAL NATIONAL REPORT ON THE DRUG SITUATION
(EDITION 2009)
The report on the Drug Situation in the G. D. of Luxembourg has been edited by the Luxembourgish focal
point of the EMCDDA and provides an overview of current developments regarding the political and legal
framework, the epidemiological situation, demand reduction interventions and selected key issues of current
interest in the fields of drugs and drug addiction.
Drug policy: legislation, strategies and economic analysis
In 1999 the government entrusted the Ministry of Health with the overall coordination of drug-related
demand and risk reduction actions. This led to the creation of the national drug coordinator’s office in 2000.
The 2009 governmental programme has introduced no changes concerning competences and attributions
in the drugs field and constitutes the framework for the elaboration of the third national strategy and action
plan (2010-2014) for the fight against drugs and addictions. The national strategy and action plan 2010-
2014 relies upon the priorities of the Ministry of Health and a sustained collaboration with field actors and
civil society. In order to optimize its impact, the new action plan has taken into account relevant issues from
EU and EC treaties, the EU anti drugs strategy 2005-2012 and the EU drugs action plan 2009-2012. The
general aim of the national strategy and action plan is to contribute to a high level of protection in terms
of public health, public security and social cohesion.
The national drug strategy relies on two pillars, namely on demand reduction and supply reduction and on
four transversal axes: 1. risk, damage, nuisance reduction, 2. research and information, 3. international
relations and 4. coordination mechanisms. The national drug coordinator, jointly with the Interministerial
Committee on Drugs (ICD), follows up and adjusts the implementation process of the national drug action
plan. 
The global budget of the Ministry of Health granted to drug-related services and programs went up from
1,270,169 EUR in 1999 to 5,770,643 - EUR in 2004, indicating a progression rate of 354% since 1999.
The 2008 budget figures 7,288,000.- EUR. In regard to the 2009 budget, 7,991,583.- EUR have been
allocated to drug care services representing an increase of almost 40% referred to the implementation
period of the 2005-2009 drugs action plan. Human resources dedicated to specialised state financed drug
agencies have known a significant increase from 30.75 full time posts in 2000 to 83.75 in 2009. The 2005-
2009 action plan targeted the creation of 26 new full time posts; 24 new posts were eventually created.
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Epidemiological Indicators
Referred to most recent prevalence data from 2007 (UNODC 2009), between 172 and 250 million persons
aged 15-64 yearly use illicit drugs at least once, worldwide. The same estimates suggest that there were
between 18 and 38 million problem drug users in 2007, 11 to 21 million being injection drug users. 
Cannabis remains by far the most widely used drug (173 to 190 million people), followed by amphetamine-
type stimulants (16 to 51 million), which include amphetamines and ecstasy (12 to 24 million). The number
of opiate abusers is estimated at between 15 and 21 million persons. The number of cocaine users, as
defined, range between 16 and 21 million users. 
In the last decade, the markets have been showing signs of stabilisation or regression for opiates, cocaine
and cannabis and an increasing trend for ATS. A similar evolution is observed within the EU and the micro-
geographical level of the Grand Duchy of Luxembourg, however, accompanied by more or less sustained
local variations in prevalence.
NATIONAL DRUG PREVALENCE IN THE GENERAL POPULATION
Drug prevalence in school population and in general population
Comparable data from national school surveys conducted between 1992 and 2000 have been showing
increasing lifetime prevalence in young people (16-20 years) for all common illicit substances. Use of
opiates in school populations is consistently very low. 
New data available from the serial HBSC study (2005/2006) show a recent decrease of last 12 months
prevalence of cannabis use in youngsters aged 13 to 17 years. Last 12 months heroin and cocaine use have
been showing a fair overall stagnation between 2002 and 2006 whereas ATS, LSD and magic mushrooms
consumption in youngsters has sensibly decreased over the same period. A more detail analysis reveals that
the age category of 15 years old youngsters is the only to show increasing use specifically for XTC and
cocaine. Also, a higher proportion of 15 years old students report repeated lifetime drunkenness when
compared to the data from 2002 (HBSC, 2002).
NATIONAL PREVALENCE OF PROBLEM DRUG USE (PDU)
Data on institutional contacts and drug treatment demands
The number of PDUs contacts indexed by national institutions in 2008 figured 4,6551 (2002: 4,701) 
For comparison, 2,383 users have been indexed by national specialised drug demand reduction agencies
and 2,318 drug law offenders by supply reduction agencies in 2002. In 2008 the same agencies have
indexed 2,836 and 1,819 persons respectively. Overall the number of persons showing drug related contacts
with DR or SR agencies has reached a plateau since 2002. During the referred period a sensible increase in
drug treatment demands has been observed whereas contacts with law enforcement agencies have been
decreasing. Referred to the general population aged 15-64, the proportion of persons in contact with DR or
SR agencies for drug related matters, likewise PDU prevalence rates in particular, has clearly been
decreasing since 2002 (1,385/100,000 inhabitants in 2008 and  1,598/100,000 inhabitants). The same applies
to SR contacts taken separately knowing that DR contact rates remained stable over the last 7 years. 
8
1 In this figure double counting is included meaning that a given person could have been indexed twice and more by different
institutions. It is thus not representing the actual prevalence, which has to be assessed by other methods. 
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Socio-demographic profile of PDUs
The male/female ratio of the PDU population has stabilised at 3:1. The last nine years the proportion of
indexed non-native PDUs has shown strong variations but a clearly increasing tendency since 2003,
confirmed by 2008 data. The population of non-native drug users largely consists of Portuguese nationals, a
proportion constantly increasing until 2004 but decreasing remarkably since, although it is still consistently
higher than the one observed in general population. Notably, one observes a strong and continuous increase
of PDUs of French origin (28%). This trend is confirmed by last 8-years data on drug law offenders.
The mean age of indexed PDUs evolved from 28 years and 4 months in 1995 to 31 years and 8 months in
2008. Mean age of male PDUs has been increasing faster than for females. The gap between youngest and
oldest PDUs continues to grow. The mean age of native and non-native problem drug users tends to
balance. One observes an average aging of the population of long-term drug injectors and a sensitive
decrease in age referred to “new” PDUs. Worth mentioning is also the significant increase of the average
age of overdose victims during the last years and an important but currently decreasing proportion of
minors among drug law offenders until 2006, having stabilised since around 4.5%. Rates of first cannabis
use, in 11-13 years old youngsters levelled off at 35% in 2008. Respectively 90% and 46% of current PDUs
have tried cannabis and heroin (i.v.) while being minor of age. In 1995 the same proportions figured 71%
and 23%. Most interestingly, evolution of drug use patterns tend to accelerate in terms of shorter time
spans separating first non-iv use from first iv-use. This acceleration is also observed as far as first treatment
demands are concerned. PDUs tend to contact drug treatment facilities at an earlier stage, which may be
due to a more diversified offer developed over recent years.
Problem drug use prevalence and consume trends
National data are provided by serial prevalence studies on PDUs aged between 15 and 64 years performed
in 1997, 1999, 2000 and most recently on 2007 data (Origer 2009)2. The estimation performed on 2007
data provides an absolute prevalence of problem HRC drug users (PDU-HRC) of 2,470 persons (C.I. (95%):
2,089 to 3,199). In terms of prevalence rates estimates for the same age categories, 7.67 out of 1,000
habitants aged between 15 and 64 years show problem drug use. According to available serial data for the
period 1997 to 2007, absolute prevalence and prevalence rates of PDU-HRC have been showing an
increasing trend until 2000. After a brief plateau, a decrease has been observed from 2003 onwards. A
similar evolution occurred also for problem heroin use (2007: 1,900 PDUs: 5,90/1000). Although absolute
prevalence of intravenous drug use (IDU)3 has slightly increased compared with the situation observed at
the end of the 20th century, IDUs prevalence rate in the national population aged 15 to 64 years shows an
obvious decreasing trend over the referred period. 
Intravenous heroin use associated to poly-drug use has been reported being the most common consume
pattern in PDUs. As already reported, the switch to intravenous drug use occurs earlier. The ratio of
intravenous opiates consume to the inhalation mode has stabilised at 3:2. The prevalence of the use of
cocaine as primary drug increased until 2006 and from there on tends to stabilise.
The number of persons in contact with the national specialised network for (preferential) cannabis use had
known a sensitive increase at the beginning of the 21st century but decreased again to stabilise between
2006 and 2008. Amphetamine type substances and ecstasy related treatment demands are only weakly
represented, which, however, does not inform on their prevalence in general population as RELIS data refer
to PDUs and not to the overall population of recreational drug users. 
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The proportion of poly drug use (89% in 2008) stabilised at high level after a record level of 92% in 2004.
The average ages at first time consumption of a preferred drug and illicit drugs in general, show a slow but
continuous decrease for the last 9 years with a tendency to stabilise. In 2008, age of first use of cocaine
(iv/non-v) and heroin (iv) shows a weak decrease. 
Drug-related treatment
Specialised drug treatment agencies are relying on state financing and on ministerial control and quality
insurance mechanisms. Treatment offers are decentralised and most commonly provided by accredited state
financed NGOs.
In 2008, 2,836 drug treatment demands were recorded nationwide (multiple counts included). Since 2002
a sensible increase in drug treatment demands has been observed until 2007. The number of substitution
treatment demands, however, begun to plateau around 2002. Outpatient counselling demand started to
level off (1,050) in 2007 in contrast to the number of contacts in low threshold services, having increased
and reached almost 68.000 in 2008. 4.6% of respondents are first treatment demanders, all treatment
centres included. 
Health correlates and responses to consequences
HBV (hepatitis B) and the HIV/AIDS prevalence in PDUs have not been increasing in recent years while the
infection of HCV (hepatitis C) showed a clear progression. Data from the Laboratory of Retrovirology of the
CRP-Santé suggest a long term and discontinuous decreasing tendency of average proportion of IDUs in
newly diagnosed HIV cases until 2004. From 2004 to 2008 this proportion has been varying between 7
and 14 %. HIV infection rates in IDUs situate around 4 percent and are witnessing a currently stable trend.
A recent study (Origer and Removille, 2007) based on serological testing, confirmed a significant increase
in HCV prevalence in PDUs and IDUs during recent years, especially in prison settings.
The implementation of the 2000-2004 and 2005-2009 action plans has been accompanied by a significant
yet discontinuous decrease of overdose cases in the Grand-Duchy of Luxembourg (2008: 10 cases). This
decrease was mainly observed in male victims, the number of female overdose victims has remained fairly
stable for the last 7 years. 
In terms of number of overdose cases in the general population of the Grand-Duchy of Luxembourg, this
proportion figured 1.76 overdose deaths per 100,000 inhabitants aged 15 to 64 years in 2005 (2000: 5.9
cases per 100,000 inhabitants). In 2008, however, 3.04 (2007: 5.67) acute OD cases per 100,000
inhabitants were registered, which represents a decreasing tendency likely to be confirmed by 2009 figures.
An expert working group analysed possible reasons for this evolution and stressed the impact of high purity
variation of street drugs currently on the market and generalized polydrug use including a series of
prescription drugs with potentially dangerous interactions patterns with illegal drugs. Forensic data from
1992 to 2008 show that the most frequently involved substance in drug-related death is heroin, followed
by methadone and cocaine. Since 2000, methadone traces in blood samples of overdose victims have been
increasingly detected.
The vast majority of victims were male (83%) and their mean age at the moment of death shows an
important increase over the past 15 years (in 1992: 28.4 years and in 2008: 33.16 years). Although the
mean age of drug overdose victims has been increasing, the number of victims aged less than 20 years
remained relatively unchanged and the proportion of those older than 35 has been increasing during the
retained observation period. No underage victims were reported in 2008.
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Considering the nationality of overdose victims, 80% were natives while 20% had foreign nationalities.
During the entire observation period Portuguese citizens stand in second place, followed by Italian and
French residents. Recently, one could observe an increasing number of victims from the frontier zone (BE,
DE, F) and a decreasing number of victims of Portuguese origin, which is consistent with nationality trends
in the general PDU population.
A confirmed majority of acute drug death victims are known by law enforcement agencies for their drug user
“career”, with average durations of 10 years. Half of the latter report accommodation that could be qualified
as stable. As far as the place of death is concerned, since 2004 approximately 50% occurred at the victims’
home, followed by public places. 
In 2008, 10 indirect drug death cases have been indexed. Main causes of indirect deaths between 1996
and 2008 are, in order of importance: suicide, traffic accidents, undefined intoxication, associated cardio-
vascular or pulmonary complications, drug (pharmaceutics) addiction, liver failure and immune deficiency
diseases. 
The overall number of indexed direct and indirect drug death cases informs about drug-related mortality.
Drug-related mortality prevalence has been showing small variations between 1998 and 2008 figuring
roughly 20 to 38 cases per year. In 2008, 20 drug-related deaths have been reported (10 direct and 10
indirect drug related death cases).  
Social correlates and social reintegration
Social correlates of problem drug use are manifold and touch upon family, professional, financial and legal
areas. For instance, according to RELIS data, the use of illegal drugs or abuse of alcohol or psychotropic
pharmaceuticals in the family of origin of indexed PDUs is highly prevalent (63%). The educational levels
of PDUs are low and mostly incomplete. The average age at the end of studies shows a global decreasing
tendency and currently situates at 16 years and 8 months. 39% of the population of PDUs have major debts
(1997: 54%). 
The residential status of indexed respondents has improved over the last years. In 1995, 31% of the users
reported stable accommodation; in 2008 the same proportion figured 77%. This improvement is partly due
to various accommodation and housing offers for addicted people set up in the framework of the drug
action plan. 
All indicators included, employment status of PDUs suggest a stabilised situation since 2007, as the rate of
PDUs set around 47%. After a high level plateau (46-50%) over several years a new increase is reported
between 2006 and 2008 (63%).
Law enforcement indicators 4
Seizures of illicit substances at the national level
Great variations have been observed as to the quantity of illicit substances seized since the beginning of the
nineties. A longitudinal data analysis indicates a general decreasing tendency of heroin, cocaine and
cannabis seizures until 20025. Since 2002 however, one observes a significant increase in the quantity of
drug seizures mainly concerning heroin and herbal cannabis. Cocaine seizures (quantity) are highly variable
since the beginning of the nineties. Compared to 2007 data, the quantity of seizures of nearly all listed
substances went up in 2008 (except for heroin). This observation particularly applies to cannabis and
cocaine.
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The number of seizures did not show significant variations during the same period, with the exception of
cannabis going up. Markedly, the number of cannabis seizures has indeed risen from 167 to 580 between
1994 and 2008. Also, the number of offenders involved in seizures has been showing an overall decreasing
trend. This may suggest that greater quantities of drugs are distributed by smaller groups of traffickers. The
total number of persons involved in traffic has followed a constant upward trend until 2000 and stabilised
afterwards (2008: 1,487 (1,072) persons). A confirmed majority of offenders are involved in cannabis traffic
and are non-natives. 
Crack (cocaine-base) seizures have not been reported to date by national authorities. The first national
seizures of ecstasy type substances (MDMA, MDA, etc.) were recorded in 1994. The availability of ecstasy
appeared to soar between 1994 and 1996 however stabilization at low level occurred over the last decade.
Drug law offenders and prison sentences
The number of police records for presumed offences against the modified drug law of 1973 went from 764
in 1995 to 1,219 in 2008. A similar evolution has been observed with regard to the number of drug law
offenders. In 2008, 188 (225 in 2006) arrests for presumed offences against the modified 1973 drug law
have been reported. Overall, in recent years, the number of police records, the number of drug law offenders
and the number of persons arrested for the same charge have discontinuously decreased. 
The population of drug law offenders is composed of 88% males; a proportion that has been varying
between 79% and 89% during the past decade. The spectacular increase in 2002-2003 of the proportion
of first drug law offenders is not confirmed by 2007/2008 data reporting a decrease from 808 in 2003 to
546 in 2008. Also the percentage of minors (< 18 years) among drug law offenders having increased
between 1994 (4.9%) to 2000 (8.7%) shows a clear decrease in 2004 (5.7%) and tended to stabilize from
there on (2008: 5.5%). Heroin and cocaine are the main drugs involved in registered first drug offences.
Since 1998, non-natives (58.7% in 2008) have been representing the majority of drug law offenders (52-
68%). 36% (32%) of the registered cases were first drug law offenders; the percentage of minors in drug
law offenders has decreased from 13.8% in 2003 to 6.7% in 2008. National prison data of 2007 refer to
990 (1,030) new admissions of which 332 (33.5%) were related to drug law offences; a proportion having
represented 42.6% in 1996. 
Profile of the national drug market
The national production of illicit drugs appears to be irrelevant in terms of quantities and quality. In 2008
no clandestine drug-manufacturing laboratory has been dismantled at the national level. According to
observational data provided by the Judicial Police and all decentralised national police units, a majority of
illicit drugs consumed in the G. D. of Luxembourg originate from the Netherlands (cannabis production and
transit of other drugs), followed by Belgium (ecstasy and ATS production) and Morocco (cannabis
production). Till the beginning of the nineties, most of the persons involved in illicit drug distribution were
consumers who supplied themselves in the Netherlands or acquired limited extra quantities of drugs in order
to sell them within restricted local networks. Since the opening of EU borders, more organised distribution
networks tend to develop within the national drug market. 
For several years, the expansion of more structured distribution networks by organised criminal associations
has been observed. More recently different ethnic groups have started to create synergies in drug
distribution and traffic, whereas previously these groups have been operating separately. Moreover, it has
been noted that traffickers tend to delocalize their selling points to locations or settings less visible for police
as for instance private flats or bars. The proportion of non-natives involved in drug trafficking has been
increasing until 2005 and has since then been decreasing quite sensibly although non-natives drug
traffickers represent 74% (60% in 2007). 
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In regard to heroin trafficking, no predominant profile of nationality has been reported. A large number of
drug traffickers come from North Africa by transiting through Belgium. Numerous traffickers have changed
from heroin to cocaine traffic and currently are also involved in cannabis traffic. Given the geographical
position of Luxembourg, the national police forces closely cooperate with border countries and the
Netherlands and do participate in large scale joint operations in the framework of international policy
cooperation agreements aiming at the setup of a surveillance and intervention mechanism to fight illicit
drug traffic originating from the Netherlands and drug trafficking and consumption at the regional level. 
Over the last 5 years, purity of heroin has remained fairly stable whereas average potency of cocaine has
been on the decrease for the last 2 years. Attention has to be paid to the striking differences in maximum
and minimum purities as well as to a historically high maximum concentration of THC (over 30%) in herbal
cannabis samples seized in Luxembourg in recent years. Prices show broad ranges for heroin and cocaine,
and a still ongoing decrease for ecstasy like products. Cannabis and derivates however have known certain
stability during the last 6 years as far as street prices are concerned. 
Harm reduction activities
The number of contacts indexed by low threshold agencies has increased dramatically over the last ten years
(2008: 67,494 / 2005: 47,739), and so has the number of syringes distributed by the same agencies,
although the number of syringes distributed has stabilised in 2005 and subsequently even decreased. The
proportion of new clients within low threshold settings is on the increase. Approximately 42% of clients are
aged between 25 and 34 years, and an increasing proportion (36%) of clients aged 35 and more is
observed. 56% (56%) of clients are natives.
The number of distributed syringes distributed in the framework of the national needle exchange program,
stabilised in 2005 and has been significantly decreasing from 2006 onwards (2008: 259,607/ 1996:
76,259) although the return rates continue to increase. An increasing majority of injectors (32%) procure
their syringes in specialised agencies followed by pharmacies and automatic dispensers. 
Most Relevant Trends
All indicators included, a decrease in PDU prevalence rates has been observed over recent years. An
increasing number of PDUs enter treatment or use low threshold offers and less come in contact with law
enforcement agencies. 
Intravenous opiate use, combined with polyuse, still is the predominant PDU pattern. However, overall
quality of street drugs went down, which had as a side effect an overall spread of polydrug use. The number
of drug-related deaths reached 20 cases (10 acute, 10 indirect) in 2008 which represents a first decrease
after two years of increase. However, the drug mortality indicator has to be considered with caution since
a series of external factors such as the overall aging of heroin users, high variations in the purity of street
drugs, generalised polydrug use including non therapeutic use of prescription drugs, presenting dangerous
interaction effects with illicit substances’ use, may strongly influence its evolution. 
Although current PDU prevalence shows a decreasing trend, new phenomena such as early drunkenness and
binge drinking in youngsters must be monitored closely since they may have a relevant impact of PDU
incidence in the future.
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There is also great concern about infectious diseases in drug users and in particularly IDUs. HIV rates in
PDUs are low and stable; however, hepatitis C has been increasing continuously. Latest research results
based on serological testing (Origer & Removille, 2007) suggest HCV infection rates over 70% and even
higher prevalence rates in prison populations.
The national drug market is led by more aggressive selling techniques and distribution strategies due to
improved collaboration between criminal groups of different ethnic origins previously operating
independently. A tendency to move selling points to locations or settings less visible for police as for
instance private flats or bars is also observed in this context. Attention has finally to be paid to the striking
differences in maximum and minimum purities of street drugs as well as to a historically high maximum
concentration of THC (over 30%) in herbal cannabis samples seized over the last 3 years. Heroin purity has
remained fairly stable, but cocaine and MDMA purity in XTC-like products has been decreasing over the last
10 years.
The most relevant developments at the response side result from the implementation of the national drug
strategy and its associated action plans. Over the last years counselling and specialized care networks have
been developed, which had as a positive and documented consequence that PDUs start treatment at an
early stage of their drug career. Drug action plans have allowed disposing of financial means that have
known an important increase compared to the time preceding drug action plans. If primary prevention is
considered most important, there have been visible improvements in early intervention measures. Major
efforts have also been made in the diversification of care offers and finally harm reduction measures have
been significantly developed. Housing offers and reintegration programmes have obviously contributed to
improve socio-professional situations as documented by latest RELIS data. Substitution treatment, special
care and low threshold offers have been decentralised and continue to be so.
Coordination mechanisms have been reinforced between NGOs and national authorities and evaluations
mechanisms are in place. A first external evaluation of the national drugs action plan has been performed
and outcomes have been integrated together with recommendations from a series of national expert groups
and outcomes of user/clients surveys in the elaboration of the new drugs strategy and action plan 2010-
2014.
Consistency between Indicators
Demand reduction indicators are highly consistent with supply reduction data (see fig. 4.2). Indirect PDU
prevalence indicators reflect trends documented by in-depth PDU studies except for admission statistics in
low threshold drug agencies from 2000 onwards and the number of fatal overdoses between 2005 and
2007. These trends are respectively to be linked to an increase in capacities of low threshold offers and
better access to harm reduction measures at the national level and significant changes in supply and
consume patterns.
Both indicators thus appear to be influenced by external factors not directly linked to a presumed increase
of PDU prevalence and thus not in contradiction with a general stabilisation of the latter.
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Selected Issue 1 : Market and production of cannabis 
In the course of the 70s, heroin, cocaine and cannabis have been the most prevalent drugs of illicit use in
the Grand Duchy of Luxembourg. Whereas other illegal substances than cannabis show more or less
important variations in terms of appearance on the national market and in terms of users preferences, from
the eighties onwards, cannabis use remained steadily prevalent and mainly in youngsters. Until the nineties,
the majority of persons involved in cannabis related traffic were self-supplying consumers who acquired
limited quantities of drugs mainly in the Netherlands in order to consume them and sell part of them within
a restricted local network. 
In recent years more organised distribution networks have been developing nationally. The expansion of
these structured distribution networks by criminal associations thus contributing to a significant increase in
drug availability, and particular in the supply of cocaine and cannabis. National production of cannabis is
limited to small indoor cannabis cultivations mostly for personal use or for botanical interest and not
primarily meant to procure economic profit.
Selected issue 2 : Problem amphetamine and methamphetamine use, related consequences and responses
At national level, 93% of PDUs reported polydrug use in 2008. A total of 79% of PDUs referred to opiates
as main drug (i.v. and non i.v.). One percent of PDUs declared amphetamine type stimulants as main drug
of use. This figure suggests a low degree of consumption of amphetamine type stimulants by national PDUs.
However, little is known about out-of-treatment populations of (meth)amphetamine users.
In 2003, the first and until now only clandestine laboratory of amphetamines has been detected in the
Grand-Duchy of Luxembourg. To date, no methamphetamine seizures have been registered. Thus far, no case
of (meth)/amphetamine related death has been reported at the national level.
NATIONAL REPORT TO THE EMCDDA
“GRAND DUCHY OF LUXEMBOURG”
New Developments, Trends and in-depth
Information on selected issues
PART A: 
NEW DEVELOPMENTS AND TRENDS
1. DRUG POLICY: LEGISLATION, STRATEGIES AND
ECONOMIC ANALYSIS
Introduction
Drug use is defined as a behavioural pattern potentially associated to health and social damage.
Consequently national drug policies are based on shared political competencies and responsibilities.
Furthermore, in terms of intervention strategies, the more holistic concept of addictive behaviour has gained
in importance and influences increasingly policy debates. This tendency is reflected by the recent
enlargement of ICD (Interministerial Committee on Drugs) competences and its increased external visibility
as well as the general framework set by the new national drugs strategy 2010-2014 still to be approved. 
National parliamentary elections of June 2009 have confirmed the previous coalition government of social
democrats (CSV) and labour socialists (LSAP) as well as the previous Minister of Health, Mr. Mars Di
Bartolomeo. Competencies and ministerial attributions in the drugs field have not been modified. The
governmental programme 20096, foresees to further develop the national drugs action plan and specifically
refers to the decentralisation of care and harm reduction structures, to a critical revision of drug substitution
treatment, to the creation of a heroin assisted treatment programme and to the further development of
post–therapeutic offers. More efforts should also be invested in effectiveness and efficiency evaluations of
drug treatment offers and services.  
By the end of 2009, the Minister of Health will present the new drug strategy and action plan 2010 – 2014,
elaborated by the National Drug Coordinator who was also appointed chair of the ICD by the Minister of
Health in 2006. The referred action plan is based on the evaluation outcome of previous action plans and
the assessment of current and future needs. In this context a mid-term implementation review of the 2005-
2009 drugs action has been published in April 2008 and for the first time a final external output and
progress evaluation of the national drug strategy and action plan 2005-2009 has been performed by a
specialised Dutch institute. The results of the latter, to be presented in November 2009, will thus be
integrated in the elaboration of the new drugs strategy.
16 6 Gov. Declaration of 2009, http://www.gouvernement.lu/gouvernement/programme-2009/programme-2009/index.html
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LEGAL FRAMEWORK  
Drug legislation and recent drug related laws
The basic national drug law, namely: ‘Loi concernant la vente de substances médicamenteuses et la lutte
contre la toxicomanie7 regulates both, the selling of controlled medicaments and the fight against drug
addiction and dates back to the 19 February 1973. It has been last amended by the law of 27 April 2001.
- law of 27 April 20018 modifying the basic drug law of 19 February 1973. Besides the decriminalisation
of cannabis use, alleviation of penalties for simple drug use, and an enhanced overall differentiation of
penalties according to the type of drug offences and the nature of controlled substances involved, the
law of 27 April 2001 foresees a legal framework for a series of harm reduction and maintenance
measures, namely, drug substitution treatment, needle exchange and other state accredited means,
which, in addition to article 13 of the grand ducal decree of 30 January 2002 (see below) could
materialise in shooting galleries or medically controlled heroin distribution programmes. 
- law of 11 August 20069 on the fight against tobacco regulates advertising of tobacco and related
products, the prohibition of smoking in certain areas and the prohibition of sale of oral tobacco.  Main
legal amendments concern an increase of the number of smoke free public areas, a prohibition of smoking
in catering establishments, a general prohibition of advertising, the prohibition of tobacco sale to minors
under 16 and the prohibition of import and sale of tobacco in forms of candy or toys. The prohibition of
smoking in spaces where food is served can be compassed by the implementation of separate smoking
rooms, not exceeding 25 % of the total area, with specifically installed smoke extraction systems. Access
is denied to youngsters aged less than 16 years. Pubs and bars are only concerned during core hours as
far as they serve meals. Hospitals are allowed to install one smoking room exclusively reserved to patients
Fines in relation to offences in regard to publicity, sale and import of oral tobacco and tobacco-like toys
and candies range from 25 to 50,000 euros. Fines related to smoking in prohibited areas vary from 25
to 250 Euros for clients and up to 1,000 euros for the operator or manager of the venue. Sanctions for
selling tobacco to minors lie between 251 to 1,000 euros. Legal amendments also concern the modified
law of 17 June 1994 on security and health at workplace, the modified law of 16 April 1979 on general
status of state civil servants and the modified law of 24 December 1985 on general status of communal
civil servants. These amendments concern the protection of non-smokers at the workplace which underlies
the responsibility of the employer. Due to the extend of modifications, the modified law of 24 March
1989 has been abrogated
- law of 13 July 200710 referring to the markets of financial instruments and including the implementation
of the : - directive 2004/39/CE of the European Parliament  and of the Council from the 21 April 2004
concerning markets of financial instruments, modifying the directives 85/611/CEE and 93/6/CEE of the
Council and the directive 2000/12/CE of the European Parliament and of the Council and abrogating
the directive 93/22/CEE, - article 52 of the directive 2006/73/CE of the Commission of the 10 August
2006 executes the directive 2004/39/CE of the European Parliament and of the Council with regard to
the organisational requirements and operational conditions applicable to investment companies and the
definition of some terms of the aforesaid directive.
- law of 18 September 200711 lowers the alcohol concentration tolerance level from 0.8‰ to 0.5‰ and
the introduction of a level below 0.2‰ for specific categories of drivers (young drivers and professional
drivers). Fines are applied and driving licence “points” are subtracted if alcohol level is equal or superior
to 0.5‰, respectively 0.2 ‰. An immediate driving license withdrawal will be applied for 8 working
days:
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7 Official gazette A 1973, p.319 
8 Official gazette A 2001, p.1180 (Adoption: 27/04/2001, Entry in force: 17/05/2001
9 Official gazette A 2006, p.2265 (Adoption: 13/07/2006, Entry in force: 05/09/2006)
10 Official gazette A 2007, p.2076 (Adoption: 13/07/2007, Entry in force: 01/11/2007)
11 Official gazette A 2007, p. 33475 (Adoption: 18/09/2007, Entry in force: 01/10/2007)
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12 Official gazette A 2007, p. 4410 (Adoption: 18/12/2007, Entry in force: 28/12/2007). See also ELDD
13 Official gazette A 2008, p. 1495 (Adoption: 17/07/2008, Entry in force: 23/07/2008). See also ELDD
14 Official gazette A 2004 (Adoption: 30/01/2004, Entry in force: 13/02/2004). See also ELDD
Règlement grand-ducal du 30 janvier 2004 modifiant le règlement grand-ducal modifié du 2 février 1995 relatif à la fabrication et à
la mise sur le marché de certaines substances utilisées pour la fabrication illicite de stupéfiants et de substances psychotropes.
http://www.legilux.public.lu/leg/a/search/resultHighlight/index.php?linkId=1&SID=e0622007c5892b499e6269171b466eaf
15 Official gazette A 2004 (Adoption: 13/02/2007, Entry in force: 22/02/2007). See also ELDD
Règlement grand-ducal du 13 février 2007 relatif à la surveillance du commerce des précurseurs de drogues […].
16 Official gazette A 2007 (Adoption: 30/01/2004, Entry in force: 13/02/2004). See also ELDD
Règlement grand-ducal du 30 janvier 2004 modifiant le règlement grand-ducal modifié du 2 février 1995 relatif à la fabrication et à
la mise sur le marché de certaines substances utilisées pour la fabrication illicite de stupéfiants et de substances psychotropes.
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- in case of an alcohol level equal or superior to 1,2‰
- in case of refusal to submit oneself to an alcohol or drug test,
- in case of exceeding the speed limit of 50% of the authorised maximum speed, the excess being of at
least 40km/h.
It also provides a legal framework to roadside (illegal) drug testing by means of rapid tests (Drugwipe II).
Tolerance levels according to types of drugs are as following:
THC: 2ng/ml      ATS: 50ng/ml     Cocaine: 50ng/ml      Opiates: 20ng/ml.
- Law of 18 December 200712 regarding the approbation of the United Nations Convention against the
organised transnational criminality, adopted by the annual general meeting of the United Nations in New
York, on the 15th of November 2000. The object of the Convention consists in the development of the
cooperation in order to prevent and to fight the organised transnational criminality in a more efficient
manner.    
NEW!
- Law of 17 July 200813 on the fight against money laundering and financing of terrorism. This law
transposes the EC regulation 2005/60/CE of the European Parliament and of the European Council of
26 October 2005. It thereby modified laws related directly to the national drug legislation.   
Grand Ducal Decrees (2004/2009)
- The grand ducal decree of 30 January 200414 modifies the substance lists annexed to the grand ducal
decree of 2 February 1995. (List cf. footnote.)
As regards regulation mechanisms on the control of substances and precursors, the national drug
legislation relies on the following Grand ducal decrees, amended (text or annexes) according to decisions
on new substances’ inscription into national law:
- Grand ducal decree of 4 March 1974 regarding certain toxic substances
- Grand ducal decree of 20 March 1974 regarding certain psychotropic substances
- Grand ducal decree of 26 March 1974 establishing the list of controlled narcotics
- Grand ducal decree of 8 May 1993 regarding commerce of narcotics and psychotropic substances
- Grand ducal decree of 2 February 1995 regarding the production and distribution of certain substances used in the
illicit production of narcotics and psychotropic substances
- Grand ducal decree of 6 February 1997 regarding substances listed in schedules III and IV of the UN Convention on
psychotropic substances of 21 February 1971.
- Grand ducal decree of 30 January 2004 modifying the grand ducal decree of 2 February 199515 
- Grand ducal decree of 13 February 2007 on the surveillance and commerce of drug  precursors16 
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17 Official gazette A 2004 (Adoption: 07/10/2004, Entry in force: 21/10/2004). See also ELDD
Règlement grand-ducal du 7 octobre 2004 modifiant le règlement grand-ducal modifié du 20 mars 1974 concernant certaines
substances psychotropes ainsi que le règlement grand-ducal modifié du 6 février 1997 relatif aux substances visées aux tableaux III
et IV de la Convention sur les substances psychotropes, faite à Vienne, le 21 février 1971.
http://www.legilux.public.lu/leg/a/search/resultHighlight/index.php?linkId=4&SID=e598ed3498d37aa98708757b0b038d49
18 Official gazette A 2005 (Adoption: 18/01/2005, Entry in force: 14/02/2005) Règlement grand-ducal du 18 janvier 2005
déterminant le modèle du carnet à souches prévu à l’article 30-1 de la loi modifiée du 19 février 1973 concernant la vente de
substances médicamenteuses et la lutte contre la toxicomanie. 
http://www.legilux.public.lu/leg/a/archives/2005/0211402/0211402.pdf?SID=cac954462991e49701fd54f107a49282#page=5
19 Official gazette A 2006, p.1156 (Adoption: 16/03/2006, Entry in force: 31/03/2006). See also ELDD
20 Official gazette A 2008, p. 754 (Adoption: 14/04/2008, Entry in force: 28/04/2008). See also ELDD
21 Official gazette A 2009, p. 1077 (Adoption: 20/04/2009, Entry in force: 05/05/2009). See also ELDD
22 e.g. spores of magic mushrooms.
The full text of the current basic national drug law as well as recent decrees can be accessed trough the
following web sites: http://www.legilux.public.lu or http://eldd.emcdda.europa.eu.
- The grand ducal decree of 7 October 200417 modifies the national list of controlled psychotropic
substances.
The following substances complete annex A:
2C-I (2,5-diméthoxy-4-iodophénéthylamine)
2C-T-2 (2,5-diméthoxy-4-éthylthiophénéthylamine)
2C-T-7 (2,5-diméthoxy-4-(n)-prophylthiophénéthylamine)
TMA-2 (2,4,5-triméthoxyamphétamine)
Annex B includes GHB, “acide gamma-hydroxybutyrique” in the list of nationally controlled substances.
- The grand ducal decree of 18 January 200518 establishes the model of prescription forms of narcotic
based pharmaceutics. The referred prescription form contains 2 separate annexes. The first to be used in
case of substitution treatment and the second to be completed in case of other types of medical
treatments.
- The grand ducal decree of 16 March 200619 defines maximum prescription periods for methylphenidate,
oral morphine, transdermic fentanyl, buprenorphine, hydromorphone and methadone.
New!
- The grand ducal decree of 14 April 200820 modifies the annex of the grand ducal decree of 4 March 1974
on certain toxic substances by putting GHB (Gamma hydroxybutiric acid) under national control.
- The grand ducal decree of 20 April 200921 put the following molecules and materials under national
control:
a) BZP
b) CP-47,497, JWH-018, HU-210 and all other synthetic agonists of cannabinoid receptors. 
c) Organisms or part of organisms containing a nationally controlled substance in its natural state or after
human intervention.
d) Biological material22 capable of producing organisms referred to under c).
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Laws implementation
Legally speaking, police has no discretional power: every offence, once disclosed, must be reported.
However, depending on the case, (e.g. first offence for cannabis use) it may occur that no further action is
taken. Once a drug law offence case has been reported to the Public Prosecutor, the latter decides on the
opportunity to prosecute or not. The legal concept of ‘prosecution opportunity’ may be applied, which
implies a case-by-case decision.
Narcotic offences are covered by the law (concerning the sale of medicinal substances and the fight against
drug addiction) of 19 February 1973 (hereinafter referred to as ‘the 1973 law’) that was modified by the
law of 27 April 2001.
The modified 1973 law essentially remains a repressive law, towards drug consumers as well as dealers. Even
though the 1973 law does not specifically provide for alternative measures to prison for drug-addicted
delinquents, the following options, constituting a medical alternative, are available during the investigation,
the pre-trial stage and at trial.
In accordance with Article 23 of the 1973 law, cases involving personal use of drugs (individually or in a
group) and/or cases involving offences against Article 8 of the 1973 law are dropped if the offender, before
the illegal use was discovered, undertook treatment for drug addiction. Moreover, the public prosecutor can
offer the offender the option of voluntary treatment for the addiction. If the offender successfully completes
the treatment proposed by the prosecutor, the charges have to be dropped.
According to the terms of Article 24 of the 1973 law, when preliminary charges are brought for personal
use of drugs and when it is established that the offender is the subject of medical treatment, the
investigative judge may order treatment for drug addiction at the request of the prosecutor or the accused
person.
Article 25 of the 1973 law makes provision for the juvenile court to refer an addicted minor to treatment.
Article 26 of the 1973 law provides for the courts to order a drug addict to undergo treatment, in which
case the verdict can be postponed. If the accused person meets all conditions imposed by the courts, the
charges for illegal use may be dropped.
The above measures are only available to drug users and no other categories of offenders.
In addition to the special measures set forth in the 1973 law, the courts can still avail of the reformed
sentencing measures or of any of the extenuating circumstances which are an option for all offences, as
outlined in the Code of Criminal Law and the Code of Criminal Investigation. The extenuating circumstances
outlined in Articles 73 to 79 of the Code of Criminal Law allow the judge the option of ordering community
service or a fine, or even to forgo sentencing in favour of a police fine (between EUR 25 and 248).
Articles 619 to 634(1) of the Code of Criminal Investigation allow the judge the option of either postponing
the verdict, with/without a trial period, or suspending the sentence, with/without probation and with a trial
period.
The last measures are the most used (mainly the extenuating circumstances and suspended sentencing). The
legal option for a medical alternative, provided by the 1973 law, are only rarely used, for cases where the
judge is convinced that the drug addict is sincere in his desire to be treated.
The law of 27 April 200123 modifying the basic drug law of 19 February 1973 by decriminalising cannabis
use, and enhancing the differentiation of penalties according to the type of drug offences and the nature
of controlled substances involved and the grand ducal decree of 30 January 200224 on substitution
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23 Official gazette A 2001, p.1180 (Adoption: 27/04/2001, Entry in force: 17/05/2001) See also ELDD
24 Official gazette A 2002, p.232 (Adoption: 30/01/2002, Entry in force: 12/02/2002) See also ELDD
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treatment, have largely contributed to increase the congruity between drug legislations and prosecution
routines. Also, current drug legislation and prosecution policies put higher priority on drug dealing and
trafficking than on drug consumption and promote harm and risk reduction measures.  The creation of a
national supervised drug consumption room has been welcomed by law enforcement since street and public
drug use as well as related public nuisances have decreased significantly. Also police officers have the
possibility to refer exclusive (injecting) drug users to the injection room as an alternative to street drug use
thus contributing to the harm and nuisance reduction strategy.
The reaction to an offence committed by a drug user must be proportional to the harm it aims to prevent.
All the legal experts of Luxembourg are in agreement with this statement, and the principle is applied in
practice. In fact, as long as the drug addict remains a simple user, any damage caused is to himself/herself
and the legal response remains minimal as long as public order is not greatly disturbed. However, if the drug
addict causes harm to others, the response will become firmer according to the seriousness of the offence.
In line with the same principle and in a public health perspective, the law of 2001 has introduced a special
article on prosecution of drug law offenders having called for medical aid in case they witness an overdose
of another user. The law abolished prison sentences and fines for witnesses being simple users and reduced
penalties for users having sold or delivered drugs to the overdose victim(s). In practice, however, the second
category of users is generally not prosecuted in case they tried to assist another user by calling for
specialised help.
Overall, the highest priority is given to trafficking of ‘very dangerous’ drugs. Such traffickers may be
considered to be trafficking in death. Since the first objective of Luxembourg’s drug policy is to prevent
addiction and related risks, it is fundamentally important to pursue the dealers. As long as there are widely
available ‘dangerous’ drugs on offer, the price will be relatively low. This situation will increase the
temptation for consumers of other drugs (even the legal ones, such as alcohol and tobacco) and access to
‘very dangerous’ drugs will remain easy. Consequently, all efforts must be concentrated on fighting dealers
in ‘very dangerous’ drugs, in order to limit the availability of such drugs. The penalties handed down to
traffickers should have a deterrent effect. All the legal experts, the police and the social workers agree on
this. It is not possible to tolerate any trafficking of hard drugs if an efficient fight is to be conducted against
drug addiction.
Another priority is the fight against serious offences (other than drug offences) committed by drug addicts.
The majority of crimes and property offences are committed by drug addicts to finance their drug
consumption, which is a considerable infringement of public order. A significant reduction of such offences
would inevitably reduce public order disturbances, which would encourage the public to regard drug addicts
as sick people in need of help. It is possible to foster this view of drug addicts by continuing to be vigilant
against drug use and sale of drugs in public.
For drug offences committed in private, other procedures, such as criminal mediation, decriminalization,
postponement or suspension of a sentence, or enforced treatment for drug addiction, are an option –
particularly in cases of minimal public nuisance or a first-time offence.
The courts in Luxembourg impose a prison sentence, sometimes suspended, and then offer the accused the
option to submit to treatment programme in order to avoid imprisonment. However, many social workers
believe that such a response is inappropriate, since such treatment is thought effective only when an addict
chooses to follow it according to his own free will and not when he/she is ‘forced’ to do so, which has in
fact been supported by outcomes of such treatments over recent years.
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In Luxembourg, it is generally agreed that drug users are sick people in need of treatment in the first place
and that simple drug use should not be subject to criminal proceedings. Measures such as warnings, fines
and forfeiture of drugs are more appropriate, and are already applied in practice by various competent
authorities in Luxembourg in cases involving minor disturbance to public order. There is, however, consensus
among the legal experts that these measures should not be the only ones available, since there are cases
where even simple drug use seriously disturbs public order (particularly when it occurs in schools, for
example), for which specific penalties should be developed. 
There is also consensus among the experts that police, in direct contact with the users, should not have the
power to apply any further action. Such decisions should be reserved for the magistrates, who can
objectively assess a case based on the facts. There are differing viewpoints as to whether use/possession of
drugs for personal use should warrant imprisonment. Social workers generally believe that, if an addict is to
be considered as a sick person, consumption of drugs should never be penalized, or, at most, a fine should
be imposed. The legal experts, on the other hand, consider that the option of imprisonment for drug use
should remain, even if it is only for users of ‘very dangerous’ drugs, since situations sometimes arise where
imprisonment is the only solution to ongoing public nuisance.
Other drug policy developments: Initiatives in Parliament and civil society
Following a series of Parliamentary initiatives and debates on drug strategies and policy in 2006 and 2007,
the national drug coordinator was invited twice during 2008 and 2009 to report the state of
implementation of the national drugs action plan to the Parliamentary commission on Health and Social
Security. 
Parliamentary questions during the reporting period mainly addressed the state of play regarding the Spice
phenomenon and progress made in implementing a permanent low threshold centre for drug addicts
(TOXIN: injection room + day and night shelter). The geographical location of the referred centre also
continued to be subject to sustained discussions between the Ministry of Health, the City of Luxembourg,
civil society and local citizens’ interest groups.
No projects or propositions of law in relation with drugs or drug addiction were introduced in 2008.
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NATIONAL ACTION PLAN, STRATEGY, EVALUATION
AND COORDINATION
Coordination mechanisms                                                                 
The coordination of drug demand reduction, risk reduction and drug related research is a competence of
Ministry of Health. Since 2000 a National Drug Coordinator, appointed by the Minister of Health, has been
mandated with the overall coordination (including interministerial coordination) in the domains of drug-
related demand and harm reduction and represents Luxembourg at the international level. Supply reduction
and international cooperation aspects remain a competence of the Ministry of Justice and the Ministry of
Foreign Affairs respectively. 
At the national level, the coordination among the competent ministries takes place in the Inter-ministerial
Commission on Drugs (ICD). In 2006, the national drugs coordinator has been appointed chair of the ICD
by the Minister of Health. The ICD is composed of senior delegates from the main governmental
departments and constitutes the top decision level with respect to coordination and orientation of actions.
Both, the ICD and the Ministry of Health are responsible for the implementation of national drugs strategies
and action plans, supervise field activities and are bound to guarantee an effective consultation process
with other involved ministries (e.g. Justice, Foreign Affairs). The ICD meets 4 to 6 times yearly. There are four
permanent agenda items: the implementation of action plans, the early warning system on drugs, emerging
trends and legal changes and international affairs. Outcomes of the ICD meeting are transmitted to all
competent ministers and national media in order to ensure complete public visibility. Since 2006, the ICD
has been granted an enlarged mandate and addresses currently issues ranging from illicit drug use to
alcohol use and prescription drugs under the general heading of addictive behaviour and its consequences.
In May 2008 the ICD issued its first press communication on alcohol misuse in youngsters, first to raise
awareness and secondly in order to give increased visibility to the work and priorities of the ICD. 
At the governmental level, there exists a Special Parliamentary Commission on Drugs as an advisory body
to the government. Currently, however, the referred commission is not active.
A close link between the EMCDDA national focal point and the policy level is ensured by the fact that the
head of focal point has been appointed National Drug Coordinator. The National Drug Coordinator is also
the head of the national delegation within the Horizontal Drugs Group and the national permanent
correspondent within the Pompidou Group. Furthermore, he is a member of the national substitution
treatment surveillance commission and the national AIDS surveillance commission.
At the micro-level the drug coordinator meets periodically with conventioned NGOs (collaboration
platforms) in order to share information and elaborate responses to emerging trends. A forum called
‘COCSIT’ has been created by specialised drug agencies with the objective to follow up drug trends and to
advice national authorities. The national drug coordinator is regularly invited by COCSIT and sporadically
participates in its work. Recently common recommendations on reducing drug-related mortality have been
edited as an example of good practice in the field of collaboration between national Health authorities and
NGOs specialised in drug care.
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National plan and strategies
The national drugs strategy and action plan 2005-2009 has been presented in detail in previous annual
reports. Having taken into consideration the EU drugs strategy 2005-2012 endorsed under Luxembourg
Presidency in June 2005 and the EU drugs action plan 2009-2012, the national strategy and drugs action
plan are meant to contribute to a high level of health protection, public security and social cohesion and
rely on two policy pillars, namely supply reduction and demand reduction. 
Furthermore the national action plan includes, in addition to international cooperation and research,
information, evaluation (retained by the EU action plan), two more cross-cutting themes: coordination and
harm, risk and nuisance reduction. Luxembourg considers the latter two activity fields to be essential and
of transversal nature.
The national plan contains 43 separate actions associated to a clear definition of tasks, involved
management actors, financial requirements and deadlines. The action plan reflects priorities set by the
government: primary prevention (4 projects), treatment and care (6), socio-professional reintegration (5),
reduction of risks and damages (5), research, evaluation and information (8), supply reduction (7),
coordination and international relations (8). Special focus is placed on primary prevention (considered as
crucial), offers of accommodation and housing, socio-professional reinsertion measures and therapeutic
offers. 
As the new governmental drugs strategy and action plan 2010-2014 will only be presented by the biginning
of year 2010, a detailed presentation of their final and approved version will be provided in the annual
report 2010.
Implementation of policies and strategies                                                    
The outcome of a national drugs action plan highly relies on the way it has been elaborated. The successive
action plans reflect the general strategy of the Ministry of Health in order to optimize the overall
interventions in the fight against drugs and drug addiction in the light of stated priorities, assessed needs
and available resources. It constitutes an open framework meaning that complementary projects can be
included if required. 
In 2009, in order to best meet current needs in the elaboration of the 2010-2014 action plan, the national
drug coordinator has launched a third multilateral consultation process involving ministerial departments,
specialised NGOs and civil society. A special working group, chaired by the Ministry of Health, performed a
needs assessment and elaborated national recommendations focusing on specialised drug care and
rehabilitation offers. A more restricted group composed of representatives of the Ministry of Health and the
National Addiction Prevention Centre drafted the action plan in the framework of primary prevention
strategies. The priorities set by the Ministry of Health were discussed and, if necessary, complementary
measures were added. A consensus on priority rankings of listed actions has been reached among involved
parties. Finally all retained actions were structured in a clear, simple and output oriented way as follows: ‘1.
Description/objective of action – 2. Responsibilities – 3. Budget – 4.Outcome – 5. Deadlines for outcome
and evaluation’.
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The active involvement of specialised NGOs and civil society from the very start of the conceptualisation
work and consensus making prior to the implementation phase have shown to be a major criteria to
guarantee an effective implementation process. Summarily, one should stress that the multilateral
involvement of competent actors and the fact that most agencies involved in the implementation process
are financed and controlled by the centrally coordinating Ministry of Health highly promote the
effectiveness of the national strategic model.
Evaluation of policies and strategies                                                            
Implementation progress of the drugs action plan has been kept on the political agenda since its start in
2000 and consequently the pressure to perform was continuously high. Media also contributed to this
enhanced awareness and activity boosting, especially since they have been able to identify a central
personalised key actor in the person of the national drug coordinator. Another positive side effect of
consecutive drugs action plans is an increased commitment of NGOs and civil society in the drug policies
as they have been involved since the very beginning of the process. The general public has largely welcomed
drug action plans since it enables them to follow up public efforts to fight a problem that is of great concern
for them and to compare announced objectives with achieved actions.
Over the last 10 years the concept of implementation follow-up, evaluation and external evaluation
strategies have gained in importance in the field of drugs and drug addiction.
A mid-term progress review of the state of implementation of the 2005-2009 drugs action plan has been
published by the ICD in April 2008. In summary, 82% of planned measures are progressing timely or have
been implemented in due time, while the action plan is only halfway from the end of its foreseen duration.
13% of the actions are in progress but will be finished after the deadline or have been accomplished with
delay. 7% of the measures had to be suspended for budgetary or other reasons. It should be noted that the
observed delays are not of conceptual order or attributable to respective project managers. They are partly
due to delays in administrative procedures and to the necessity to include the lessons of some innovative
projects in the planning of other projects (e.g. program of controlled heroin distribution). 
Beside the efforts made by the totality of involved actors and networks, the positive outcome has also to be
related to the considerable increase of the budgetary means allocated to the fight against drug addiction.
An increase of 287% of the budget invested by the Ministry of Health in drug demand reduction occurred
between 2000 and 2009.
Budgetary means invested allowed to increase resources in terms of primary prevention, to extend admission
capacities of low threshold services, to increase the number of post-therapeutic offers, to regionalize
ambulatory treatment offers, to improve technical control measures related to substitution treatment, to
reduce risks and damages, especially related to synthetic drugs and the transmission of certain infectious
diseases, endemic to the population of PDUs, to reduce considerably the number of drug overdoses and
finally to promote research activities in the field.
By the end of 2009, the Minister of Health will present the new drug strategy and action plan 2010 – 2014,
elaborated by the National Drug Coordinator. The referred action plan is based on the evaluation outcome
of previous action plans and the assessment of current and future needs. In this context and for the first
time nationally, a final external output and progress evaluation of the national drug strategy and action
plan 2005-2009 has been performed by the Dutch Trimbos instituut.
The contractual scope of the evaluation is a critical analysis of the implementation of the National Drug
Action Plan 2005-2009. It builds upon the above mentioned mid-term evaluation of the Drug Action Plan.
The aim is to serve policy relevant information to the stakeholders involved in making and implementing
drug policy in Luxembourg. The following questions were addressed:
2
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• Priorities: Does the Action Plan address in an appropriate way the priorities put forward by the different
stakeholders, e.g. by clear problem definitions and clearly defined actions?
• Conditions: Were conditions given to realise the actions formulated in the Action Plan, e.g. by serving the
necessary instruments and resources, and by dividing and defining the responsibilities and by facilitating
cooperation between the different stakeholders? Has the existing coordination structure proved to be
appropriate and efficient?
• Results: Did the implementation of the National Drug Action Plan result in the realisation of the
envisaged actions?
• Process: Did the process of policy formulation and implementation go well (managed appropriately,
allowing and taking-up input from all stakeholders, etc.)?
In implementing the evaluation the following guiding principles were applied: 
• The evaluation is  based on reliable and verifiable facts/results;
• The evaluation process is  transparent to all stakeholders;
• All relevant parties are invited to participate in the evaluation process;
• All these parties must feel free to express their opinions;
• The evaluation is meant to formulate concrete recommendations that could lead to improvement of the
quality, efficacy and efficiency of the Luxembourg drug policy;
• The evaluation does not take a stand in the political debate in Luxembourg.
The evaluation will result in a report answering the above mentioned questions resulting in a set of
recommendations regarding the next National Drug Action Plan, the coordination structure and the policy-
making process. 
The final output of the external evaluation exercise (not yet available at the time of reporting) in addition
to the recommendations of previously referred to working groups will and have been serving the national
drug coordinator and the Interministerial Commission on Drugs to elaborate the new national drugs action
plan 2010-2014.
26
09Édition 
ECONOMIC ANALYSIS25
Public expenditures                                                                                     
The fight against drugs is multidisciplinary. Thus, in Luxembourg: 11 ministries and 13 departments are
involved to a different extent in the enforcement of national drug policies. As in most EU Member states,
the structure of the national state budget does not allow for a drug budget allocation analysis exclusively
based on labelled expenditures. Following are some of the preliminary problems one typically is confronted
with in a public expenditure study:
- Budget lines may be generic (legal & illegal drugs), aggregated (addiction prevention), over inclusive
(social solidarity) or unidentifiable (others),
- Apportionment of budgets may not be provided,
- Difference between provisional budget, voted budget and final expenditure (provisional budget often
more detailed than voted budget),
- Expenditures may be annual, multiannual, unique, ordinary, extraordinary, etc. If they occur during the
study reference year, they should be included even though they might give a biased picture of average or
routine expenditures, especially when they are important (e.g. investments in real estate)26, 
- In terms of follow-up: budget lines may be restructured, integrated or divided over time,
- In the field of public health, expenditures may result from direct state financing or social security
reimbursement,
- Lack of clarity due to National mixed (Multi-ministries) financing (e.g. Public research Centres – multi
projects’ financing) or National & EU & International shared financing,
- Eligibility of cooperation projects vs. variability of yearly contributions,
- Assessment of impact of general education and educational interventions (e.g.) on DDR impossible.  
This list is not exhaustive. Nevertheless drug related public expenditure studies are feasible although they
demand a considerable amount of analytical work for labelled or dedicated budget lines as they require a
certain degree of creativity as far as non-labelled expenditures are concerned. Researchers may be forced to
take decisions whether to include or not a series of expenditures. It is important that those decisions are
taken according to reproducible standards and, even better so, according to harmonized and ultimately
widely recognized methodological benchmarks.
As these standards are only about to be developed, the answer to a general question should guide the
researcher in each single decision he or she has to take, namely: Would the service, offer, measures, action,
institution, etc. also exist or be the same if there were no drug addicts or illegal drugs to be dealt with?
In order to tailor and fine tune a methodology that fits the national context and in line with the work plan
of the EMCDDA, a national study on direct economic costs of drug policies and interventions has been
performed from 1999 to 2002 and refers to data from 1999 (Origer 2002 b). (Etude du coût économique
direct des interventions et de la politique publique en matière de drogues et de toxicomanies). The original
research report can be accessed under:  http://www.relis.lu. In the framework of 2006 EMCDDA
contractual requirements an update of the Origer 2002 study has been performed. A detailed description
of the methodology applied in 2002 can be consulted in the original study. The same methodology has
been applied for the present and other yearly updates. 
Given the geographical size of Luxembourg and its political organisation, listed expenses are of centralized
and national nature. There are no significant regional or local drug related budgets to be considered in the
present analysis.
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METHODOLOGY
The objective of the present analysis is to assess direct public expenditures for the fight against drugs and
drug addiction.  The constituent concepts are defined as follows:
DIRECT: Excluding ‘costs of indirect consequences’ (e.g. loss of income, taxes) and ‘non quantifiable costs’
(e.g. loss of welfare) as well as expenditures related to the acquisition of illicit drugs by the consumer him-
or herself.
ECONOMIC: Monetary impact and not social impact (costs) or loss of life quality e.g.
COSTS: Expenditures and not revenues created by illegal drug market.
NATIONAL DRUG POLICIES: Public finances and not private expenditures or investments.
The applied methodology refers to the concepts of the ‘Cost of Illness’ (C.O.I.) theory in opposition to “Cost-
Benefit” approach. COFOG and REUTERS classifications were applied as recommended by the EMCDDA. The
following techniques have been applied and combined according to existing contexts:
- Analysis of state budget and provisional state budget 
- Clarification meeting with involved financial authorities
- Qualitative interviews
- Analysis of activity reports of ministerial departments and NGOs
- Analysis of state conventions and financial statements of specialized NGOs
- Detailed financial breakdown and budget apportionment provided on demand by a series of institutions
(NGOs, Social Security, Hospitals)
Main reference documents: 
- Laws and projects of law regarding the budget of revenues and expenditures of state 
- Annual ministerial activity reports
- Activity reports of specialised agencies
- State conventions with NGOs
- Annual financial statements of specialised NGOs
- Statistical registers of UCM
The main data sources referred to in the framework of this chapter are as follows:
Ministère des Finances (2007). Projet de loi concernant le budget des recettes et des dépenses de l'Etat.
Ministère des Finances, Luxembourg.
Ministère des Finances (2008). Projet de loi concernant le budget des recettes et des dépenses de l'Etat.
Ministère des Finances, Luxembourg.
Ministère des Finances (2009). Projet de loi concernant le budget des recettes et des dépenses de l'Etat.
Ministère des Finances, Luxembourg.
Ministère de la Santé (2009). Rapport d’activités 2008, Ministère de la Santé, Luxembourg.
Ministère de la Santé (2005). Stratégie et plan d’action national en matière de lutte contre les drogues et
les toxicomanies 2005 – 2009. Ministère de la Santé. Luxembourg.
Ministère de la Santé (2009). Stratégie et plan d’action national en matière de lutte contre les drogues et
les dépendances 2010 – 2014. Ministère de la Santé. Luxembourg.
Origer, A. (2002b). Etude du coût économique direct des interventions et de la politique publique en
matière de drogues et de toxicomanies. Séries de recherche n°4, Point focal OEDT Luxembourg – CRP-Santé,
Luxembourg.
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2. Non labelled drug-related expenditures and definitions of attributable proportions
Table 1.2 provides an exhaustive overview of non labelled drug-related public expenditures as well as
information on proportion calculations. In case the attributable proportion keys are complex, a more
detailed description is provided below.
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Tab. 1.3 Overall expenditure in fiscal year 2008 by 1st level COFOG functions
COFOG 1st level function Labelled expenditures Non-labelled expenditures TOTAL
 REUTERS
3 (Public Order and Safety) 13,000.- 20,197,330.- 20,210,330.-  (57%)
7 (Health) 8,171,488.- 6,890,958.- 15,062,446.- ( 43%)
TOTAL   35,272,776.-
Tab. 1.4 Overall expenditure in fiscal year 2008 by 2nd level COFOG functions  
COFOG 2nd level function Labelled expenditures Non-labelled expenditures TOTAL
 REUTERS
3.1 (Police services) / 4,853,960.- 4,853,960.-
3.3 (Law courts) / 1,120,000.- 1,120,000.-
3.4 (Prisons) 13,000.- 14,203,670.- 14,216,670.-
7.1 (Medical Products, 
appliances and equipment) 510,000.- / 510,000.-
7.2 (Outpatient services) 7,348,268.- 558,706.- 7,906,974.-
7.3 (Hospital services) / 5,926,498.- 5,926,498.-
7.4 (Public Health services) 152,000.- 138,054.- 290,054.-
TOTAL 34,824,156.-
ADDITIONAL EXPLANATORY NOTES ON ATTRIBUTABLE PROPORTION CALCULATION KEYS
(NOT ADDRESSED IN TABLES)
05 Ministry of Finances Treasure and Budget
05 FLTS: (Eligibility? / revenue - expenditure). Confiscated assets re-invested in the fight against drugs. Only
financial means invested in national projects as these would have to be financed by public money if the
FLTS did not exist.
07 Ministry of Justice
07.2 State prisons.
Distinction between new entries and stock of prisoners/year is to be made. 
Prison administration provided proportion of “drug offenders” in prison (prevalence: 25%) (Incidence: 21%
new entries):
A) Calculation of total costs             
B) 25% of total costs
34
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But: Estimation bias: Prevalence based estimation does not take into account duration of prison stays. Better
method if data available: 
Estimation key = Sum drug prisoners days =  e.g. 140,160 days = 20.5% 
Total prison/person days per year 28,800 days                                             
17 Ministry of Social Security (Health expenditures)
II.1 HIV/AIDS treatment (IDU related infections and health costs) 
For HIV/AIDS treatment rates the following calculation formula has been applied:
- A: Total number of registered PLW HIV/AIDS infected via IDU (diagnosis reporting) (status: alive)
(If not available: Total number of PLWHIV/AIDS infected via IDU x mortality rate of target population)
(Higher precision (if available): Total number of PLW HIV/AIDS IDU in treatment during year X that might
be provided directly by central social security department )
- B: Average cost of HIV/AIDS treatment / year X provided by UCM 
- TOTAL COST OF PLW HIV/AIDS IDU TREATMENT = A x B 
01 Ministry of Foreign Affairs and Immigration
II.1 National Contribution to the EU ‘drugs budget’
The first national study on public drug-related expenditures (Origer, 2002) also included the national
Contribution to the EU “drugs budget” as public money is at stake. The following method has been applied:
a) Assessment of the EU “drugs budget” (x EUR) = difficult since EU drug budget lines are scattered,
affected to internal and external programmes and there are multiannual budget lines. At the time of study
only an inventory of drugs related EU budget did exist (COM (2001) 301 final).
Methodology: Sum of annual EU drugs budget lines + proportional share of multiannual EU drugs budget
lines for year of study.
b) Determination of the national contribution share to the total EU budget (y%)
c) Estimation of national contribution: X x Y.
Remark: Other international contributions are accounted for in the budget lines of the Ministry of Foreign
Affairs and Cooperation. The referred expenditures have not been included in the present analysis since
EMCDDA guidelines do not refer to.
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Relevant or pertinent expenditure breakdowns:
The following minimum breakdowns on total expenditures should be performed if required data are
available:
- Expenditure per inhabitant (EUR)
- Expenditure per est. PDU or IDU (EUR)
- Demand reduction / Supply reduction / Risk/damage reduction / Research (COFOG level 3 and 7 is
insufficient)
- % of GDP
- % of total national public expenditures / state budget
- % of total national social expenditures / social budget
BUDGET
The NFP follows up the annual budgetary evolutions by means of the most representative indicator, which
is the annual budget of the Ministry of Health allocated to drug-related activities. Figure 1.1 shows the
budgetary progression since the implementation of the first drugs action plan in 2000 and figure 1.2
summarises the annual progression of budget of the Ministry of Health and human resources allocated to
drug-related activities to the mid-term evaluation period.
Fig. 1.1 Annual budget of the Ministry of Health allocated to drug-related activities 2000 - 2009
Year 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Budget (EUR) 2,066,00 0.- 3,210,000.- 4,294,000.- 4,862,000.- 5.771.000.- 6,196,000.- 6,584,000.- 6,689,000.- 7,288,455 7,991,583
Progression Reference 55% 108% 135% 180% 200% 217% 224% 253% 287%
rate year
Source: Projet de loi concernant le budget des recettes et des dépenses de l’Etat pour l’exercice 2009. Volume 1.  (Ministère des
Finances 1999-2009)
Fig. 1.2 Annual progression of budget of the Ministry of Health and human resources allocated to drug-related
activities 2004 - 2009
Budget Year 2004 2005 2006 2007 2008 2009
Budget (EUR) 5,771,000.- 6,196,000.- 6,584,000.- 6,689,000.- 7,288,000.- 7,991,583.-
Annual progression rate Reference year 7.36% 6.27% 1.59% 8.97% 9.65%
Annual cumulative progression rate Reference year 7.36% 14.09% 15.91% 26.29% 38.48%
Dedicated human resources Full Time Equivalent (FTE) 59.5 63.5 69.25 73.5 78.5 83.75
Annual progression rate Reference year 6.72% 9.06% 6.14% 6.80% 6.70%
Annual cumulative progression rate Reference year 6.72% 16.39% 23.53% 31.93% 40.76%
Source: Projet de loi concernant le budget des recettes et des dépenses de l’Etat pour l’exercice 2006/2009. Volume 1. (Ministère des
Finances 1999-2009)
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Funding arrangements (NNIA)
Funding of drug-related interventions is centralised at state level. There exist no specific regional or local
funding mechanisms. Few drug prevention activities are subsidised by council districts on an ad hoc basis.
Respective ministries or governmental departments, according to their attributions, are co-ordinating the
creation, the implementation and the funding of required infrastructures. Governmental departments
directly rely on the state budget while NGOs involved in drug treatment or research activities have either
signed a financial and quality control agreement called ‘convention de collaboration’ with concerned
ministries or are financed on basis of regular subventions. The convention between the ministries and NGOs
entitles the former to control the functioning and the financial management of each NGO via a
governmental delegate within a management committee, called ‘coordination platform’.
The Ministry of Health guaranteed financial and human resources required for the implementation of the
drugs action plans. The funding of drug action plan is subject to annual budgetary decisions. Specific local
projects designed by non-governmental actors requiring external financial support are generally submitted
to respective ministries or to other national funding sources (Fund Against Drug Trafficking, Foundations,
private funds, etc.) or international bodies (EU, EMCDDA, etc.). Proposals are analysed and might be
supported by short-term state subventions. One may add that the EDDRA questionnaire is applied as a
standard application form for drug-related projects’ funding requests addressed to the Ministry of Health.
Social costs                                                                                                  
Origer (2002) assessed the direct economic costs of policies and interventions in the field of illicit drug use
referred to year 1999 (see www.relis.lu). An update of the Origer 2002 study has been performed according
to data requirements for 2007 selected issues. Between 1999 an 2005, total public drug-related
expenditures went up from 23,345,000 to 35,345,000, which equals to an increase rate of 51%. More
specifically, the budget allocated by the Ministry of Health to drug related services and programmes, as
foreseen by the national drug action plan, has known an increase rate of 217 % between 2000 and 2006.
Concerning the 2006 budget 6,584,000.- EUR have been granted to involved services representing a
progression rate of 6.27% compared to 2005. Further results of the referred study can be found in chapter
11.
In July 2006, the STATEC (Central service of statistics and economical studies) published a study estimating
the economic impact of the illegal drugs related activities in Luxembourg over the period 1999 to 2004
(Statec, 2006). The study was carried out within the framework of a European project intended to improve
the comparability and the coverage of national accounting.
One of the main aggregates of national accounting, the gross national income (GNI), is accounted for in
the calculation of the contribution of the Member states to the EU budget. The concept of the European
system of accounting (SEC95) also includes illegal activities. Due to methodological difficulties and a lack
of reliable data, illegal activities have not yet been integrated at this stage in the national accounts of the
EU Member States. The European Commission expressed the wish to include the illegal activities in the
national accounts in view of equal treatment of its Member States.
Similar studies are underway in other countries of the EU. These studies must allow the Commission to
decide upon the feasibility of the future inclusion of the illegal activities in the national accounts of the
Member States.
Luxembourg had at its disposal for this exercise statistical data of high quality as far as problematic drug
use is concerned (RELIS). However, the data allowing to assess consumption of drugs by the
occasional/recreational users are insufficient given there are no regular surveys in general population
covering this topic.
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The economic and geographical situation of Luxembourg makes an extrapolation of statistical data on the
seizures impossible and did not allow for a valid confrontation of drug supply and drug demand on the
national market. Thus, the estimate on drug consumption has provided the main benchmark for the study.
The annual consumer households’ expenditure for drugs is estimated at 37.8 million Euro over the period
1999 to 2004. According to information provided by field experts, it was possible to set down realistic
hypothesis concerning the provisioning of the drug market in Luxembourg. Nevertheless these results must
be interpreted with caution as they are rough estimates.
The impact of the illegal drugs-related activities for 2004 is estimated at 0.11% of the GDP (gross domestic
product) and 0.08% of the GNI (gross national income). Although this impact is limited, it reflects those
observed in the European Union countries having carried out similar estimates. Three substances have a
major impact: heroin, cocaine and cannabis representing together more than 90% of the measured impact.
Nonetheless, levels observed during the period 1999 to 2004 highly vary according to the evolution of the
consumption and the traffic of heroin, which clearly has the most important economic impact in this field.
National media coverage of drug-related issues
Relation with the media is an indispensable tool in communications strategies aiming at informing a broad
public by providing up-to-date and reliable data on the numerous topics related to drugs and drug use. In
2008 the NFP performed an in-depth analysis of national written media base on an exhaustive press review
and focusing on thematic areas touched upon and frequency of appearance. Of 425 articles on drug related
matters, 90% were published by the most read national daily newspaper. Most represented topics in order
of importance are: doping in sports, international short news, national short news and infectious diseases.
Table 1.3 summarizes main results and covers the period from August 2008 to July 2009.
38
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Fig. 1.3 National coverage of written media27 regarding drug-related topics from August 2008 to July 2009
Paper/magazine 1 2 3 4 5 6 7 8 9 10 11 12 TOT %
Topic
SR, law enforcement 76 18
National short news item (arrests, seizures) 56 1 2 59
Court news (convictions, sentences) 4 4
National drug scene (perquisitions, etc) 9 1 10
Prison related topics 3 3
Research 0 0
Substances and addiction 147 35
Addictions in general 2 2
Cannabis 1 1 2
Spice and analogues 2 1 1 2 1 7
Alcohol / Alcopops 6 6
Doping 135 135
Campaigns, prevention, laws 58 13.65
Drugs in general 10 1 1 1 2 1 16
Alcohol 6 6
Tobacco 12 12
Infectious diseases 23 23
Others 1 1
Specialised drug agencies 27 6
NGOs 18 1 3 22
TOXIN / Drug injection room 3 1 1 5
EMCDDA National Focal point 5 1.18
Activities and publications 2 1 1 1 5
Ministry of Health , Government, Parliament 25 6
EU drugs strategy and action plans 1 1
Health Commission, Questions to government, 
Interministerial Groups on Drugs 14 2 2 1 19
Heroin Assisted Treament 1 1 1 1 1 5
External relations 85 20
Organised crime/ trans-border cooperation 4 4
International Organisations 2 3 1 6
Afghanistan 7 7
The Netherlands 5 5
International short news 63 63
Miscellaneous 2 0.47
Readers letters 2 2
TOTAL 384 3 0 6 12 5 11 0 0 2 2 / 425 100
PERCENTAGE 90 0.71 0 1 2.82 1.18 2.59 0 0 0.47 0.47 / 100
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27 Daily newspapers : 1. Luxemburger Wort, 2. Woxx, 3. Zeitung vum Letzebuerger Vollek, 4. Journal, 5. Tageblatt, 6. La Voix, 7. Le Quotidien,
Weekly magazines : 8. Revue, 9. Telecran,
Weekly newspapers : 10. Letzebuerger Land, 11. Le Jeudi, 12. Contacto.
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2. DRUG USE IN THE GENERAL POPULATION AND
SPECIFIC TARGETED GROUPS
Introduction
Drugs referred to in the present report include narcotic drugs and psychotropic substances covered by the
international drug control conventions (the Single Convention on Narcotic Drugs of 1961, as amended by
the 1972 Protocol, the Convention on Psychotropic Substances of 1971 and the Convention against Illicit
Traffic in Narcotic Drugs and Psychotropic Substances of 1988). Drugs not listed in the latter UN
conventions are addressed by the present strategy only in the context of their associated use to listed drugs.
‘Drug use’ is hereinafter defined as the self-administration of a psychoactive substance, that, when ingested,
affects mental processes. Psychoactive substances may be of licit or illicit production, sale, or use and
associated risks may be considered more or less important.
Prevalence estimations on drug use in the general population are based on data collected in more (e.g.
schools) or less (general population: age group 15-64 years) targeted and representative samples of the
national overall population. According to the most recent surveys, cannabis and derivates are by far the
most common illicitly used psychoactive substances in the national population followed by Amphetamine
Type Stimulants (ATS). Cannabis use in youngsters has been stabilizing over recent years but still shows the
highest prevalence regardless considered age categories, whereas the prevalence of other psychoactive
drugs varies according to age and data collection setting factors.
‘Hard drugs’ and ecstasy are considered to be the most dangerous substances by general public. The
hierarchy of perceived risks associated to referred drugs is independent of respondents’ age.
DRUG USE IN THE GENERAL POPULATION
To date, no national, large-scale (representative) general population survey on drug use has been conduced.
Several community or targeted population surveys however allow estimating current prevalence. 
A primary prevention pilot project at community level was launched by the CePT in 1995. In 2000, 13
council districts participated in this project. In the framework of this project a non-representative survey on
drug use in the general population (reference 1: “Fischer 1999 study”) was conducted. The survey results
currently indicate most valid data in terms of non-representative description of drug use in general
population. 
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REFERENCE 1. Fischer U. CH. Et Krieger W. (1999) Suchtpräventioun an der Gemeng
– Entwicklung, Durchführung und Evaluation eines Modells zur
gemeindeorientierten Suchtprävention, CePT, Luxembourg.
EN: Drug prevention at the communal level
Year of data collection 1998
Single/repeated study Single study   
Context Drug Prevention – Public Health – Cross sectional
Area covered 7 council districts of the Grand Duchy of Luxembourg
Age range 12-60 years 
Data coll. Procedure Anonymous self-administrated questionnaires                   
Sample size 667 valid cases
Source: Fischer 1999
Fig 2.1: Lifetime prevalence according to age (valid %) (Fischer 1999)
A second survey organized by the CePT was published in 2000 (“Fischer 2000 study”). Even if cannabis
consumption was the main subject of the study, several other substances have been taken into account.
The samples have been drawn on the one hand from a cinema visitor’s population in Luxembourg City
(ref.:2.1) and on the other hand from a population of 6 council districts (ref.:2.2).
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REFERENCE  2.1: Fischer U. CH. (2000) Cannabis in Luxemburg – Eine Analyse der
aktuellen Situation, CePT, Luxembourg. EN.: Cannabis in Luxembourg
Year of data collection 1999
Single/repeated study Single study  
Context Drug Prevention – Public Health – Cross sectional
Area covered              Cinemas in Luxembourg-City
Age range 15 to 64 years 
Data coll. Procedure On-site interviews
Sample size 991 valid cases
Sampling procedure Random sampling of cinema customers 
Remark Detailed results of both surveys are provided in EMCDDA
standard tables
Fig. 2.2 Current and lifetime prevalence of cannabis use according to age: Cinema sample (valid %)
(Fischer 2000)
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REFERENCE 2.2 : Fischer U. CH. (2000) Cannabis in Luxemburg – Eine Analyse der
aktuellen Situation, CePT,  Luxemburg. 
EN.: Cannabis in Luxembourg
Year of data collection 1999
Single/repeated study Single study 
Context Drug Prevention – Public Health – Cross sectional
Area covered 6 district councils
Age range 12 to 60 years 
Data coll. Procedure Mail questionnaire 
Sample size 486 valid cases
Sampling procedure Random sampling
Response rate 27.7%
Fig. 2.3 Current and lifetime prevalence of cannabis use according to age Sample: Council districts (valid %)
(Fischer 2000)
Regarding lifetime prevalence, the Fischer 1999 study reveals that youngsters from the age group 17 to 25
(18.9 %) are most vulnerable to cannabis consumption. The Fischer 2000 study even reveals 40.1% of lifetime
prevalence concerning cannabis use (cinema sample).
Discussions are currently held with the CRP-Santé to collaborate in a general study on health behaviour in
general population in order to include items on drug use. This study may be conduced in 2010 if necessary
financial means are granted.
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DRUG USE IN THE SCHOOL AND YOUTH POPULATION
National school surveys may be divided in two categories. A first category refers exclusively to drug
prevalence surveys in schools; the second refers to cross-sectional surveys combining data collection in
school settings and other youth environments. 
SURVEYS: CATEGORY 1
REFERENCE 1 : Matheis J. et al. (1995) ‘Schüler an Drogen’, IEES, Luxembourg.   
EN.: Students and Drugs.  
Year of data collection 1992
Single/repeated study Repeated study 1983 – 92
Context Public Health
Area covered Nation wide
Type of school 5th years of all types of secondary school classes 
at the national level
Age range 16-20 years (AGE ENTERING 5TH CLASS)
Data coll. Procedure Anonymous self-administrated questionnaires 
in school classes
Sample size 1,341
Response rate (M, F, T) 96%
Matheis and Prussen (1985) have conducted a survey on
1983 data relying on the same methodological criteria 
than the 1995 survey. The referred study will be addres
sed in the comparative analysis part. 
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Fig. 2.4 Lifetime prevalence of drug use according to age (valid %)         
(Matheis, Prussen 1995)
REFERENCE 2 : Dickes P. et al. (1996), La consommation de drogues légales et illégales
des élèves des 6ième de l’enseignement secondaire et des 8ième de
l’enseignement secondaire technique, CEPS/INSTEAD. Luxembourg.
EN.: The use of licit and illicit drugs by students in 6th and 8th classes
of national secondary schools.
Year of data collection 1994
Single/repeated study Single study
Context Drug prevention. Commissioned by the National Drug 
Prevention Centre (CePT)
Area covered City of Luxembourg
Type of school 6th secondary school level and 8th secondary technical 
school level
Age range 13-16 years
Data coll. Procedure Anonymous self-administrated 
questionnaires in school classes
Sample size 650
Response rate (M, F, T) 100%
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Substance Lifetime prevalence Current use prevalence 
(13-16 years) (13 – 16 years)
Cannabis 4.5% 2.9%
Solvents 3.7% 2.9%
Heroin 5.2% 0.8%
Cocaine   1.4% 1.2%
LSD 1.8% 1.4%
Source : Dickes 1996
REFERENCE 3: Das Wohlbefinden der Jugend – HBSC Studie (2000), Ministère de
l’Education Nationale de la Jeunesse et des Sports, Direction de la
Santé, Luxembourg. 
EN.: Health and Health Behaviour of Young People
Year of data collection 1999
Single/repeated study Repeated study (intended each 4 years)
Context Health and Health Behaviour among
Young People – WHO cross-national study
Area covered Nation wide, representative
Type of school Secondary schools
Age range 12-21 years
Data coll. Procedure Anonymous self-administrated questionnaires 
in school classes
Sample size 7,347
Response rate (M,F,T) 97%
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Fig. 2.5  Lifetime prevalence according to age (valid %) (HBSC 2000)
The consumption of illegal drugs has clearly increased the last years. A comparison of the Matheis 1992
study and the HBSC 2000 study reveals that in 1992, 18.1% of secondary school students of 5th class in
secondary school (16-20 years) declared having had contact with illegal drugs. In 2000, this proportion
increased to 41.1%. The HBSC study even reports a proportion of nearly 50% of youngsters aged 18 having
consumed at least once in their life an illegal drug. However, the consumption of “hard” drugs is not
widespread among youngsters. Approximately 4 to 5% of youngsters report consumption of “hard” drugs,
mostly due to experimenting, while a lower proportion effectively develops a related dependency. Cannabis
consumption however increased the last years. A major proportion of students (15.1%), not especially
youngsters from risk groups, reported repeated cannabis consumption over the last year.
It should be stressed that a new HBSC study referring to 2005/2006 data has been presented in 2008
(Ministry of Health, in press). The section on drug use in youngsters thus allows to updating a series of
former data.
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Tab. 2.1 Comparative results from the serial HBSC 2002 and HBSC 2005/2006 surveys
HBSC 2002 HBSC 2005/2006
age 11 age 13 age 15 age 11 age 13 age 15
BOY GIRL BOY GIRL BOY GIRL BOY GIRL BOY GIRL BOY GIRL
TABACCO
ever smoked tobacco - - 39.4% 38.8% 59.6% 57.9% 13% 8% 34% 29% 57% 60%
at least once a week 0.5% 0% 9.2% 8% 24.7% 26.1% 2% 1% 6% 6% 17%* 21%*
daily smoking 0.5% 0% 5% 5,5% 20% 21% 1% 0% 4% 5% 13% 16%
ALCOHOL
Drunkenness (proportions  2.3% 1.4% 6% 21.9% 2% 1% 6% 5% 27% 20%*
that reported having been (11 and (11 and (HBSC 2006: (HBSC 2006:
drunk at least twice) 12 years) 12 years) 5.5%) 23.5%)
weekly drinking - - 17.1% 13.4% 37.7% 22.9% 4%* 2%* 9% 6% 30%* 19%*
(proportions that reported 
drinking any alcohol at 
least every week)
CANNABIS
Lifetime use 3.9% 0.2% 3.5% 21.8% 25% 21%
(at least once) (HBSC 2006: 23%)
Recent use –  13%* 7%*
last 30 days – at least once 
Cannabis use 3.8% 0.6% 3.5% 21.8% 21% 16%
in the last 12 months (11 and (11 and (HBSC 2006: 18%)
12 years) 12 years)
* indicates a significant gender difference (p <0.05)
48
09Édition 
SURVEYS: CATEGORY 2
REFERENCE 4 : Meisch, P. (1998), Les drogues de type ecstasy au Grand-duché de
Luxembourg, CePT, Luxembourg. EN: Ecstasy type drugs in the G. D. of
Luxembourg
Year of data collection 1997
Single/repeated study Single
Context Public Health – primary drug prevention
Area covered Nation wide
Type of school 2nd and 6th years of classical (N: 311) 
and technical (N: 355) secondary schools
Age range 13-22 years (13-14: N347; 15-17: N193; 18-22: N118)
Data coll. Procedure Self-administrated questionnaires
Sample size 666
Sampling frame Schools participating in the “European ‘Health-Schools’ 
network
Response rate (M,F,T) 100%
Fig 2.6  Lifetime prevalence of drug use according to age groups (valid %) (Meisch 1998)
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REFERENCE 5: Fischer U. CH. (2000), Cannabis – Eine Analyse der aktuellen
Situation, CePT, Luxembourg. EN.: Cannabis – Rapid assessment of
the current national situation.
Year of data collection 1999
Single/repeated study Single
Context Cannabis prevalence 
Area covered Nation wide
Type of school 2nd and 6th years of secondary schools
Age range 13-20 years
Data coll. Procedure Self-administrated questionnaires
Sample size 562
Sampling frame Schools selected on basis of their geographical situation 
(national representativity), exhaustive student 
sampling within the selected schools.
Response rate (M, F, T) 100%
Fig. 2.7 Current and lifetime prevalence of cannabis use according to school levels (valid %) (Fischer 2000)
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SYNOPSIS OF MAIN COMPARABLE RESULTS AND OBSERVED TRENDS
LIFETIME PREVALENCE: SCHOOL POPULATION:
Prevalence figures for age group 12-20, provided by HBSC (2000) and Fischer (1999) vary between narrow
limits and stress increasing lifetime prevalence rates for cannabis, psilocybin and amphetamines/ecstasy, in
accordance to results of previous surveys. The most relevant differences according to gender are lower
prevalence figures for females with regard to cannabis, amphetamines and magic mushrooms use but a higher
prevalence of medicament use. 
The HBSC study (2000), the Fischer study (2000) and the serial surveys by Matheis (1985/95) provide trends
in lifetime prevalence between 1983 and 1999 applied to age group 16-20. Cannabis use has shown the most
significant increase during the referred period. Also on the increase in order of importance are magic
mushrooms, ecstasy, cocaine and heroin. LSD and solvents use show stable figures since 1992.
Regarding age group 13-14, one should emphasise the increase of cannabis (9.7 - 10.5%) and cocaine (1.6 -
2%) lifetime prevalence over the last two years. In age group 15-16 years, all prevalence rates show increasing
figures since 1992 (cannabis: 27.7%, psilocybin: 4.1%). Compared with the latter group, age group 17-18
(HBSC) shows doubled lifetime prevalence rates except for cannabis, medicaments and solvents.
Fig. 2.8 LIFETIME PREVALENCE: SCHOOL POPULATION - 12-20 years   
Fig. 2.9 LIFETIME PREVALENCE: SCHOOL POPULATION - 16-20 years         
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Fig. 2.10 LIFETIME PREVALENCE: SCHOOL POPULATION - 13-14 years         
Fig. 2.11 LIFETIME PREVALENCE: SCHOOL POPULATION - 15-16 years         
LAST 12 MONTHS PREVALENCE: SCHOOL POPULATION
The HBSC surveys (2000, 2006) provide last 12 months national prevalence figures in 12 to 20 years aged
schoolchildren. Results mirror respective proportions of lifetime prevalence rates with particular emphasis on
high cannabis (22.5%), psilocybin (3.3%) and amphetamines (2.2%) prevalence. Gender differences reflect
the results of the lifetime prevalence surveys except for amphetamines use that is proportionally higher in
females during the last 12 months. Medicaments use in females is more prevalent than in males. 
Fig. 2.12  LAST 12 MONTHS PREVALENCE: SCHOOL POPULATION - 12-20 years (HBSC 2000)        
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New data available from the serial HBSC studies (2002 and 2005/2006) show a recent decrease of last
12 months prevalence (tab.2.2) of cannabis use in youngsters aged 13 to 17 years. This observation is
particularly obvious in youngsters aged 14, 16 and 17. Last 12 months heroin and cocaine use have been
showing a certain overall stagnation between 2002 and 2006 whereas XTC, amphetamines, LSD and magic
mushrooms consumption in youngsters has sensibly decreased over the same period. After a more detailed
analysis, one notices that the age category of 15 years is the only to show increasing use specifically for XTC
and cocaine. This age group should be monitored with greater attention in coming years.
Tab. 2.2 HBSC 2002 and 2005/2006: Analysis according to age (last 12 months prevalence) 
13 14 15 16 17
HBSC / Year 2002 2006 2002 2006 2002 2006 2002 2006 2002 2006
Cannabis 3,5 3 15,4 7,9 21,8 18,3 33,4 18,8 35,8 23,9
XTC 1 0,6 2,3 0,8 1,1 1,5 2,6 1,1 3 1,4
Amphetamines 2,2 0,8 2,2 1,3 2,7 1,8 3,5 1,5 3,9 1
Heroin 0,3 0,3 1,1 0,9 0,7 1,3 1,2 0,8 1 0,5
Medicaments 0,6 0,8 2,2 1,3 2,1 2,4 3,6 1,6 2,9 1,9
Cocaine 0,8 0,8 2,2 1,4 1,5 3,2 1,6 1,4 2 1,6
Glue/solvents 2,8 0,9 3,8 1,5 3,8 2 3,6 1,5 4,2 1,3
LSD 0,3 0,1 1,7 0,4 1,3 0,8 1,7 0,6 2,7 0,7
M. Mushrooms   0,3 0,5 2,3 0,8 3,2 2,1 4,9 1,8 7,1 2,1
LAST 30 DAYS PREVALENCE: SCHOOL POPULATION
Fischer (1999) provides last 30 days prevalence figures for 13 to 20 year old school children. Cannabis and
ecstasy prevalence figure 13.8% and 1.1%, respectively. Heroin, cocaine and LSD prevalence rates are close
to last 12 months prevalence rates. Gender breakdowns are currently not available.
Fig. 2.13  LAST 30 DAYS PREVALENCE: SCHOOL POPULATION - 13-20 years (Fischer 2000)         
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DRUG USE AMONG TARGET GROUPS
In 2007, the National EMCDDA focal point published the results of action research on HIV and hepatitis
infections in drug users (Origer and Removille, 2007).
REFERENCE  c.1 Origer A., Removille N., (2007) Prévalence et propagation des hépati-
tes virales A,B,C et du HIV au sein de la population problématique
de drogues d’acquisition illicite, Point Focal OEDT / CRP-Santé.
Luxembourg.
EN: Prevalence study on HIV, HCV, HBV and HAV in PDUs in
Luxembourg
Year 2007
Single/repeated study Single
Context HIV, HCV and injecting drug use prevalence national 
PDU population 
Area covered In- and outpatient drug agencies and national prisons
Type sample Random sampling during 8 months in 2005 
Age range > 17 
Data coll. Procedure ANONYMOUS SELF-ADMINISTRATED 
QUESTIONNAIRES AND SEROLOGICAL TESTING
Sample size 366
Sampling frame Random sampling
Response rate (M, F, T) 33.96%
MAIN RESULTS: 
- 67.21% of PDUs reported at least 1 prison stay during the last 10 years
- of which 56.1% report drug use in prison
- of which 54.3% report IVDU in prison
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3. PREVENTION 
Introduction
Capacity building, awareness raising and mobilization of individual resources and promoting protective
factors are the main benchmarks as far as national prevention strategies are concerned. Measures may
target the general public or selective, specific or risk populations or communities. 
The present chapter provides a summary of recent universal and selective prevention measures undertaken
at the national level. More detailed information and examples of good practice can be found in the EDDRA
database of the EMCDDA under:  http://eddra.emcdda.eu.int/
The national drugs action plan 2005-2009 addresses primary prevention as a main intervention area.
The priorities of the drug prevention action plan as approved in 2005 are as follows:
- Interventions in school and youth environments, peer education and multipliers;
- Drugs at the workplace;
- Cannabis, Alcopops and XTC use in youngsters;
- Primary prevention intervention methods and impact assessment;
- Mass media campaigns;
- Multidisciplinary training programmes;
- Documentation strategies.
The National Prevention Centre on Drug Addiction (CePT), which has started its activities in 1996, covers
illicit drug use prevention as well as other types of addictive behaviour. Legally speaking the CePT is a
foundation co-financed by the Ministry of Health.
A second important actor in the field of primary drug prevention is the Division of Preventive Medicine of
the Directorate of Health. Although the latter coordinates activities in the larger field of public health
promotion and prevention, it plays a major role, jointly with the CePT in the definition of the overall
framework of addiction prevention.
The overall coordination of counselling, treatment and low threshold interventions is within the competence
of the AST (Department of Directorate of Health, future division of Drug Addiction and Social Medicine)
and the national drug coordinator’s office. The AST has coordination and financial control missions
(supervision of financial contract implementation of subsidised NGOs) in the field of drug addiction and
psychiatry. Furthermore, the national drug coordinator is responsible for the conceptualisation and the
implementation of activities included in the drugs action plan 2005 - 2009 (see 1.1).
Direct drug prevention expenditures reached 672,000.- euros in 2000 and 900,000.- EUR in 2007. These
figures include staff and operating costs of agencies and ministerial department specialised28 in drug
prevention.
Training interventions in drug demand reduction are increasingly developed at the national level. The CePT
publishes an annual training directory including training activities ranging from evaluation methodologies
to demand reduction action-research strategies targeted at drug prevention and public health actors,
educators, youth animators and teachers. The ‘Recherche et Innovation Pédagogiques et Technologiques
(SCRIPT)’ department is actively involved in the referred training activities. The Department for Scientific
and Applied Research may finance training activities following request. In the framework of its 10th
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Education, leisure activities, sport, etc may have a positive impact on resources building; they however cannot be quantified in terms
of exclusive input.
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anniversary, the CepT published a manual on the training of multipliers in primary drug prevention available
at www.cept.lu. 
As regards ad-hoc continuous training of national field actors, most of the involved structures are
conventioned by the government and as such rely on the Ministry of Health’s regulation on continuous
training.
UNIVERSAL PREVENTION
School
Drug prevention programmes in schools are not mandatory. National drug prevention activities integrated
within national school programmes have mainly resulted from corporate actions of different governmental
and non-governmental actors: Ministry of Family and Integration – National Youth Service (SNJ), Ministry
of Health - Division of Social and Preventive Medicine, Ministry of National Education – Psychological Care
and Educational Orientation Department (CPOS) and since 1996, the National Addiction Prevention Centre
(CePT).
The CPOS is permanently represented in all secondary schools by at least one trained psychologist and
several ad hoc teachers. In major schools there are supplementary trained social workers. Among other
tasks, they are supposed to detect, at the very early stage, problems or behaviours in relation to substance
abuse. Drug and addiction topics are included in more general courses as for instance, hygiene or ethics,
which might not be mandatory. However, on the school director’s demand, trained staff from the CePT does
intervene. Furthermore, the Grand-Ducal Police organises school courses for the 6th classes of primary school
and 7th classes of secondary schools provided by specialized police teams out of regional police units and
from the drug department of the Judicial Police.
In 2000, the CePT in collaboration with the SCRIPT started a pilot project called ‘d’Schoul op der Sich’
(School on quest) (see EDDRA and standard table 19) running for two years and having been evaluated in
2003. The aim of this participative project consisted in creating so-called prevention groups among all
participating secondary schools in order to initiate a process of reflection on drug related themes. In 2004,
the CePT managed to set up a primary prevention tool adjustable to the needs of the different secondary
schools. Prevention groups are now operating routinely in several secondary schools in order to find
solutions that fit each particular context.
As far as training activities are concerned, around 1,400 persons have participated in training sessions and
conferences organized by the National Prevention Centre on Drug Addiction (CePT) during 2008 in
collaboration with the Service of Coordination of Research and of Pedagogical and Technological
Innovations (SCRIPT). The CePT proposed for instance pedagogical training for teachers of secondary
schools, for educators of the primary schools in the city of Luxembourg, for the police academy of the Grand-
Duchy of Luxembourg or for the employees of the penal institutions.
Various schools have also been involved directly in the elaboration of prevention programmes. Thus, a group
of students from private schools have conceived, jointly with the prevention service of the local police, a
project called ‘Clean is cool’ to draw attention on the dangers of cannabis abuse. The main objective was
to incite youngsters to actively and autonomously seek for information and knowledge in order to promote
self-motivated preventive attitudes. 
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A mobile interactive exhibition on prevention called the ‘Extra-Tour Sucht’ and aiming to reach students
aged 15 to 18 years in school settings was further developed and adapted for instance to new trends such
as shisha smoking. It was specifically designed for the Luxembourgish schools settings by the German
company KomPass.
Several projects against smoking were also initiated in 2008. A contest called ‘Mission not smoking’
involved 133 school classes, thus reaching 2,800 students from 12 to 16 years. The participating students
committed not to smoke during six months. A second project on the subject ‘School without tobacco’ took
place. In this context secondary school students met in the pedestrian area in the city of Luxembourg and
Ettelbrück and kindly asked people to extinguish their cigarettes, thus creating a non-smoking area.
The project ‘Nach ëmmer allcool’ was developed in 2008, jointly by the CePT, the National Theatre of
Luxembourg (TNL) and SCRIPT. The outcome was a theatre play, addressing prevention of alcoholism
presented in secondary schools from January to Mars 2009.
The youth centre of Pétange is the first Luxembourgish organization to participate in an European action
on drugs. In this context, a forum on the prevention of drug addiction took place in May 2009, in which
students from the technical schools of Pétange, Esch-sur-Alzette and Arlon participated. This forum on drug
addiction and the prevention in general, was organised together with the grand-ducal police, responsible
young drivers, ‘Main tendue a.s.b.l.’ and local action for youth.
Finally, trained police staff periodically visits various schools of the country, to inform students on drugs and
their risks.
Family
Even though interventions aiming at the promotion of positive life experiences within the family and the
kindergarten are not expressively addressed in the national drug prevention action plan, there are local or
regional initiatives focusing on information and advice providing to teachers and the organisation of
parents’ evenings during which educational and health topics are discussed.
Active collaboration between the CePT and parent’s association at each education level does exist. In 2001
CePT has released the so called ‘prevention boxes’ (see standard table 19) including didactic material
destined to potential multipliers as for instance teachers, parents and youth animators. The first prevention
box, targeting 3 to 6 years old children has been released in September 2001. Due to its success, the 3-6
years prevention box will be reedited and a second one for children aged 11 to 15 years has been released
in 2002. In 2004, seminars on the “prevention boxes” took place in different communities participating in
the project of addiction prevention in local communities.
To date, there exists no outreach prevention programme specifically aiming at parents, pregnant women,
childbirth or young parents. Discussions are currently held whether to include capacity building counselling
sessions to drug addicted pregnant women and drug addicted recent parents in the new national drug
action plan.
Community
As most of drug-related interventions and strategies prevention in community settings are organised
centrally and nation wide, projects are rarely initiated by the local community level without close
collaboration of national authorities.
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Generally speaking, local and regional communities do rarely dispose of a comprehensive drug prevention
strategy. Commonly, a given national agency initiates projects, defines the general intervention framework
and seeks active collaboration with community authorities in order to meet local needs. The observed
situation is mainly due to geographical parameters of the Grand Duchy. At present only one agency focuses
on interventions in recreational settings, namely the CePT (community project29). 
The CePT is continuously developing the project “adventure circuit”, an instrument for interactive and
tangible drug prevention targeting general population. This itinerant exhibition has been prepared in 2004
by more than 40 volunteers who since then have fine-tuned and further developed the concept for national
prevention tours.
SELECTIVE PREVENTION
At-risk groups
In 2006, MDs without frontiers - Youth Solidarity (currently Jongenheem asbl) in collaboration with the
Public Prosecutor's Department of Youth Protection and the Judicial Police- Drugs Unit launched a new
project called CHOICE, which is based upon a pilot project of “early intervention of first drug offenders”
(FreD) initiated by the Federal Ministry of Health and social security of Germany. The target group consists
of youngsters aged 12 to 17 who entered in conflict with drug law. The overall aim of CHOICE is to offer
youngsters an early and short-term intervention in order to prevent further development of drug abuse and
drug addiction. An "in-take" interview allows assessing whether a participation in the CHOICE project or an
individual psychological follow up is indicated. A CHOICE group consists of four interactive sessions (6 to 8
participants) which provide information on drugs, legislation and treatment services, promote auto-
reflexion, reinforcement of personnel skills and motivation to change attitudes towards drugs. In a first
phase, the project is regionally limited to the judicial district of Luxembourg City. Police officers hand out
CHOICE flyers to youngsters in breach with drug law including all information on the intervention and
inform the Public Prosecutor's department of Youth Protection. The youngsters and eventually their parents
contact the CHOICE team within two weeks and the latter inform the Public Prosecutor on the participation
level. A certificate testifies the participation of the youngster. In 2008, 32 CHOICE sessions have been
organized (48 in 2007). An external evaluation is foreseen for 2009.
The 2004-2009 governmental programme also underlines the necessity to further develop prevention
programmes for youngsters with regard to polydrug use and in particular the increasing use of alcoholic
mix-drinks. Furthermore, special attention is currently given to a series of vulnerable groups.
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29 In the beginning of 1995, a pilot project on community-based drug prevention has been launched by CePT (see EDDRA). The main
idea was to focus prevention activities on the very environment and daily life experiences of young people. Various demand
reduction activities have been undertaken, either developed by CePT, SNJ and several youth centres, or initiated by the respective
District Councils. 13 district councils and 150 volunteers are currently involved in the project. The funding of this community project
is jointly ensured by the involved district councils, the EU (Drug Prevention Programme DG-V) and CePT. 
The primary aim of the project is to improve communication skills on drugs, to increase participants’ abilities in handling conflicts,
stress and frustration (age range: 12 to 65 years) and to set up autonomous groups to continue implementing local prevention
measures. In each participating municipality, prevention groups were composed of local volunteers who were asked to organise local
drug-prevention activities related to their specific needs. Cornerstone concepts of the project are as follows: - Multidisciplinary drug
prevention, - Tailor-made community solutions, - Health promotion with regard to risk and protective factors, - Holistic and systemic
approach, - Target groups oriented, - Routine evaluation.
The community-based prevention network is an ongoing project, which is expected to develop its proper dynamic over the time. The
idea was to switch from a centrally coordinated pilot project to routine and autonomous local programmes.
Thus, in 2009 Aidsberodung Croix-Rouge in collaboration with the Ministry of Health and the CHL launched
a project called ‘DIMPS’ (Intervention mobile for sexual health) in the framework of the national action plan
on Aids 2006-2010. DIMPS is meant to inform on risk behaviour and provide free infectious disease testing
in difficult-to-access populations, such as immigrants. Combined rapid tests for HIV and HCV are proposed
and the new drugs action plan foresees to broaden the mobile offer to vaccination of hepatitis A and B in
case of medical indication. Currently the DIMPS van visits low threshold drug agencies, gay meeting places
and immigration centres. As the project only started in 2009 no user statistics are yet available. However,
the offer appears to show high acceptance and interest in the target groups.
In this context and due to an increased prevalence of HIV infection cases, AIDS and drug related problems
in the Portuguese speaking community of the Grand-Duchy of Luxembourg, the Committee of AIDS
Surveillance in collaboration with the Ministry of Health have commissioned an exploratory study on current
knowledge and needs of the target group in relation to HIV prevention (Dellucci, 2006). By means of
anonymous questionnaires and semi-structured interviews, 270 persons, thereof 24 persons interviewed,
have answered questions addressing their way of living, perceived importance to HIV prevention, HIV
screening, drug dependence, sexual behaviour, needs of information.
Special attention has been paid to the section “AIDS and Drugs” of the questionnaires. Intravenous drug
use (29.1%), sexual intercourses (28.9%) and homosexual intercourses (12.4%) have been referred most
frequently as HIV transmission risk factors. Also 93.2% of the respondents identified a high risk of infection
associated to the sharing of injection material with an HIV infected person. Accordingly, 82.9% would
recommend a HIV test in case injection equipment had previously been used by other persons. Among
respondents, 6 persons qualified themselves as injecting drug users. Five of them (83.3%) indicated to
undergo an HIV screening in case of using shared injection material, a proportion identical to the one
observed in the total sample (82.9%). Concerning the exchange of injection material, 5 persons declared
practicing exchange, one of them frequently, the others rarely.
Finally the CePT introduced an EU project in the framework of the Grundtvig-Programme called ‘Promotion
of social and personal competences in socially unprivileged persons’ – PROSKILLS. Its objective is to
elaborate didactic material for multipliers working in the field of the promotion of social and personal
competences. Germany, Finland, Greece, Italy, Slovenia and Hungary collaborate in the project. The material
output has been presented in 2008.
At-risk families 
Since 2003 the Youth-and Drughelp foundation (JDH) is running a parental project with the aim to provide
psycho-social aid to drug-dependant parents and their children. The primary objective of the project is to
ensure security and well-being to children and to strengthen parents’ educative capacities. This long term
project is based upon contractual commitments, co-intervention, home visits and functions in close
collaboration with involved services. In 2008, 57 different family situations have been reported, 38% of
them were monoparental situations involving all in all 94 children. An essential part of the project
constitutes the outreach work. Meetings and interviews are held within the natural environment of the
family (at home).
Moreover the CePT, in collaboration with JDH offers training courses for at risk mothers in order to build up
their capacities as parent and improve mother-child relationship. (Project: O Mamm O Kanner)
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Recreational settings 
Numerous programmes in recreational settings take place at the community level, church and youth
organisations or sport-oriented clubs. The latter are not necessarily drug specific and as such difficult to list
exhaustively.
Since its creation in 1995, the CePT, has initiated projects in the field of active leisure organisation: anti-
drug discos, art performances, theatre, media supports (films, cartoons, etc.), seminars, ambulatory
exhibitions, travel experiences, etc. The CePT increasingly ensures the national coordination of such
activities. A broad offer of activities for youngsters integrating the drug prevention topic as one of the
various components of Health education is developing. The latter approach is believed to have more impact
on youngsters (users and non users) than a drug-centred approach. Indeed, human interactions in daily life
situations as for instance adventure or sports activities are most adequate as a conceptual framework for
the progressive integration of drug-related prevention initiatives.
In this respect, the demand reduction activities organised by the ‘Mondorf Group’ (joint initiatives of border
regions of France, Germany, Belgium and Luxembourg) jointly with the CePT and SNJ combine a non drug-
centred approach with intercultural components in organising corporate leisure activities for youngsters
from border countries based on the concept of “adventure pedagogy”. The annual “adventure weeks30” do
fit in a broader programme named “Adventure pedagogy and primary addiction prevention”. Those activities
primarily aim to provide the opportunity to youngsters to experience group dynamics, conflict management,
limit and risk assessment as well as the feeling of solidarity within a group of socially and culturally different
people. The programme further aims at the reduction of risk factors and the enhancement of protection
factors, by focussing on youngsters and their environment, rather than on drugs and addiction. Regional
teams specialised in drug prevention meet in autonomous working and training groups and report activities
to the Mondorf Group.
The CePT continued its close collaboration with the National School for Physical Education and Sports
(ENEPS) in the framework of a project called ‘Give strength to children’. Information and training sessions
in presence of a top professional sportsman have been organised. 
Currently there exists no legal framework regulating prevention and harm reduction interventions in
recreational settings such as on site information providing or pill testing. Discussions and a related
parliamentary motion during the amendment process of the national drug legislation (amended in 2001)
did not bring up a final decision on the matter. Prevention material and info flyers on synthetic drugs and
multiple drug use are provided to bars and nightlife establishments by the initiative of CePT or on demand.
There remains however an obvious lack of interventions in the referred settings. 
Since May 2008, the National Prevention Centre on Drug Addiction (CePT) is an active member of the
working group on health promotion in festive environment and this especially for the project “Democracy,
Cities and Drugs”, a project derived from a collaboration with the European Forum for the Urban Security.
CePT has also participated as associated partner in the elaboration of the project called “Club Health-
Healthy and Safer Nightlife of Youth”.
The governmental programme of 2009 puts emphasis on the phenomenon of binge drinking and its
increasing prevalence in youngsters. The government also intends to promote the selling of non alcoholic
drinks at a lower price than alcoholic drinks in recreational setting and overall. A special working group
chaired by the Ministry of Health has received a mandate to continue its work. Measures implemented
according to recommendations from the referred group included a significant raise of taxes imposed on
alcopops, 16 years minimum age for the purchase of alcoholic beverages and zero tolerance for young
drivers. It may well be that the group will be invited to elaborate a sub-action plan on alcohol to be
integrated in the general framework of the national strategy to fight addictive behaviour.
60 30 See EDDRA
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Occupational settings
In cooperation with the human resources department of the City of Luxembourg, the CePT runs a pilot
project to prevent addiction behaviour and its consequences in City employees based on a preliminary
situation and needs assessment.
INDICATED PREVENTION
Children at risk with individually attributable risk factors
Three basic mechanisms are in place in order to prevent the onset of problem drug use related to
behavioural problems including for instance ADHD. Outpatient psychiatric care by trained psychiatrist or by
specialist consultation centres is a first option. In more severe cases the national juvenile psychiatric service
may provide in-patient care. More specifically targeting drug use the parentality service of JDH is aiming to
assist drug dependant parents to take care of their children and to build up capacities helping them to deal
with potential related problems. 
A special CD-Rom has been developed by the Ministry of Education providing information on ADHD in
school settings and to parents. Teachers are also trained to recognise ADHD symptoms and to react
adequately.
NATIONAL AND LOCAL MEDIA CAMPAIGNS
In the framework of the international day against drug abuse and illicit traffic the new cooperate identity
of the National Prevention Centre on Drug Addiction (CePT) was presented to the press. Since September
2007, CePT has enlarged its offer of existing information (library, leaflets, brochures and homepage) by
adding a telephone line, which is accessible every day from 9 am to 1 pm, as well as an electronic help-line
(FRO NO). The redesign of the CePT homepage simplifies the search and the access to information related
to drugs and addictions. 
Furthermore, leaflets on alcohol and cannabis, informing the general public on effects of referred
substances, their legal status, related risks, were diffused to a very broad national public. 
A flyer on solvent abuse was exclusively addressed to adults taking care of children and adolescents. A rapid
assessment study within different professional groups planned in 2009 is supposed to provide a better
insight in this phenomenon in Luxembourg. 
In June 2009, CePT launched a new awareness raising campaign on what dependency is actually about.
Without further explanation, yoyos with the inscription ‘I make dependent’, the phone number and the e-
mail address of the national prevention centre were distributed next to the central railway station and in
the pedestrian area of Luxembourg City. Additionally, newspaper articles with provocative questions on
different consumption behaviours were published: Chocolate makes dependent? Cannabis makes
dependent? Mobile phones make dependent? Alcohol makes dependent? Yoyos make dependent? 
The main objective of this campaign was to tackle interest of the general public, to motivate them to ask
questions and to realise the versatility of the concept of addiction.
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4. PROBLEM DRUG USE  
Introduction
At the national level ‘problem drug use’ (PDU) or ‘harmful use’ is defined according to the WHO Lexicon of
Alcohol and Drug terms (Geneva, 1994): ‘A pattern of psychoactive substance use that is causing damage to
health, physical or mental. Harmful use commonly, but not invariably, has adverse social consequences […]’. In
contrast to the EMCDDA definition, the mode of administration (injection) is not a selective criterion in the
national definition although types of substances involved are identical. Regular / long duration use of heroin
via inhalation is thus included. According to the national definition, problem drug use is associated to a high
probability of intervention or the need of involvement of a third party from the law enforcement or the care
sector. This approach is consistent with the fact that PDU surveillance systems in Luxembourg are based on the
institutional contact indicator and not exclusively on the treatment demand indicator.
Data on PDUs in this chapter originate from the national drug monitoring system RELIS developed and
maintained by the national EMCDDA focal point. The RELIS network includes specialised drug agencies (100%
coverage), law enforcement agencies, national prisons and since 2009, psychiatric departments of general
hospitals nationwide. 
According to the latest serial and multi-methods prevalence study (Origer 2009) performed in 2009, national
prevalence of PDUs situates at 2,470 persons (C.I. (95%): 2,089 to 3,199). A decreasing trend in PDU
prevalence has been observed from 2003 onwards. A similar evolution occurred also for problem heroin use
(2007: 1,900 PDUs: 5,90/1000). Although absolute prevalence of intravenous drug use (IDU) has slightly
increased compared to the situation observed at the end of the 20th century, IDUs prevalence rate in the
national population aged 15 to 64 years shows an obvious decreasing trend over the referred period. Almost
all indirect PDU prevalence indicators reflect trends documented by in-depth PDU studies. 
Intravenous heroin use associated to poly-drug use has been reported as the most common consume pattern
in PDUs. Low quality cocaine use in combination with heroin continues to be observed. Ecstasy-like substances
and ATS are still popular even though seizure figures do suggest an inverse and currently stable trend.
Methamphetamine use in Luxembourg is very limited. The use of most ‘new synthetic substances’31 recently
detected in other EU Member States has not been reported thus far. All indicators on cannabis use
(problematic and recreational) have been on the increase for several years but tend to stabilise more recently.
Cannabis showing high THC concentrations (max: around 30%) is increasingly found on the national market.
Marijuana shows the highest purity but also the most important variations in terms of quality. 
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31 Substances such as MBDB, 4-MTA, Ketamin, PMMA 2C-I, 2C-T-2, 2C-T-7, 2C-D, 2C-E, TMA-2, BZP, TFMPP, 5-MeO-DIPT, 5-MeO-DMT,
AMT, ALEPH 7, DXM, DPT.  
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PREVALENCE AND INCIDENCE ESTIMATES OF PDU
NATIONAL PREVALENCE DATA
Data presented in the present chapter have been provided by serial drug prevalence study on PDUs aged
between 15 and 64 years performed on 1997, 1999, 2000 and most recently on 2003 and 2007 data
(Origer 2001, in press)32. The latest, yet unpublished study, was performed in 2009 in the framework of the
evaluation of the 2005-2009 national drug action plan. With this latest study based on robust 2007 data,
it became possible to assess the evolution of PDU prevalence over the last decade knowing that applied
methodologies and data sources referred to, during the same period, are highly comparable. 
The research strategy relied on the methodological framework of the Luxembourgish Information System on
Drugs and Drug Addiction (RELIS), set up in 1995 by the national focal point of the EMCDDA. RELIS stands
for a nationwide multisectorial information network, including specialised drug treatment institutions,
general hospitals, counselling centres and competent law enforcement agencies. As such, it provides for the
most comprehensive and reliable data on problem drug users indexed by national institutions. In
compliance with RELIS case definitions, the present study specifically aims at the prevalence estimation of
problem use of illicitly acquired high risk drugs (HRC) in the national population aged 15 to 65 years. 
The following methods have been applied: Case finding (CF), capture-recapture on 2, 3 and 4 sources (CR
2,3,4), truncated Poisson model associated to Zelterman’s and Chao’s estimators (tPm), and four different
multiplier methods using data from law enforcement sources, drug mortality registers (D1,2,3) and
treatment agencies (T).
Fig 4.1. Absolute prevalence estimation of problem HRC drug use (2007)33 and confidence intervals  
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32 Downloadable at http://www.relis.lu
33 CR2 / CR3 : Method « capture-recapture »  2 and 3 sources
CR4 DIC : Capture-recapture 4 sources (weighted mean of Bayes)
D1 : Benchmark multiplier based upon police and overdose registers.
D2 : Benchmark multiplier based upon number of drug law offenders and law enforcement contact rates of PDUs
D3 : Benchmark multiplier based upon mortality rates (DRD standard)
T : Treatment multiplier
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Fig 4.2. Absolute prevalence estimation of problem HRC drug use (1997 – 2007)  
Tab. 4.1. Prevalence and prevalence rates according to selected sub-groups (1997 – 2007)
1997 1999 2000 2003 2007
GENERAL POPULATION
National population on 1st January 418,300 429,200 435,700 448,300 476,200
National population aged between 
15 and 64 years on 1st January  281,100 287,100 291,000 300,800 322,000
HRC USERS IN CONTACT WITH THE NATIONAL INSTITUTIONAL NETWORK
(low threshold agencies not included)
Total number of indexed users 
(multiple counts excluded) / 887 986 1,065 1,200
Number of drug treatment demanders in
specialized institutions exclusively
(Liberal GPs intervention excluded) / 317 372 582 756
Number of drug law offenders exclusively 
(ad minima consume of HRC drug(s)) 378 365 375 373
Numbers of drug treatment demanders 
AND drug law offenders / 192 249 108 71
PROBLEM USE : HRC DRUGS 
Average prevalence 2,100 2,350 2,450 2,530 2,470
Average C.I. p.d. 1,994 -2,758 1,933 - 3,126 2,144 - 3,290 2,089 - 3,199
Total prevalence rate 5 /1000 5.48 /1000 5.62 /1000 5.64 /1000 5.19 /1000
Total prevalence rate - age :15-64 7.47 /1000 8.19 /1000 8.42 /1000 8.41 /1000 7.67 /1000
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PROBLEM USE: MAIN DRUG – HEROIN
Prevalence heroin 1,680 1,975 2,010 1,570 1,900
Total prevalence rate - heroin 4.01/1000 4.60  /1000 4.61 /1000 3.50 /1000 3.99 /1000
Total prevalence rate - heroin -
age :15-64 5.98 /1000 6.88  /1000 6.91 /1000 5.22 /1000 5.90 /1000
INTRAVENOUS DRUG USE (IVDU)
Prevalence IDU 1,000 1,380 1,447 1,270 1,482
Total prevalence rate - IDU 2.40 /1000 3.22 /1000 3.32/1000 2.83/1000 3.11/1000
Total prevalence rate - IDU 
- age :15-64 3.65 /1000 4.84 /1000 4.97/1000 4.22/1000 4.6/1000
Source : Origer 2009
Fig 4.3. Prevalence rates of PDU, heroin use and iv use (1997 – 2007) per 1,000 inhabitants  
Source : Origer 2009
The average of estimations performed on 2007 data provides an absolute prevalence of problem HRC drug
users (PDU-HRC) of 2,470 persons (C.I. (95%): 2,089 to 3,199). In terms of prevalence rates estimates for
the same age categories, 7.67 out of 1,000 habitants aged between 15 and 64 years show problem drug
use.
According to serial data available for the period 1997 to 2007, absolute prevalence and prevalence rates
of PDU-HRC have been showing an increasing trend until 2000. After a short stabilisation phase, a
decreasing trend has been observed from 2003 onwards. A similar evolution occurred also for problem
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heroin use (2007: 1,900 PDUs: 5,90/1000). Although absolute prevalence of intravenous drug use (IDU)34
has slightly increased compared to the situation observed at the end of the 20th century, IDUs prevalence
rate in the national population aged 15 to 64 years shows an obvious decreasing trend over the referred
period.
The stabilization and subsequent decrease of national PDU prevalence occurred within the implementation
phase of the first and second national drug action plans, having started in 1999. The observed trends are
also confirmed by most of pertinent indirect indicators related to demand and supply reduction. 
INDIRECT INDICATORS OF PDU PREVALENCE TRENDS
In order to validate PDU estimates and follow up prevalence trends between two successive prevalence
studies a set of indirect indicators have been compiled and analysed.
Fig. 4.4. Prevalence estimates (problem use of high risk drugs) and evolution of selected indirect indicators 
Source: Origer 2008
Indirect PDU prevalence indicators reflect trends documented by in-depth PDU studies except for admission
statistics in low threshold drug agencies from 2000 onwards and the number of fatal overdoses between
2005 and 2007.
As for the first contradictory indirect indicator (low threshold contacts), its inversed evolution might be
explained by the fact that since 2000 major efforts have been invested to increase capacities of low
threshold offers and to facilitate access to harm reduction measures at the national level. This positive
evolution, in terms of public health, had as a result that those users never in touch with drug agencies got
into contact with the national care system. This said, the increasing use of low threshold offers resulted
primarily in an increase of the visibility of previously hidden users and does not allow to conclude that the
absolute prevalence of PDU user has increased since the beginning of the 21st century.
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34 IDU prevalence rates have been processed on basis of proportion of IDU in PDUs indexed by the highly representative RELIS data
sets for respective years  
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The number of fatal drug-related overdoses has known a decreasing trend between 2000 and 2005, a brief
increase towards 2007 and a subsequent decrease to date. Likewise other EU Member States, the evolution
of the referred indicator is known to show fairly important variations due to factors such as quality of
available drugs, consume patterns, availability of harm reduction services, etc. A national expert group
studied these variations and came to the conclusion that high variability in substances’ purities, increased
polyuse and especially the combination of street drugs, substitution drugs and prescription drugs in general
in out- and in-patient settings and gaps in the follow-up of patients after institutional release
(detoxification, therapy, prison, etc.) are major risk factors at stake if it comes to drug-related mortality and
morbidity but do not support the assumption of a significant increase of the PDU prevalence in general.
Moreover, although annual variations are observed, the trend line of recent years clearly shows a decrease
in acute overdose death rates which is in concordance with national prevalence figures. 
LOCAL OR REGIONAL PREVALENCE STUDIES 
Due to the specificity of the national drug scene and the geographical dimension of the country, local
prevalence studies are not considered being a priority. 
CHARACTERISTICS OF INDEXED PDUs
Relying on a multi-sectorial data network including specialised in- and outpatient treatment centres and low
threshold facilities, general hospitals as well as law enforcement agencies and national prisons, RELIS
enables the assessment of new trends in the problem drug users population in general as well as in drug
treatment demanders in particular. NFP has opted for a holistic monitoring of the drug population. The
following data are provided by RELIS thus referring to all HRC drug users indexed by the national specialised
treatment and law enforcement network and, as such, defined as problem drug users.
The number of problem PDUs indexed by national institutions in 2008 figures 4,542 (2002: 4,701) (in this
figure double counting is included meaning that a given person could have been indexed twice and more
by different institutions. It is thus not representing the actual prevalence, which has to be assessed by other
methods explained). 
For comparison, 2,383 users have been indexed by national specialised drug demand reduction agencies
and 2,318 drug law offenders by supply reduction agencies in 2002. In 2008 the same agencies have
indexed 2,733 and 1,487 persons respectively. 
Tab. 4.2. Main characteristics of PDUs indexed by the national drug monitoring system, RELIS (valid percentage)  
2000 2004 2008 TREND
Gender
Male 77% 78% 77%
Female 23% 22% 23%
Nationality
Natives 54% 54% 48%
Non-natives 46% 46% 52%
- of which
Portuguese 51% 58% 38%
French 17% 11% 28%
Others 32% 31% 34%
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Mean age
Male 29Y4M 31Y2M 31Y8M
Female 26Y10M 28Y4M 28Y5M
Total 28Y9M 30Y6M 30Y11M
rimary drug
Opiates 84% 76% 72%
Cocaine 7% 16% 17%
Others 9% 8% 11%
Polydrug use 87% 93% 89%
Primary administration mode
Iv 56% 55% 45%
Non-iv 44% 145% 55%
Infectious disease
HIV 4.3% 4% 4%
HCV 40% 58% 65%
HBV 25% 22% 21.1%
The male/female ratio of the PDU population is stable at 3:1. During the last nine years the proportion of
indexed non-native PDUs has shown strong variations but a clearly increasing tendency since 2003,
confirmed by 2008 data. The population of non-native drug users largely consists of Portuguese nationals,
a proportion constantly increasing until 2004 but decreasing consistently since although it is still
consistently higher than the one observed in general population. Notably, one observes a remarkable and
continuous increase of PDUs of French origin (28%). This trend is confirmed by last 8-years data on drug
law offenders.
The mean age of indexed PDUs evolved from 28 years and 4 months in 1995 to 31 years and 8 months in
2008. Mean age of male PDUs has been increasing faster than for females. In general, the proportion of
PDUs aged more than 39 years and of users less than 19 years is increasing continuously as also the gap
between these two groups. In reference to years 2004 to 2008 a discontinuous decrease of minors in the
overall PDU population has been observed in treatment and police data.
The mean age of native and non-native problem drug users tends to balance. One observes an average
aging of the population of long-term drug injectors and a sensitive decrease in age referred to “new” PDUs.
The average ages at the moment of first consume of the current main drug and illicit drugs in general have
shown a slow but constant downward trend for the last 9 years. In contrast to 1995 data, the switch to
intravenous drug use occurs earlier in 2008.
Worth mentioning is also the significant increase of the average age of overdose victims during the last
years. Respectively 90% and 46% of current PDUs have tried cannabis and heroin (i.v.) while being minor
of age. In 1995 the same proportions figured 71% and 23%. Most interestingly evolution of drug use
patterns tend to accelerate in terms of shorter time spans separating first non-iv use from first iv-use. This
acceleration is also observed as far as first treatment demands are concerned. PDUs tend to contact drug
treatment facilities at an earlier stage, which may be due to a more diversified offer currently available.
Intravenous heroin use associated to poly-drug use has been reported as the most common consume pattern
in PDUs. The proportion of poly drug use 89% has reached stabilisation after a record level in 2004 (93%).
As already indicated, the switch to intravenous drug use occurs earlier. The ratio of intravenous opiates
consume to the inhalation mode went from 2:1 over the last years to 3:2 in 2008. Provision of ‘blowing
paraphernalia’ (e.g. aluminium foils) by specialised drug agencies may have influenced consume patterns.
The prevalence of the use of cocaine as primary drug shows an increasing trend since 2000. Ecstasy-like
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substances and ATS use appears to be stable which however does not inform on prevalence in general
population as RELIS data refer to PDUs and not to the overall population of recreational drug users.
All indicators on cannabis use (problematic and recreational) have been on the increase for several years.
The number of persons in contact with the national specialised network for (preferential) cannabis use had
known a sensitive increase at the beginning of the years 2000 but decreased again in 2004 and stabilised
towards 2008. 
PDUs show fairly stable infection rates of HIV (4%) and HBV (21-22%) between 2000 and 2008, whereas
HCV prevalence rates (65%) are high and increasing.
The residential status of indexed PDUs has improved over the last years. The geographical distribution
suggests that the southern region (45,9 %) and the centre region (33,2%) are the most representative. The
northern region, after a decrease in 2005 (11,5 %), has shown stability over the last three years
(2008:13,9%).
All indicators included, employment status of PDUs suggest a stabilised situation since 2007, as the rate of
PDUs set around 47%. After a high level plateau (46-50%) over several years a new increase is reported
between 2006 and 2008 (63%). The decrease of financial autonomy of PDUs is associated to an increasing
social dependency. A stabilisation at the level of revenues of illegal origin has been observed during last
years as well as a slowly but continuous stabilisation of the proportion of PDUs presenting major depths.
DATA ON PDUS FROM NON-TREATMENT SOURCES
Data on PDUs from non-treatment sources are mainly provided by the national specialized drug unit of
Judicial Police. The profile of these users is similar to PDUs from treatment settings knowing that the
national drug monitoring system indexes both sources. 
The ratio of male and female PDUs is almost identical to PDUs from treatment sources (81% male, 19%
female offenders). Their mean age is 30 years 6 months, women being slightly younger than men (31y for
male 28y4m for female offenders).  
38% of the offenders are natives and 53% are foreigners. As for the last year, most foreigners were
Portuguese citizens (32%) followed by French natives (28%).  
75% are recidivists (had more than one police record during their lifetime). 25% were arrested for dealing
drugs, 30% are charged with illegal drug possession and 41% for other crimes related to drugs. Drug-law
offenders (who are also problematic drug users) are mostly arrested for heroin and cocaine. 91% are
reported polydrug users, which represents a higher proportion than PDUs in treatment. 95% of these PDUs
had more than one treatment episode during their lifetime.
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5. DRUG-RELATED TREATMENT: TREATMENT
DEMAND AND TREATMENT AVAILABILITY
Introduction
Drug treatment is the ‘use of specific medical and/or psychosocial techniques with the goal of reducing or
abstaining from illegal drug use thereby improving the general health of the client’.35
Specialised drug treatment infrastructures are relying on state financing and on ministerial control and
quality insurance mechanisms. Treatment offers are decentralised and most commonly provided by state
accredited NGOs.
For the purpose of the present chapter, drug treatment is divided in the following categories:
- Outpatient treatment: the patient receives drug treatment without staying overnight, pharmaceutically
assisted or not36;
- Inpatient treatment: the patient is staying overnight, pharmaceutically assisted or not; (including
detoxification);
- Substitution treatment: a type of medical treatment provided to opiate addicts primarily based on the
delivery of a similar or identical substance to the drug normally used. Substitution treatment may be
accompanied by psycho-social care;
Drug treatment is monitored and quality assurance occurs via a series of mechanisms that are described
under the treatment system section.
In recent years outpatient drug treatment demand has been slightly increasing. Inpatient treatment
demands are fairly stable as is the number of substitution treatment demands. A more recent trend is the
increase of treatment demands for cannabis use related problems and combined alcohol abuse in
youngsters at the national level and reported by the Medical Control Department in charge of referrals to
specialised treatment centres abroad. Treatment demand related to cocaine use is difficult to assess as in
most PDUs concomitant use of heroine is observed.
DRUG TREATMENT STRATEGIES AND POLICY
In the mid seventies the cooperation between state and NGOs working in the social field has progressively
gained structure. The first (financing) convention between the Ministry of Family and a series of NGOs,
signed in 1975, was the starting point of what is known today as the “Conventionned sector”. Over the years
the collaboration schemes between State and NGOs evolved and were extended to the Public Health sector.
In 1998 the so-called ASFT law37 entered in force, regulating the relationship between State and private
organisations working in the social, family and therapeutic fields.  
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35 SOURCE: Classification of drug treatment in EU member states and Norway, Expert meeting, 8-9 February 2002
36 ‘Drug free treatment focus on psycho-social and therapeutic techniques and is not primarily based on the routine prescription of a
substance or medicament with the goal of reducing or abstaining from illegal drug use thereby improving the general health of the
client’.
37 Loi du 8 septembre 1998 réglant les relations entre l’Etat et les organismes ?uvrant dans les domaines social, familial et
thérapeutique (entry in force: 24/09/1998)
Treatment needs’ assessment as well as quality control largely rely on the ASFT legal framework and the
existing network of conventionned service providers who have to meet a series of quality standards and be
granted a special accreditation from the Ministry of Health. The elaboration of the demand reduction
section of the national drugs strategies and action plans builds upon the expertise and involvement of the
referred network. A detailed description of collaboration and control mechanisms in place is provided below.
The first specialised drug agency (JDH) was created in 1986 and addressed both drug addiction and Youth.
Originally services developed bottom-up and were seeking financial support of the State. Preliminary work
done in the framework of first drug action plan 1999-2004 allowed to better assess national needs and to
initiate and develop interagency coordination mechanisms. To date treatment agencies are specialised
whether in polydrug use including illegal drugs, in alcohol abuse, or gambling, etc. As far as illegal drugs
are concerned drug care providers address the whole range of substances meaning that no specialised offers
exist according to given type of substance or problems related to it. Currently there are signs that the
national drug treatment strategies are evolving towards a more holistic concept of addiction treatment
(including illegal substances related addictions and others).
TREATMENT SYSTEMS
ORGANISATION AND QUALITY INSURANCE
All specialised drug treatment services are relying on governmental support and control. Specialised
agencies need an accreditation to sign a convention with the ministry of Health that guarantees their
annual funding. Outpatient drug treatment is provided free of charge by specialised agencies. Inpatient
treatment and detoxification is covered by health insurance schemes. As far as substitution treatment is
concerned, health insurance takes in charge medical interventions and counselling and State covers
pharmaceutical costs and pharmacy fees.
NGOs involved in drug treatment fall under the obligation of the above referred to 'ASFT' law (8/09/98)
and the subsequent grand ducal decree of 10 December 199838, both regulating the relation (duties and
rights) between State and NGOs or organisation providing psycho-medico-social and therapeutic care. The
overall management of the referred agencies is ensured by a 'coordination platform' that includes a
maximum of 3 members of the concerned institution and at least one representative from the competent
ministry. All major decisions have to be approved by the coordination platform. All referred institutions work
in close collaboration and have to be viewed as an interdependent therapeutic chain. A series of formal
collaboration agreements have been signed in 2008 and 2009 between various agencies in order to insure
rational use of resources and through-care. The 2010-2014 national drugs action plans foresees to further
develop this synergy by creating a national network of unique reference persons for each drug treatment
demander entering the specialised care system. 
The governmental quality standard certification, as foreseen by the law ‘ASFT’ of 8 October 1998, represents
the main instrument of a standardised quality control of drug treatment offers. General guidelines on
setting requirements and human resources/clients keys are set by a grand-ducal decree of 10 December
1998 regarding the accreditation of services from the medical, social and therapeutic field. Funding is,
however, not a direct function of mandatory evaluation or outputs requirements. The quality standard
certification commits respective NGOs to undertake necessary evaluation measures of their activities by
means, however, they deem adequate. Drug treatment agencies have developed proper evaluation
strategies mostly in collaboration with external evaluators. Recent examples are the evaluation of current
offers in the field of socio-professional integration, which future development has been promoted by the
national drugs action plan, the implementation of a computer based evaluation procedure by the national
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38 Règlement grand-ducal du 10 décembre 1998 concernant l’agrément à accorder aux gestionnaires de services dans les domaines
médico-social et thérapeutique (entry in force 18/12/1998)
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substitution programme and prevention interventions in schools by CePT. The external evaluation of the
drugs action plan also significantly contributes to assess the functioning and the gaps of the national
treatment network.
Also, the RELIS database on problem drug users provides relevant data for evaluation purposes since it
includes detailed data on drug consume patterns, socio-economic situation, risk behaviour and treatment
or law enforcement contacts, etc. In the long run, drug ‘careers’ can be analysed by means of the RELIS
indexing system, which allows following up treatment demands and law enforcement contacts of indexed
drug users. These data can be used to assess the impact and the performance of specific treatment
approaches. A practical example of the application of evaluation results is to be seen in the
conceptualisation and external evaluation of the national drug action plan 2005-2009, which did greatly
rely on RELIS data and ad hoc evaluation initiatives from field institutions. 
Table 5.1 records admission and contact statistics of national drug treatment agencies according to applied
typology from 1994 to 2008. Intra-institutional multiple counts are excluded meaning that all treatment
demanders indexed by a given agency is only indexed once by the referred agency during a reporting year.
Inter-institutional multiple counts are not excluded since a given treatment demander may have contacted
several national agencies during a given year. More detailed admission data, including low threshold
agencies are provided in respective sub-chapters.
AVAILABILITY AND DIVERSIFICATION OF TREATMENT
As can be seen on map 5.1 drug treatment facilities are regionalised showing, however, a high
concentration and diversity within the area of Luxembourg City. All listed services are specialised with the
exception of regional general hospitals providing detoxification treatment via their respective psychiatric
departments. In July 2005, the first ‘consumption room’ has been opened in Luxembourg City. It has been
integrated in the ‘TOX-IN centre’ providing day care, night shelter and low threshold services to drug addicts.
Legend :
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JDH : Counselling, substitution, low threshold and after care
TOX-IN (CNDS) : Low threshold
TOX-IN (CNDS): Night shelter, Injection room
SOLIDARITE JEUNES : Youth counselling
CENTRE EMMANUEL : Counselling and referral
CHNP : Treatment and referral
CTM : Residential therapy, reintegration measures
CTM : Aftercare, supervised housing
General hospitals providing detoxification
Map 5.1 Geographical coverage of specialised drug agencies in the Grand Duchy of Luxembourg (status 2008) 
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The following treatment typology is applied:
Outpatient: services and offers for adults
The most relevant national outpatient treatment facility is the ‘JDH Foundation’. Regional antennas of JDH
are respectively implemented in Luxembourg City, in the South and in the North of the Grand Duchy and
are entirely financed by the Ministry of Health. ‘The Emmanuel Centre’ implemented in Luxembourg-City is
primarily a counselling and referral agency.
A third specialized outpatient service is also implemented in Luxembourg-City (Alternative Counselling
Centre). The main objectives of the referred centre are the following:
•  Establish a first contact with the drug-addicted clients
• Help the drug-addicted clients in the development of a therapeutic project with orientation either
towards the intermediate-term structures, or towards residential therapy centres.
• Organization of detoxifications in local psychiatric services or further psychotherapeutic interventions
• Informative and therapeutic discussions with the drug-addicted clients and their families before and
after the detoxification.
Further agencies provide social care or therapeutic settings that are attended by drug addicts. These
agencies, however, rarely provide drug specific treatment and separate data breakdowns are not available.
Outpatient: services and offers for minors
Specialised drug care agencies for minors exist in the centre and since 2007 in the north of the country.
Although drug counselling agencies accept underage treatment demanders, part of the latter are referred
to a specialised service established in the centre of the country (Solidarité Jeunes – Jongenheem asbl). 
Outpatient: substitution treatment
Substitution treatment is currently defined as a medical assisted treatment with opiods’ agonists and with
antagonists (and antagonistic agonists). The objectives of substitution and maintenance treatment are
manifold. They range from no-digressive dose, out-patient low threshold maintenance to abstinence
oriented (digressive doses) rehabilitation offers. The primary goal is the psychosocial and medical
stabilisation of the patient by replacing ‘street’ drugs by quality controlled substitution drugs. The further
development and outcome of the treatment is assessed individually. Both components, condition of the
patient and reduction of public nuisance are considered.
Substitution treatment is provided at the national level since 1989 (JDH). Until the beginning of 2001,
however, there has been no legal framework regulating drug substitution treatment. The law of 27 April
2001 modifying the basic drug law of 19 February 1973 introduced a legal framework for substitution and
maintenance treatment. The grand ducal decree of 30 January 200239 regulates the practical modalities of
substitution. The referred law regulates drug substitution treatment in general rather than it legalises a
single national substitution programme. The law does this by means of substitution treatment licenses
granted to MDs and specialised agencies, the application of training requirements for prescribing MDs and
adequate control mechanisms of multiple prescriptions (i.e. centralised register of substituted patients). It
should be stressed that following the application of the new legal framework, there still exists a structured
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39 The decree of 30 January 2002 regulating the modalities of substitution treatment can be downloaded at:
http:www.eldd.emcdda.org
substitution treatment programme (JDH - mainly liquid oral methadone provided by specialised agencies)
and a lower threshold substitution treatment offer provided by freelance state licensed MDs (MEPHENON®,
METHADICT® and SUBUTEX®). 
The grand-ducal decree of 30 January 2002 lists medicaments as well as preparations containing
methadone (liquid oral form in programme and pill form in lower threshold prescription) and buprenorphine
if the notice mentions substitution treatment as a possible therapeutic indication. Furthermore, morphine-
based (salts) medications can be prescribed if the listed substances are deemed inadequate by medical
authority. Finally, the decree allows for heroin prescription in the framework of a pilot project managed by
the Directorate of Health. The list of substitution substances may be rapidly modified by amending the
referred decree. In addition to drug prescription and medical care, the grand ducal decree on drug
substitution treatment (30/01/2002) defines a series of psychosocial counselling services to be provided
by licensed specialised centres. Licensed MDs may refer substitution patients to licensed treatment centres
for more in-depth psychosocial counselling.
A central substitution register is about to be implemented jointly by the ‘Surveillance Commission on
Substitution Treatment'40’, the national drug coordinator and involved specialised treatment centres. The
permission for its creation has been granted by the national data protection commission in June 2006 and
it has entered its test phase in November 2007. At the moment of writing, discussions have been ongoing
with the national MD association in order to find the best way to make the implementation of the
substitution register and other surveillance mechanisms compatible with daily medical practice. 
Outpatient: low threshold services and offers
Currently two agencies offer harm reduction services in the Centre, the South and the North of the country
including offers such as day and night shelter and supervised injection facilities (currently only in the
centre). A new integrated low threshold centre for drug addicts is planned to be implemented in the main
city of the South of the country.
Inpatient: detoxification services and offers 
Physical drug detoxification is provided by 5 different hospitals via their respective psychiatric units. The
most important detoxification unit implemented within a specialised department of the CHNP (15
detoxification beds) has been restructured and does not provide detoxification treatment anymore. The
‘Hôpital du Kirchberg’ has joined the list of national institutions providing detoxification treatment in 2005.
Medical interventions and psychosocial support are provided to control and reduce withdrawal symptoms in
the framework of a 1-2 week detoxification programme. Ideally, detoxificated patients are referred to more
psychotherapeutic oriented institutions. 
Detoxification treatment is provided by psychiatric units within five general hospitals: 
Clinique St. Louis – Ettelbrück (North) 
Centre Hospitalier Emile Mayrisch – HVEA (South) 
Centre Hospitalier de Luxembourg – CHL (Centre) 
Hôpital Ste. Thérèse (Centre) 
Hôpital du Kirchberg (Centre)
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40 The decree of 30 January 2002 replaces the former ‘Methadone Commission’ by the ‘Surveillance commission on substitution
treatment’ mandated to control all aspects of substitution treatment at the national level. Established in 2002, it is composed of
delegates from the programme, the Directorate of Health, two pharmacists and two GPs affiliated to the programme, and is in
charge of admissions, releases and exclusions of substitution treatment demanders or patients. The composition of the new
commission is similar to the one of the former Methadone commission.
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Inpatient: services and offers for adults
The national residential drug care centre called ‘Syrdallschlass’ (CTM-CHNP) is situated in the East of the G.
D. of Luxembourg. The therapeutic programme of the CTM is divided into three progressive phases. The
duration of a therapeutic stay varies from 3 months to 1 year.
In addition to individual and group therapies, the centre offers the opportunity to follow training activities
in several professional domains and post therapeutic accommodation facilities. The final objective is the
psychological, professional and social reintegration of treated clients. The latter is highly facilitated by the
quality of provided professional training to patients. The collaboration with several employers willing to
employ ex-drug addicts and the active involvement of social services offer a fair social and professional
framing to released patients.
The national drug action plan had foreseen the extension of CTM offers by creating a network of modular
therapeutic annexes for specific target groups as for instance pregnant women, drug addicted couples,
treatment demanders on methadone, etc. These annexes are operational since September 2002 and are
situated in the vicinity of the main centre (see map 5.1) in order to take advantage of training and social
reintegration facilities offered by the CTM. Based on past experience, the 2005-2009 drugs action plan has
foreseen the further development of these annexes. In 2008 a new annexe providing therapeutic offers to
specific target groups such as mothers with child/children or patients in the last therapy phase has become
operational on the very site of the main centre.
The CHNP runs a residential facility with a capacity of 15 beds called “mid-term unit” in the North of the
country. Its mission is defined as follows: 
• Contribute to the physical and mental stabilization of the patient after clinical detoxification.
• Supervise the patient during the period going from the clinical detoxification to the admission in therapy
or offer him a protected area to develop his project of social reintegration/rehabilitation.
• Free capacity of regional psychiatric services by admitting detoxificated patients for further care.
As the national inpatient therapeutic facilities are limited and not covering the whole spectrum of drug
related symptoms (e.g. double diagnosis) a series of patients are referred to specialised institutions abroad.
If approved, related costs are covered by the national social security schemes.
Tab. 5.1 Drug treatment abroad covered by health insurance scheme (1998-2008)
AGE GROUP 1998 2000 2002 2004 2005 2006 2007 2008 Males Females
(2008) (2008)
N N N N N N N N N % N %
< 20 years 3 5 3 3 1 5 n.a. n.a. n.a.
20 à 25 years 33 33 37 29 41 32 n.a. n.a. n.a.
> 25 years 66 63 72 89 74 86 n.a. n.a. n.a.
TOTAL 71 102 101 112 121 116 123 n.a. n.a. n.a.
Mean Age 27Y9M 28Y 28Y5M 30Y7M 30Y 30Y1M n.a. n.a. n.a.
Source : Administration du Contrôle Médical : Cures de désintoxication (drogues dures et polytoxicomanie) à l’étranger - Exercices 1996-2007
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Inpatient: services and offers for minors
A specialised residential centre for problematic youngsters has been opened in the beginning of 2007 in
the North of the country under the management of CHNP. A new project defined as a residential referral
and rehabilitation centre for minors in a rural setting is supposed to become operational in 2009. The
referred case management programme will contribute to fill current gaps in the care system for minors. 
For further information on treatment availability please consult standard table 24.
CHARACTERISTICS OF TREATED CLIENTS AND TRENDS OF CLIENTS
IN TREATMENT
Table 5.2 summarises drug related institutional contacts of PDUs. Inter-institutional multiple counts are not
excluded meaning that a given PDU could be indexed twice and more. Hence, these data do not provide
the national prevalence of PDUs but they allow following up the increase or the decrease of the latter.
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Tab. 5.2 Drug related institutional contacts (Inter-institutional multiple counting included) 
41 Including F11 F14, F16, F18 and F19 episodes with or without over night stay. Source: CNS
The present section is divided in a general description of the drug treatment population and a more in-depth
analysis of clients’ characteristics and observed trends. Both parts are based on RELIS data and on in-house
statistics of specialised drug treatment agencies at the national level. 
Overall the number of drug related contact episodes with national DR or SR agencies has reached 4,542 in
2008. Over the last decade a sensible increase in drug treatment demands has been observed (having
stabilised in 2008), whereas contacts with law enforcement agencies have been decreasing. The number of
substitution treatment demands begun to plateau around 2002. Outpatient counselling demand started to
level off (1,050) in 2007 in contrast to the number of contacts in low threshold services, having increased
and reached almost 68,000 in 2008. 4.6% (14%) of respondents are first treatment demanders, all
treatment centres included. For the first treatment demanders, the proportion of female clients is 40%
against 60% of male first clients.
Of clients in drug treatment, 72% are male against 28% females. The mean age treatment demanders has
significantly increased during the last ten years (1997: 28 years/ 2008: 31 years and 8 months) and this
mainly because of an observed increase in average male age (1997: 28Y2M/ 2008: 32Y8M). The mean age
of the female clients is consistently lower (2008: 29Y1M). Respectively 66% of clients in treatment are
natives against 34% of non-natives. The population of non-natives consists for the vast majority of
Portuguese nationals, followed by French, Italian and German citizens.
Regarding educational level of the clients in treatment, 39% have completed primary school, 59% have
completed secondary school and 1% obtained a higher degree. 50% of respondents reported stable
employment (weak decrease - 1997: 65%) against 10% who are benefiting from unemployment allocations.
Furthermore, 22% are students or engaged in a training contract. Half of indexed treatment demanders
(53%) had experiencing one or more overdose. As far as the exchange of syringes is concerned, 72%
reported that they never shared syringes. IDU combined to polydrug use (89%) is the most observed
consume pattern in drug treatment demanders.
Below is presented a more detailed analysis of treatment demands and trends according to type of
treatment:
Outpatient: services and offers for adults
RELEVANT TREND: Stabilisation of total number of clients (1,162) and decrease of first treatment rates.
Stabilisation of female treatment demanders. Increasing proportion of clients aged 30 and more and under
20 years. Currently one observes a fair increase of patients presenting for cannabis related problems in non-
specialised drug agencies. A current trend is also to be seen in the increasing number of young mothers and
child/children seeking out and inpatient treatment.
After several years of decrease, national outpatient drug counselling centres have been showing stable
admission rates over recent years and decreasing first treatment rates intra and inter-agency wide. Gender
distribution shows an overall stability over the last 10 years (2008: 29%). Age distributions are varying
according to the geographical situation of treatment centres. All in all, however, the proportion of treatment
demanders aged 30 years and more (2008: 58%) (2006: 57%) has sensibly increased during recent years
and so did the proportion of treatment demanders aged less than 20 years (9.6%) (2006 (5.6%)).
Underage clients tend to decrease until 2007 and stabilised since then, mainly because specialised agencies
for minors have been implemented meanwhile. Treatment demands for problem i.v. opiate use associated
to multiple-use is the main demand pattern and has been on the increase from 2005 to 2007 to decrease
in 2008 (2008: 53% / 2007: 57% / 2006: 51% / 1997: 72%). Cannabis-related demands have shown
a clear upward trend in 2008.The prevalence of problem cocaine use is showing a weak increase compared
to 2007 data.
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Outpatient: services and offers for minors
RELEVANT TREND: Increasing number of clients due to the development of new treatment capacities for
underage users and/or offenders.
The rate of new treatment demanders has discontinuously increased since the implementation of the
referred specialised agency. The proportion of clients aged below 14 years has increased and those aged
between 14 and 15 years have decreased since 2002. Cannabis use is the main reason of treatment
demands (69.4%) witnessing a currently stable trend. However, the use/abuse of licit drugs and polydrug
use is increasingly reported as reason of treatment. An increasing proportion of youngsters presenting
psychiatric symptoms and/or socially deviant behaviour in addition to drug abuse are reported by
specialised field agencies.
Outpatient: substitution treatment
RELEVANT TRENDS: Since 2002, stabilisation of number of patients in structured programme and in
substitution treatment prescribed by licensed MDs - stabilisation of gender ratio (2 males/ 1 female) -
Increase of substitution treatment demanders being aged 35 years+. 
The number of patients admitted to the national substitution programme has been decreasing from 2000
to 2008 (89 patients in 2008), which is supposedly due to the increasing access to lower threshold
substitution treatment provided by independent yet specially licensed MD’s. 6 % (2%) of clients are first
substitution treatment demanders. The proportion of female substitution treatment demanders (31%
stable) is higher than the proportion of female PDUs in the overall drug treatment population. 28% (29%)
of the clients in substitution treatment are aged under 30, 36% (32%) are between 30 and 39, while 36%
(40%) are over 40 years old. The mean age of clients has significantly increased over the last 10 years (36
years), which is due particularly to the steep increase of the number of treatment demanders over 35 (60%
in 2008, 33% in 2000). The proportion of native substitution treatment demanders has stabilised in recent
years (70-75%). The socio-economical situation of substituted patients is consistently more beneficial than
the one observed in other treatment demanders. 51% of substitution treatment demanders reported stable
employment against 24% who are benefiting from unemployment allocations. 38% (36%) of this group
had at least once in their lifetime committed a suicide attempt (45%) and 43% (32%) have been
experiencing one or more overdose. Polydrug use is the most observed consume pattern (92%) in
substitution treatment demanders.
The number of patients who did receive substitution treatment by prescription from independent general
practitioners also tends to stabilise [(961 patients in 2008 multiple counts excluded (2005: 970)].
The National Health Found (CNS) annually provides the number of patients receiving referred substitution
drugs on prescription as well as the number of prescribing MDs. One observes a 4-years stabilisation of low
substitution demands addressed to accredited liberal MDs and an ongoing decrease of the number of
patients choosing the official substitution programme, more demanding in terms of therapeutic constraints.  
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Table 5.3 Outpatient, low threshold prescription of substitution drugs by the national network of liberal MDs
YEAR 2000 2001 2002 2003 2004 2005 2006 2007 2008
Number of indexed patients 
(double counting controlled) 844 849 820 913 / 970 939 979 961
Number of indexed patients  
(double counting included) / / 1,487 1,554 1,553 / / / /
Number of prescribing GPs 
(double counting controlled) 145 147 157 154 158 163 121 122 126
Source : Union des Caisses de Maladie 2008
A first scientific evaluation of the structured JDH substitution programme occurred in 1995. In 1998, new
evaluation software has been developed in collaboration with the NFP, which, in the medium term, aims at
the integration of substituted patients' data directly in the RELIS database. In 2003 a third evaluation by
an external expert occurred on basis of data provided by the referred evaluation software. 
The main conclusions of the evaluation exercise (Dellucci 2003) show the following trends:
- Significant improvements of residential status, social independence of patients, occupational situation,
financial situation and indebtedness status, frequency of penal and judicial contacts, health indicators
and frequency of risk behaviours.
Outpatient: low threshold services and offers
RELEVANT TRENDS: The number of contacts indexed by low threshold agencies has increased dramatically
over the last ten years (2008: 67,494 / 2005: 47,739 / 1996: 6,456), and so has the number of syringes
distributed by the same agencies, although the number of syringes distributed has stabilised in 2005 and
subsequently even decreased (see fig. 4.2.). The proportion of new clients within low threshold settings is
on the increase. The number of female clients has been showing a weak but constant decrease but has been
showing stability for 2 years (currently 17%). Approximately 42% of clients are aged between 25 and 34
years and an increasing proportion (36%) of clients aged 35 and more is observed. 56% (56%) of clients
are natives.
Inpatient: detoxification services and offers 
RELEVANT TRENDS: Drug detoxification units throughout the country have been showing a continuous
increase regarding number of patients until 2006 (484) and a decrease to 397 in 2008. However, number
of treatment episodes have remained fairly stable between 2004 (617) and 2008 (600). Gender distribution
has remained fairly unchanged and the mean age of clients has been on the decrease for the last six years.
Multiple drug addiction, including heroin, is the main reason for detoxification demands.
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Inpatient: services and offers for adults
RELEVANT TRENDS: The number of inpatient treatment demanders (detox. excluded) appears to be stable
(126).The proportion of first treatment demands has sets around 40%.
42% (59%) of patients in residential drug treatment are simultaneously on substitution treatment. The
proportion of male treatment demanders has set around 70-75% and an increasing mean age of clients
has been observed. The referred age distribution reflects the overall trend observed in most adult drug
treatment demanders, that is, a decrease of patients under 25 and an increase of patients older than 30
years. A stabilisation is observed as to the proportion of natives within the inpatient treatment demanders.
All treatment demands are related to opiate abuse, mainly i.v.. 
Inpatient: services and offers for minors
22 clients have been admitted in the specialised residential centre for problem youngsters (CHNP-Orangerie
3). 7 clients presented substance abuse related problems. As the centre only opened in 2007 no trend data
is available thus far. The new residential referral and rehabilitation centre for minors (CHNP- Foyer
Putscheid) is not yet operational. First data may be available in 2010. 
Treatment demand according to type of involved substance(s)
Heroin as preferential substance is reported by 66% (52% i.v./ 14% non-i.v.) of drug treatment demanders
monitored by the national drug surveillance system RELIS whereas cocaine is only reported by 13% as first
substance of use (6% i.v./ 7% non-i.v.). The average age at the first use of the preferred drug figures around
14Y8M, whereas the mean age of the first i.v. consumption is 19Y6M. More than half of the clients in
treatment were injectors at the moment where they start a treatment (52.5%). 64% of the clients consume
drugs more than once a day. 
In 2008, a weak decrease in preference for intravenous heroin (1997: 60%, 2008: 52%) use was noted
compared to 2007 (54%). The heroin inhalation mode in 2007 (22%) was highest since 1998, but
decreased again in 2008 (14%). Polydrug use is the most observed consume pattern (89%). The i.v. heroin
sub-population shows the highest mean age (31Y10M) of all treatment groups. 5% of the latter are first
treatment demanders compared to 19% of non-iv heroin users.
Cocaine use as main reason of treatment demand showed a significant increase from 2004 to 2006 and
decreased again in 2007 and showed a weak increase in 2008 (13%). Mean age of preferential cocaine
using treatment demanders in 2007 was 29 years and 6 month. With 15% (7%) of first treatment
demanders, primary cocaine users show the highest lifetime first treatment rate. Cocaine prevalence as
secondary drug has decreased from 43% in 2004 to 32% in 2008. Crack neither is reported as main
problem drug nor as secondary or occasional drug.  
The percentage of treatment demands related to cannabis use has passed from 4% in 1997 to 11% in
2002, has decreased to 1% in between 2006 and 2008. Treatment demands related to ecstasy use are rare
(1-3%) and have shown a fair stability over the last years. The same comments apply to ATS use.
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6. HEALTH CORRELATES AND CONSEQUENCES   
Introduction
At the national level two drug-related deaths indexing routines do currently exist:
1. The Special Drug Unit of the Judicial Police (SPJ) maintains a register on acute drug deaths (RSPJ). The
RSPJ indexes all direct overdose cases due to illicit drug use documented by forensic evidence. As police
forces are routinely informed by medical emergency services in case of a suspected overdose case, they
are able to collect evidence at the site of the incident and confirm or not, in combination with post
mortem toxicological evidence, the suspected overdose. RSPJ applies the following definition of
acute/direct drug-related death:  
‘Lethal intoxication, voluntary, accidental or of undetermined intent, confirmed by forensic and contextual
evidence, and caused directly by the use of illicit drugs or by any other drug(s) if the victim has been
known to be a regular consumer of illicit drugs’. Death has occurred due to an adverse somatic reaction
to substance intake’.
2. The statistical department of the Directorate of Health maintains the General Mortality Register (GMR)
indexing all deaths that occurred on the national territory by means of death certificates provided by
MDs. Since 1998 the GMR applies the 10th revision of the International Classification of Diseases (ICD-
10). Special software jointly developed by the statistical department and the national focal point allows
extracting drug-related death cases from the GMR by the application of a predefined standard (e.g.
DRD)..
Both sources are independent, meaning that for the SPJ register data collection occurs via police records
and forensic evidence, while the GMR is updated according to information contained in death certificates.
Discrepancies between the referred registers mainly originate from different encoding routines (e.g. death
certificates often only mention primary cause of death) explaining the fact that the DRD v 0.3
systematically underestimates the SPJ based number of drug-related deaths as can be seen in figure 6.5.
Even though DRD based data is provided to the EMCDDA, national figures on drug induced deaths
published in the national annual drugs report is, for reasons explained above, based on the RSPJ whose
case definition is compatible with the EMCCDA definition: […] deaths that are caused directly by the
consumption of drugs of abuse. These deaths occur generally shortly after the consumption of the
substance(s). (EMCDDA)
Infectious diseases, including HIV and viral hepatitis have to be reported (notification procedure) when
diagnosed to the Directorate of Health (Ministry of Health) that compiles data and is in charge of nation
wide epidemiological follow up. These data do however not allow to breakdown infection prevalence
according to PDU status. The national drug monitoring system RELIS therefore allows to gather self-
reported data on infectious diseases in PDUs. Furthermore specific diagnosed based studies provide
complementary information. The report includes data from the latest study on infectious diseases in PDUs
(Origer & Removille, 2007) based on serological test results to assess current prevalence rates and apply
vaccination schemes when medically indicated.
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DRUG RELATED INFECTIOUS DISEASES 
HIV/Aids, viral hepatitis, STD, tuberculosis, other infectious morbiditys
Data on drug-related infectious diseases are centralised at national level. No regional data sets exist.
Official data from the national Retrovirology Laboratory of the CRP-Santé provide the number and
proportion of IDUs in HIV infected patients. Between 1984 and 2008, 882 HIV infected persons have been
registered at the national level; 115 of the former were reported IDUs, which leads to an average proportion
of IDUs in the national HIV population of 13.04 per cent since the registration of the first HIV case in
Luxembourg in 1984. 
Currently intravenous drug use appears to be the third most reported transmission mode of new HIV
infection since 1989 (homo/bisexual and heterosexual transmission are currently in first and second
position respectively). The proportion of intravenous drug use transmission has noticeably decreased
between 1998 (23%) and 2004 (5%). IDU transmission mode figured 7.35% in 2008
Figure 6.1 Proportion (%) of  IVDUs in newly infected HIV patients (1985 - 2008)  
Source : Laboratoire de Retrovirologie – CRP-Santé. 2009 (data formatting by NFP)
A recent study by Origer and Removille (2007)42 assessed the national HIV, HCV, HAV and HBV in the
population of problematic users of illicitly acquired drugs prevalence via serological test results. Furthermore
the authors performed a cross sectional analysis of the relation between the studied infections and selected
observable factors, to increase the national vaccination coverage and to refer infected persons towards
appropriated medical treatment centres. 
Eight month data collection in 2005 allowed establishing 1,167 contacts, of which 395 were conclusive and
numerous new cases of infection have been identified. It is the first study of this type ever conducted at
national level. Main results are the following:
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Tab. 6.1 Prevalence of hepatitis B surface antigens (HBsAg), antibodies to hepatitis B core antigen (anti-HBc),
hepatitis C virus (anti-HCV), and HIV (anti-HIV 1 and 2) in PDUs and ever-injectors according to national
recruitment settings 
Total number Anti-HBc and/or HBsAg* Anti-HCV Anti-HIV 1 and 2
of respondents † N‡, n (%; 95% CI) N n (%; 95% CI) N   n   (%; 95% CI)
Total sample 362 310 67 (21.6; 17.1 to 26.2) 343 245 (71.4: 66.6 to 76.2) 272 8 (2.9; 0.9 to 4.9)
Ever injectors ø 310 239 59 (24.7; 19.6 to 29.8) 268 218 (81.3; 71.4 to 91.2) 202 5 (2.5; 0.2 to 4.8)
Outpatient drug 
treatment centres 159 147 24 (16.3: 10.3 to 22.3) 158 92 (58.2: 50.5 to 65.9) 158 3 (1.9; 0.0 to 4.0)
Impatient drug 61 53 8 (15.1; 5.5 to 24.7) 61 46 (75.4; 64.6 to 86.2) 49 0 (0.0; 0.0 to 0.0)
treatment centres
Prisons 135 110 35 (31.8; 23.1 to 40.5) 124 107 (86.3; 80.2 to 92.3) 65 5 (7.7; 1,2 to 14.2)
* Two respondents with valid blood test serology were HBsAg positive only
† Number of respondents for whom valid blood test serology for at least one infection (HBV, HCV or HIV) was available 
‡ Number of respondents for whom valid blood test serology for HBV was available
ø Respondents that have injected at least once in their lifetime a drug for non therapeutic reasons
source: Origer, A. & Removille, N. (2007)
Concerning HAV prevalence, no case has been identified in the referred study. It should be stressed,
however, that 43% of the participating PDUs were not protected against hepatitis A. 
Among persons infected by HCV, HBV and HIV, respectively 96%, 95.2% and 71.4% are ever injectors. The
highest prevalence rates were observed among the prison population. This has to be confronted to the fact
that 56.1% of the respondents with current or past prison experience (N: 246) declare having consumed
illicit drugs in prison whereof 54.3% report intravenous use during detention. Among these lifetime
injectors in prison 20% reported exclusive use of new and sterile syringes, 53.3% declared never having
exchanged syringes with other inmates and 26.7% report syringes’ exchange in prison. 
The study also refers to a series of determinants such as, inefficient disinfection methods such as cleaning
injection paraphernalia with water or urine, inadequate syringe elimination, a high proportion of PDUs not
using condoms during sexual intercourse, especially with new partners or irregular partners, the lack of or
false knowledge of serological status and finally, protection strategies based on subjective criteria rather
than on established knowledge.
Although strategies for risk reduction in the population of problematic drug users in the G.- D. of
Luxembourg exist, this study underlines the high prevalence of certain infectious diseases in the target
group and in particular hepatitis C (HCV). 
Since 1996, the national drug monitoring system RELIS allows for breakdowns of HIV and AIDS data by IDU
and treatment status. In 2008, (N=678) 84% of RELIS indexed PDUs reported a HIV test during the last 5
months. The testing rates of female PDUs were equal to those of male PDUs.
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Table 6.2 Synopsis of national data on HIV infection rate in drug using populations (valid %)
YEAR 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
HIV rate in problem drug users 
(RELIS self-report) 2.9 2.9 4.3 4.07 4.49 3.88 3.98 3.31 2.9 3.39 3.82
HIV rate in problem drug users
(serology-based) 
(Origer & Removille, 2007) 2.90 / / /
HIV rate in drug treatment demanders 
(RELIS self-report) 2.6 3.4 4.87 4.78 4.32 3.88 4.93 3.84 3.49 4.13 2.96
HIV rate in current IDUs 
(RELIS self-rep.) 3.5 3.3 3.6 3.41 4.08 4.17 5.10 3.96 2.76 3.48 1.75
HIV rate in current IVDUs treatment 
demanders (RELIS self-report) 3.4 3.9 3.9 4.24 4.32 4.24 6.41 4.59 3.33 4.27 0.76
HIV rate in life-time IVDUs
(serology-based)
(Origer & Removille, 2007) 2.50 / / /
HIV rate in current IVDUs 
prisoners (Schlink 1998) 4.4 / / / / / / / / / /
Source: RELIS 2008
Table 6.3 Synopsis of national data on AIDS rate in drug using populations (valid %)  
YEAR 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
AIDS rate in problem drug
users (RELIS) 2.5 1.25 1.35 2.03 1.72 1.71 2.13 1.81 1.19 1.86 0.87
AIDS rate in drug treatment 
demanders / 1.66 1.76 2.43 1.60 2.04 2.69 2.37 1.65 2.64 0.92
Source: RELIS 2008
HIV rates in current PDUs have been varying over the last ten years although in quite narrow margins
figuring 3 to 4%.The prevalence of HBV infection in problem drug users has been showing a decreasing
tendency during recent years based on self-reported data. The results provided by Origer and Removille
(2007) study based on blood sample provide slightly higher yet consistent rates in PDUs. The significant
increase of the HCV infection rate during the same period is particularly marked in IDUs, figuring 64.94%
to 81% according to risk groups (current, ever -injectors) and applied methodologies (self-reports vs. blood
tests). There are, however current signs of stabilisation. As far as co-infections are concerned and according
to data from the Origer and Removille study, 2.8% of respondents showed HBVxHIV and HBVxHCV acute
infections respectively, and 4.7% were simultaneously infected by HIV and HCV.
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Table 6.4 Synopsis of national data on self-reported HBV infection rates in drug using populations (valid %) 
YEAR 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
HBV rate in drug users  
(RELIS self-report) 30 30 28 25 22 20.51 21.34 18.67 17.21 17.81 16.14
HBV rate in PDUs
(Origer & Removille) 21.6
HBV rate in drug   
treatment demanders  
(RELIS self-report) 27 32 27 24 20 19.79 22.69 18.58 16.46 17.95 14.68
HBV rate in IVDUs
(RELIS self-reports) 33 35 30 30 25 22.76 23.93 20.08 18.32 20.16
HBV rate in ever-injectors
(Origer & Removille) 24.7
Source: RELIS 2008
Table 6.5 Synopsis of national data on HCV infection rate in drug using populations (valid %)) 
ANNEE 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Self-reported HCV rate 
in drug users (RELIS) 25 32 46 50 49 59.92 64.55 64.94 64.95 64.06 63.39
HCV rate in PDUs
(Origer & Removille) 71.40
Self-reported HCV rate   
in drug treatment 
demanders 29 41 53 54 54 60.49 66.16 66.22 63.23 63.08 61.11
HCV rate in IVDUs 
prisoners (saliva tests) 37 / / / / / / /
Self reported HVC rate
in IVDUs (RELIS) 45 50 53 56 53 67.97 74.14 74.38 69.58 72.02 65.48
HBV rate in ever-injectors
(Origer & Removille) 81
Source: RELIS 2008 (Origer & Removille 2007)
Summarily, HBV infection prevalence in PDUs and in drug treatment demanders is fairly stable and HCV
prevalence in PDUs appears to have reached a plateau at a high level. HIV infection rates show a decrease
especially referred to IDUs in treatment settings. This decrease is fairly remarkable in 2008 and has to be
monitored over coming years to determine whether this is a trend or just an annual variation.
The existing prevention efforts have to be completed putting particular emphasis on young and new drug
users. Although the study confirms a low compliance of the target population, screening and vaccination
facilities have to be further developed. In this context the authors put forward a series of approaches that
may contribute to reduce incidence of infectious diseases and related risks in PDUs (see Origer, Removille,
2007).
The DIMPS project (Mobile intervention facility for sexual health) described under chapter 7 aims to access
difficult to reach sub-populations and provide prevention counselling and infectious disease testing on site
to various populations. Based on experience gathered trough the new DIMPS project, discussions are
currently hold whether to extend the DIMPS offer to free HBV/HAV vaccination (where appropriate) for
clients of specialised drug agencies. This enlarged approach could also allow to collect serological based
data on infectious diseases in PDUs in a routine and cost effective way.
2
0
0
9
87
NATIONAL REPORT TO THE EMCDDA
“GRAND DUCHY OF LUXEMBOURG”
New Developments, Trends and in-depth
Information on selected issues
OTHER DRUG-RELATED HEALTH CORRELATES AND CONSEQUENCES
Psychiatric co-morbidity (Dual diagnosis)
To date any genuine study on co-morbidity patterns in PDUs has been performed at the national level. Data
presented in the present chapter have been provided by specialised drug agencies and the RELIS drug
monitoring system and thus reflect experiences and trends as observed during recent years.
Most common mental disorders observed in clients seeking help in specialised drug agencies or in contact
with other institutions are: anxiety, depression, neurosis, psychosis and borderline behaviour. Residential
drug care settings estimate that 10% of their clients show psychotic symptoms. Furthermore, Post Traumatic
Stress Disorders (PTSD) are most common and show great similarities with border-line behavioural aspects
as for instance rapidly changing mood and auto-destructive tendencies.
According to annual data provided by the national drug monitoring system RELIS the following picture can
be drawn:
Figure 6.2 Previous contacts with psychiatric services. 1998- 2008
Source: RELIS 2008
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Figure 6.3 Reasons for psychiatric care demands 1996-2008
Source: RELIS 2008
Figure 6.2 differentiates between all contacts with psychiatric services and psychiatric contacts excluding
detoxification. This distinction is necessary since, at the national level, most of detoxification treatments are
provided by psychiatric departments of general hospitals.
Data from 1996 to 2008 reveal a fluctuating but a fairly stable long term proportion of PDUs showing a
psychiatric history, unlike the proportion of clients reporting contacts for mental problems excluding
detoxification treatment, which has been following an increasing trend if compared to what happened in
the end of the nineties although stabilised around 40% since 2004. 
There seem to be no significant differences of psychiatric profiles in clients according to the type of
institutional settings. Multiple drug use is observed in almost all DD patients.
DD patients are considered as drug treatment demanders with specific and highly diversified needs that are
difficult to encounter within traditional drug care agencies. The concept of ‘multiple vulnerabilities’, that is,
concomitant vulnerabilities to drug abuse and mental disorders, tends to be recognised by professionals.
DD patients very often present a lack of behavioural structure or stability. Usually those patients are unable
to function in a regulated environment. Moreover, the requirement of most therapeutic settings include that
the patients submit to detoxification treatment prior to admission. This latter requirement is often
impossible to meet with DD clients as drug intake often represent a kind of self-managed auto-medication,
dangerous to change radically at the beginning of a therapeutic process. It is therefore most difficult to
integrate DD patients in traditional drug care settings also in terms of consistency of rules to be respected
by all drug treatment demanders. Since to date there exist no care facilities specialised in drug addiction
co-morbidity at the national level, the Department of Medical Control of Social Security Administration, in
collaboration with drug agencies, assesses whether a given patient should be referred to specialised
institutions in foreign countries. There exist agreements between the latter administration and a series of
specialised care agencies abroad. If the referral demand is approved, related costs are reimbursed by Social
Security.  
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As far as treatment of DD patients in prison is concerned a collaboration convention between the national
prison administration (CPL) and the national neuro-psychiatric hospital (CHNP) has been signed in 2002.
The convention sets the framework for the creation of a psycho-medical department within prison and
regulates prevention, care and referral of mentally disabled as well as alcohol and drug dependent inmates.
Therapeutic care, substitution treatment and counselling is provided ad hoc. In case of severe mental
disorders, imprisoned patients are referred to a high security department within the CHNP.
Compulsory treatment or confinement does only occur if there is a proved offence against the law by which
the offender is declared irresponsible of his/her own behaviour. This only occurs following a legal psychiatric
expertise. 
In line with the recommendations of the previously referred to expert group ‘Therapeutic chain’ discussions
held in the framework of the new drugs action plan 2010-2014 currently address the idea to create small
supervised housing facilities where care is provided to DD patients on a case management basis.
Somatic co-morbidity
Health indicators retained by RELIS suggest a stabilisation of the general health state of indexed PDUs
except for HCV prevalence. In 2008, 81 (82) per cent of problem drug users reported a self-perceived
satisfying general health condition against 53 per cent in 1997. Half of indexed PDUs report single or
multiple suicide attempt(s) and 43 (48) per cent report non-fatal overdose(s) during lifetime. No significant
changes have been observed during the last 6 years. 
Drugs and driving
Figure 6.4 provides data on cannabis exposure of persons involved in traffic accidents from 1995 to 2007
(2008 data not available). Around 40% of tested persons were positive on cannabinoids (which doesn’t
mean that the effect of the latter necessarily caused the accident). This proportion has remained fairly
stable over last years.
Fig. 6.4 Detection of cannabinoids - Traffic accidents (1995 - 2007) 
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Pregnancies and children born to drug users
See sub-chapter at-risk families in chapter 3.
DRUG RELATED DEATHS AND MORTALITY OF DRUG USERS
Direct Overdoses and indirect drug related deaths (see ST5 and 6)
Figure 6.5 Evolution of drug-related death cases (direct - indirect - total mortality) from 1990 to 2008 (Origer 2009)  
As can be seen in figure 6.5 the DRD v. 3.0 standard (selection B) appears to be a fairly weak proxy of direct,
indirect and total drug deaths as indexed nationally by the RSPJ. Overall drug related mortality, however,
should not be assessed by the same standard as far as Luxembourg is concerned. A very high to perfect
agreement is observed between the RSPJ register and selection D (DRD v.3.0).
The number of fatal acute overdoses indexed at the national level has shown an overall discontinuous
decrease since the beginning of the 21st century. In 2000, 26 acute drug deaths were registered whereas
10 cases were reported in 2008. Indirect drug-related deaths have known broad variations in number during
the same period. These trends appear to be consistent with latest developments in most other EU Member
states. 
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Figure 6.6 Evolution of drug-related mortality rates (direct - indirect - total mortality) per 100,000 inhabitants aged 15
to 64 from 1990 to 2008 (Origer 2009)
Confronted to most recent national prevalence figures on problem drug users referring to data of 2007 (N
= 2.470), (Origer 2009), overdose rate in PDUs situates at 0.4 % cases / PDU (1.1 % in 2000). Referred
to the total number of drug-related deaths, indexed by national law enforcement agencies and forensic
institutes, the same proportion shows weaker variations: 0.8% in 2008, 1.346% in 2000, and 1.333% in
1997. The overdose rate in the national general population figured 6.43 overdose deaths per 100,000
inhabitants43 in 2000. In 2008 overdose rates of 2.07 and 3.04 per 100.000 inhabitants and 100.000
inhabitants aged 15 to 64 years respectively have been observed. International comparison should be
considered with caution since methodologies used to determining prevalence of DRD deaths are not
necessary comparable throughout EU as shows for instance by the structural underestimation of the number
of acute drug death based on the EDMCDDA DRD v.3 standard. 
The overall discontinuous decrease of acute overdose cases from 1994 onwards has been associated to the
regionalisation and extension of the methadone substitution programme as well as to the further
development of low threshold facilities. The decreasing trend from 2000 to 2002 is thought to be a medium
term consequence of the higher proportion of non-i.v. opiate users observed during that same period
followed by a stabilisation around 4.5 percent. The positive evolution of direct drug deaths is to be
associated to the implementation of a drug consumption room in 2005. Considering that since the opening
in 2005 of the drugs injection room more than 300 overdose victims could be assisted and reanimated in
this same facility, the life-saving effectiveness of such an offer is proven.
A retrospective study (1992-2006) on drug-related death cases performed in 2007 allowed a better
understanding of risk and protective factors (Origer, 2008).
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Forensic data by the department of National Toxicology Laboratory on Health44 show that the most
frequently involved substance in overdose cases is heroin, followed by methadone and cocaine. To stress that
since 2000, methadone presence in blood samples of overdose victims has been increasing.
The vast majority of victims are male (83%) and their mean age at the moment of death shows an
important increase over the past 15 years (in 1992: 28.4 years and in 2008: 33.16 years). Although the
mean age of drug overdose victims has been increasing, the number of victims aged less than 20 years
remains relatively unchanged during the referred observation period.
Also worth mentioning is that a majority of acute drug death victims are known by law enforcement
agencies (75%) for their drug user ‘career’, which lasts for 10 years (in average). Furthermore over 80% of
the known victims made at least one treatment before their death and half of the victims had an
accommodation that could be qualified as stable. As far as the place of death is concerned, since 2004
approximately 50% occurred at the victims’ home, followed by public place and detention centre. 
Figure 6.7 Gender distribution of direct drug-related death cases (1992 - 2008) (%)
Source: RELIS 2008
Table 6.6. Age distribution of direct drug death cases indexed from 1992 to 2008
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40-44 2 2 2 1 2 3 2 1 1 3 2 1 22
45-49 1 1 2 2 1 1 1 9
≥ 50 1 1 1 1 4
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In 2008, the mean age of female overdose victims is surprisingly similar to the age of male victims, which
may, however, be due to the small number (statistically speaking) of cases. The youngest victim was aged
21 years and 6 months and the oldest reached 44 years and 5 months. No underage victims were reported
in 2008. Considering the nationality of overdose victims, 80% were natives. During the entire observation
period Portuguese citizens stand in second place, followed by Italian and French residents. Recently, one
could observe an increasing number of victims from the frontier zone (BE, DE, F) and a decreasing number
of victims of Portuguese origin.
For more detailed data on 2008 drug related deaths please refer to standard tables 5 and 6.
Mortality and causes of deaths among drug users
In terms of drug-related mortality (direct and indirect deaths indexed by RSPJ), 20 cases have been indexed
in 2008 (38 in 2007); prevalence has been showing fair variations since 1996, figuring roughly 17 to 38
cases per year.
The above mentioned study (Origer & Dellucci 2002)45, has revealed that, as far as the Grand-Duchy of
Luxembourg is concerned, the mere application of the DRD standard does not allow for a valid computation
of drug related death cases. Therefore, the authors did compute the total number of drug-related deaths by
adding cases of the SR that were not indexed by the application of the DRD standard to the GMR. The
figures resulting from corrected DRD v.3.0. data are referred to as ‘national selection’ and provide the
annual total number of controlled drug-related fatalities at the national level [20 in 2008 of which 10
direct/acute death cases (17 & 8 in 2005)]. 
In 2000, a first cohort study on the mortality in the national drug population has been performed by the
NFP in the framework of a multi-methods prevalence study (Origer & Pauly 2000). The cohort included 242
opiate drug addicts followed from 1991 to 1999. Mortality data have been collected from treatment
agencies, the RELIS database, the GMR and the Special Overdose Register of the SPJ. In accordance to
applied methodologies, results show mortality rates varying between 2.36 and 2.51 per cent.
Since the implementation of ICD-10 coding by the GMR (1998), a vast majority of acute drug death cases
have been recorded as ‘accidental poisoning’ (X40 – X49), which is consistent with the national definition
of an acute overdose death. To date over 60 % overdose cases have been indexed as follows: X42.-, T40.-,
T42.- T43.- . At a more restricted level the code sequence: X42.-, T40.- includes around 70% of all reported
overdoses.
Main causes of indirect deaths between 1996 and 2008 are, in order of importance: suicide (32%)46, traffic
accidents (22%), associated cardio-vascular or pulmonary complications (15%) undefined intoxication
(11%), pharmaco-dependance (7%), liver failure (6%), HIV/AIDS (4%) and other (2%). 
94
45 A full text version of the study can be downloaded under: http://www.relis.lu
46 Valid percentage
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7. RESPONSES TO HEALTH CORRELATES AND
CONSEQUENCES
Introduction
Responses to health correlates and consequences of drug use aim at minimising the resulting damage on the drug
users him/herself and on his/her environment and at increasing individual/collective resources. The concept of risk
and harm reduction is directly linked to health consequences of drug use, whereas nuisance reduction is seen as a
correlate of the latter.
Health care offers to drug users are provided by specialised drug care agencies as well as by the general health care
system. Major efforts have been undertaken in recent years to improve data on drug treatment demands from
general healthcare providers by including psychiatric departments of general hospitals in the RELIS data collection
network and the pilot implementation of a national substitution treatment register. In addition to the national drug
surveillance system RELIS, these new data sources and tools will allow to draw a more accurate picture of
intervention outcomes.
In May 2006 a new national HIV/AIDS action plan (MH 2006) covering the period 2006 to 2010 has been
launched by the Ministry of Health. The action plan is based on 8 pillars including prevention of infectious diseases
and harm reduction in drug using populations. It complements or enhances measures included in the national drugs
action plan 2005 – 2009. The document can be downloaded under http://www.ms.etat.lu
As far as availability of service is concerned, currently two agencies offer harm reduction services in the Centre, the
South and the North of the country including offers such as day and night shelter and supervised injection facilities
(currently only in Luxembourg City). The governmental programme 2010-2014 foresees the decentralisation of
respective offers by implementing new integrated low threshold centres for drug addicts in the South and the North
of the country
PREVENTION OF DRUG RELATED EMERGENCIES AND REDUCTION
OF DRUG RELATED DEATHS
Research and recommendations         
In the framework of the first national drugs action plan 1999-2004 foundations have been laid for a
comprehensive nation-wide strategy for the reduction of health consequences of drug use. A specific study
(Origer & Dellucci 2002) has been addressing the issue of the reduction of drug related mortality. The
following recommendations have been retained:
1. Opening of supervised injection rooms according to the national drugs action plan.
2. Medical controlled heroin distribution programme (foreseen by the national drugs action plan). 
3. First aid training courses provided to users and their relatives and partners. 
4. Gender and ethnic specific interventions.
5. Provision of morphine receptor antagonists to users and selected persons (5).
6. Creation of  ‘transition centres’ for ex or current PDUs leaving institutional settings. 
7. Development of reintegration programmes for prisoners in the framework of the recent ‘Global care
programme for drug addicts in prison’. 
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Drug injection room and low threshold shelters     
A drug injection room is defined as a facility allowing IDUs who meet certain criteria to inject their own
drugs in a medically supervised environment. Drug consumption (user) rooms meet the same definition; in
terms of target population, they, however, give access to IDUs and non IDUs meeting the admission criteria.
Articles 2 and 3 of the law of 27 April 2001 have set the legal framework for ‘user rooms and other means
duly licensed by State’, which also includes controlled distribution of certain narcotics (e.g. heroin). 
The implementation of a drug injection room has to be seen as a part of a broader harm and nuisance
reduction oriented strategy. The national drug action plan refers to the creation of low threshold emergency
shelter facilities for drug addicts to be implemented regionally. These centres do include day and night
shelter as well as a supervised drug injection room. 
A low threshold emergency centre for drug addicts (TOXIN) was inaugurated in December 2003 and initially
provided day care and night shelter. In July 2005, the first injection room at national level has become
operational and has been integrated in the TOXIN centre which from then on has been providing the whole
range of harm reduction services, counselling facilities, accommodation, washing, laundering and storing
facilities. It should be added that the night accommodation is not to be seen as a permanent housing
facility; there is indeed a daily admission procedure. Target population for the consumption room are
primarily IDUs. Inhalers might be admitted in a second phase. The main objective of the project is the
reduction of drug-related harm and nuisances. More precisely it aims at reducing the risks of infectious
diseases, overdoses and public nuisance in the neighbourhood, contact making with difficult to reach
addicts, provision of special designed night shelter facilities and avoiding unnecessary prison journeys over
night. The project was designed with the support of law enforcement agencies. 
The national drugs coordinator’s office elaborated the operational concept of the injection room based on
available international experience and evaluations. In terms of management, all involved parties meet once
a month (called ’the Monday round’) to assess the current situation and emerging problems related to the
functioning of the consumption room. Incidents, nuisance reports, trends, quality assurance, workload,
technical improvements and safety issues are addressed by the ‘Monday round’ in order to promote rapid
solution finding and continuous adaptation to fast changing clients’ profile and consume patterns. 
Table 7.1 provides an insight in clients’ and occupation statistics of the TOXIN services since their opening
and during 2008 respectively:
Tab 7.1 Clients statistics of TOXIN centre services
Injection Room June 2005 - June 2009 2008 exclusively
Number of user contracts 745 208
Number of users 63,359 24,700
Number of injections 75,001 29,787
Number of non-fatal overdoses
With loss of consciousness 53 29
Without loss of consciousness 257 119
Number of fatal overdoses 0 0
Medical emergency interventions 52 23
Day care December 2003 – June 2009 2008
Number of clients 164,858 53,053
Night shelter December 2003 – June 2009 2008
Number of residents 75,737 14,44
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Opening hours are currently from 3 pm to 10 pm 7 days a week with a capacity of 42 beds and 7 injection
tables.TOXIN facilities are mostly used by men (79%); the most commonly used drugs were heroin (83%),
cocaine (12%) or both of them (4%); age category 25-34 is most represented (50%). 
No fatal overdose has occurred thus far but over 300 overdoses have occurred and due to the immediate
intervention of ad hoc staff all victims could be assisted, reanimated and their live saved. The drug scene of
Luxembourg-City adheres to a great extend to the TOXIN concept with the positive effect that public
nuisance has significantly decreased. The current situation is also due to the fact that surveillance cameras
were installed in the referred area and a large number of abandoned houses were destroyed or closed,
reducing the urban life environment of drug users. The increasing number of users attracted by the TOXIN
services poses however an emerging problem of clients’ management given the fact that the container
structure was meant to be of provisional use and is currently reaching the limits of its capacity. A permanent
centre is planned to be constructed in the same area. The Ministry of Public Works jointly with the Ministry
of Health has finalised architectural plans in 2007. The City of Luxembourg has finally granted the
authorisation to build in September 2009. 
The concept of the drug injection room can be ordered at the Ministry of Health (alain.origer@ms.etat.lu).
As most relevant drug scenes concentrate in the City of Luxembourg and in the main city in the South of
the country, Esch-sur-Alzette, discussions are currently ongoing with the community council of Esch/A in
order to implement a similar facility in the latter city. The aim is to further decentralise low threshold offers
and enhance local city authorities’ commitment in the management of regional and urban drug problems.
Involved national and local authorities have recently found an agreement on the geographical location of
this facility although the concept has still to be agreed on. A broad political consensus exists as far as the
need of rationalised drug intervention strategies is concerned. This was recently confirmed by the fact that
a special paragraph was dedicated to this issue in the new governmental programme for the years 2009 to
2014. 
The law of 27 April 2001 introduced an important modification of the basic drug law with regard to
overdose prevention. Art.10-1 of the referred law exempts drug users who call for assistance in case another
user is in need of medical help, from prison sentences and from fines in certain circumstances. In general,
witnesses meeting these conditions are not prosecuted. The primary aim of this measure is to reduce drug-
related deaths occurring in consumer couples and groups. Moreover the ICD has put on its agenda the
implications of routine police forces’ on site presence in case of a reported and/or suspected overdose case.
As a result a new information flyer has been elaborated jointly with field agencies and the Ministry of
Health. The flyer contains useful information on safer injection and advice in case of overdose events. To
further reduce the risk of overdose the department of health has granted a market authorisation for the
national prescription of Suboxone ® (buprenorphine & naloxone) in the framework of the national
substitution programme. However, prescription of Suboxone ® remains fairly rare.
Based on the outcomes of the study (Origer & Dellucci 2002), the retrospective study (Origer, 2008) and a
related analysis performed by drug field agencies (COCSIT) jointly with the Ministry of Health, a series of
measures are to be further developed, such as information and peer education of drug users, ban multiple
prescriptions of substitution drugs and consider interaction of substitution treatment and concomitant and
persistent street drug use, ensuring through-care especially for persons with drug careers leaving prison or
residential treatment.
Heroin assisted treatment (HAT)
The future implementation of a medically controlled heroin distribution programme, as foreseen by the
national drugs action plan 2005-2009, will further contribute to reduce drug related health damage. As far
as the latter is concerned the Inter-ministerial Group on Drugs agreed on the opportunity of a national
heroin distribution programme in September 2007 and the national drugs coordinator has submitted a
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feasibility study and an operational framework concept, elaborated jointly with national experts and partly
inspired by the Swiss guidelines on Heroin Assisted Treatment (Bundesamt für Gesundheit, 2006), to the
Minister of Health in May 2008. The main conclusions of the concept report (Origer 2008) are the
following:
- The opportunity and feasibility of the conditional setting up of a controlled heroin distribution program (CHDP)
in the Grand-Duchy of Luxembourg is given.
- The CHDP is to be seen as a high threshold offer. It is aimed at a limited group of heroin addicts, notably
because of the multiple inherent constraints.
- The primary objectives of the CHDP are the improvement of the physical and mental health state of the
beneficiaries, the reduction of the risks and damages for the drug(s) user, the access to “out-of-treatment” target
groups for which existing offers are not adapted or attractive, the reduction of the public damages and the
reduction of the delinquency and the criminality associated to drug use. 
- There exists a consensus to qualify the controlled heroin distribution programme as an offer of high threshold,
which should be implemented within the general framework of the substitution treatment rather than in existing
low threshold offers. Also, the creation of one or more substitution centre, which additionally to the traditional
substitution offer includes controlled heroin distribution, is seen as a recommendable option.
- Diacetylmorphine (heroin) can be prescribed in injectable form, as tablets or for inhalation (in a second phase)
depending on the medical and contextual indications.
- Instead of considering selection criteria for the admission to the CHDP, a catalogue of ‘evaluating factors for the
opportunity of a heroin treatment’ has been elaborated. These factors have to be weighted according to their
respective importance or pertinence at the moment of admission in order to assess the situation of each
treatment demander in a holistic approach. The referred decision process, however, may also require that
retained factors must be submitted to an explicit definition of tolerance margins.
- A commission for admission and supervision of the CHDP (CAS) will be established. The CAS assesses admission
opportunity to the programme for each demander. The CAS also has to insure compliance of the programme
functioning conditions to the approved concept and respective legal constraints. The CAS follows up the
evolution of the heroin treatment programmes at the international level and advices the Ministry of Health in
case of need. 
- The CHDP is conceived as a pilot project of 2 years followed by a comprehensive evaluation.
- The evaluation of the CHDP includes two parts, namely the evaluation of operational aspects of the programme
and the evaluation of its impact. The outcome of this evaluation will decide upon continuation of the
programme and possible adaptations.
A drug scene survey was performed in 2008 (JDH 2009) in order to investigate perceptions and opinions
regarding the implementation of HAT. 174 drug users in contact with drug care institutions of different
kinds were interviewed by using a standardised questionnaire. 85% of respondents consider HAT to be a
useful complementary offer for the following reasons (in order of importance): reduction of criminality and
petty crime, clean quality controlled heroin, reduction of drug related mortality, social stabilisation and
reduction of harm and health damage. 62% of interviewees declared themselves to be personally interested
to enter HAT if available.
By the time of writing the HAT concept was approved by all nationally involved parties, a provisional budget
has been set and agreement was reached with a specialised agency in terms of future management of the
programmes. First resources are foreseen to be allocated in 2010 and the pilot phase of HAT
implementation should start in 2011.
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New specialised care structures foreseen in the framework of the 2010-14 action plan     
The lack of national detoxification capacities has become a growing problem in the drug care network in
recent years. According to international standards the number of detoxification slots in general hospitals
revealed to be sufficient however waiting lists of new treatment demanders became consistently longer. A
reason for this has to be seen in existing gaps in the preparation of drug related hospitalisations and during
the release phase. In this respect, two new projects will be adressed in the new drug action plan. 
The first refers to the set up of a so called diagnostic, referral and follow-up mechanism (DDOS). The main
idea is to attribute a single reference person (social worker freely chosen by the treatment demander) to
each treatment demander. This reference person organises together with the patient and care institutions
treatment interventions, follows up progression and guarantees access after-care offers. The reference
person also represents a single contact person for involved care institutions. Furthermore, in order to allow
hospitals and psychiatric department to concentrate their efforts to interventions for which they are
competent, mainly medical care and withdrawal, to reduce relapses and after release overdoses, a
stabilisation unit will be created with a capacity of 12 beds and a maximum stay of 3 weeks. The referred
unit aims at stabilising recently detoxificated persons by providing them with necessary medical care and
by offering them a safe environment to start their re-integration process.
PREVENTION AND TREATMENT OF DRUG-RELATED INFECTIOUS
DISEASES
Prevention
Interventions aiming at the prevention of drug-related infectious diseases have been initiated and
developed prior to the set up of a proper legal framework. At that time, services as needle exchange and
substitution programmes have been tolerated and also financed by the state. The last drug law amendment
did not only allow maintaining and to further developing existing harm reduction offers but also set the
first stone for the implementation of new services such as shooting galleries and medically assisted heroin
distribution as foreseen by the national drugs action plan.
The objective of these interventions is straightforward, that is an optimised management of risk factors and
mental/physical damage associated to drug use. Reduction of public nuisance is a secondary objective.
Traditionally harm reduction (HR) measures have been focusing on IDUs since most exposed to a variety of
health risks. Nevertheless, initiatives such as the provision of aluminium foils to heroin users and the current
discussion on the future distribution of ‘strawbags41’ for sniffing purposes witness a progressive switch from
IDUs users to PDUs being considered as target groups. Furthermore infectious diseases prevention does not
focus specifically on IDUs as shows a recent action-research project on HIV and hepatitis infection among
PDUs (Origer & Removille, 2007).Interventions aiming at the prevention of drug-related infectious diseases
as for instance needle exchange and substitution programmes have been initiated and developed prior to
the set up of a specific legal framework. The last drug law amendment (2001) did not only allow
maintaining and to further developing existing harm reduction offers but also set the foundation for the
implementation of new services such as supervised drug injection rooms and medically assisted heroin
distribution as foreseen by the national drugs action plan.
The objective of these interventions is straightforward, that is an optimised management of risk factors and
mental/physical damage associated to drug use. Reduction of public nuisance is a secondary objective.
Traditionally harm reduction (HR) measures have been focusing on IDUs since most exposed to a variety of
health risks. Nevertheless, initiatives such as the provision of aluminium foils to heroin users and the current
discussion on the creation of a drug inhalation facility in the new TOXIN centre shows the switch from IDUs
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users to PDUs being considered as target groups. Furthermore infectious diseases prevention does not focus
specifically on IDUs as shows a recent action-research project on HIV and hepatitis infection among PDUs
(Origer & Removille, 2007).
The most relevant measure in the field of prevention of infectious diseases in drug users is the national
needle exchange programme established in 1993 and co-ordinated by JDH. In addition to free of charge
needle provision by specialised drug and AIDS agencies, automatic syringes dispensers/collectors have
been placed in the most appropriate locations in five different cities of the Grand Duchy. Regarding the
quantity of distributed syringes, table 7.2 shows that the number of distributed syringes stabilised in 2005
and has been significantly decreasing from 2006 onwards although the return rate continues to increase.
The possible reasons for these trends have been addressed by a special national working group. The
hypothesis that syringes are increasingly acquired via out of NSP providers (e.g. pharmacies) could not be
confirmed since over the last five years the proportion of syringes distributed by NSP points have increased
in comparison to other providers. Following factors may have influenced distribution patterns: 
- relocation of the main drug counselling centre in Luxembourg city in 2006 and provision gaps due to it,
- intensive presence of the police at proximity of the railway station and in the direct environments of the Drop-
In service,
- the syringes distributed to the clients of the consumption room were not included in the national statistics until
2008
- the service K28 notices an increase of the distribution of aluminium sheets in 2007 (07 : 1.204/06 : 766) ; a
renewed outbreak/upsurge of the consumption mode by inhalation is however not confirmed by the other
services,
- the quality of the drugs on the illicit market widely influences the consumption behaviours and the injection
frequency,
- the fact of having introduced a new type of syringes (where the needle is more solid) might have had as result
that the same consumer uses the same syringe several times.
It is estimated, in reference to self-reported data on syringe provision from RELIS respondents, that one third
of IDUs procure their syringes primarily in pharmacies. This proportion has remained fairly stable over recent
years and do not directly impact on the decreasing figures from specialised needle exchange points.
Table 7.2 National needle exchange programme 1996-2008
Distributed syringes Collected used syringes
1996 1998 2000 2002 2004 2006 2008 1996 1998 2000 2002 2004 2006 2008
TOTAL 76,259 109,743 189,413 254,596 435,078 332,347 259,607 28,646 58,886 112,625 211,621 376,491 282,909 ~249,400
(38%) (46%) (59%) (83%) (87%) (93%) ~(96%)
Source: RELIS 2008
Quality assurance and follow-up of injection paraphernalia on the market is ensured by a special expert
group chaired by the national Drugs Coordinator. Although no mandatory guidelines have been submitted
to specialised SEPs the latter do generally agree on common standards according to recommendations of
the expert group.
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Moreover, outreach interventions targeted at (drug using) sexworkers aiming to establish contact and to
prevent dissemination of infectious diseases have taken place. According to EMCDDA’s key indicators and
with a view to improve quality of national data on infectious diseases, the NFP has set up an action-research
with the objective to estimate HCV and HIV prevalence in PDUs based on medical diagnosis data (blood
testing) and to implement required health care infrastructures (Origer & Removille, 2007). 
The project relied upon a cross-sectional study design, which analysed the relationship between the
prevalence of hepatitis A, B, C and of HIV in the population of drug users with other relevant factors.
Additionally a quantitative questionnaire (questions based on socio-demographic, illicitly acquired drugs
consumption, consume patterns, sexual behaviour, consumption in prison, piercing/tattoo) allowed
analysing associated factors. Serological analysis identified the number of contaminated cases with
hepatitis A, B, C and HIV. In case of medical indication a vaccination against hepatitis A and/or B has been
offered. Drug users meeting the selection criteria were recruited in LTS, NSEP, inpatient treatment centres,
hospitals and in the prisons of Luxembourg. The NFP has been granted a full financing of the project by the
FLTS. 
The final report has been published in September 2007 and may be downloaded at http://www.relis.lu.
The following recommendations of the report have been materialised thus far:
- increase knowledge of serological status among general population and risk groups,
- include drug users in the planning process of prevention strategies,
- reinitiate safer-use counselling for young and new drug users since they are often not aware of risks
compared to older or more experienced users,
- insure availability and free access to the whole range of injection paraphernalia (e.g. spoons, stericups,
filters) in order to neutralise a maximum of infection vectors (since 2007),
- increase syringes availability via NEPs (main low-threshold agency TOXIN enlarged its opening
schedules to 7/7 days in June 2008),
- ensuring a better vaccination coverage and above all vaccination follow up by increasingly involving the
specialised care network. A pilot project providing on-site serological testing and free Twinrix®
vaccination in specialised drug care services was approved by national Health authorities and will be
started by the beginning of 2009.
Counselling and testing                                                                                
AIDSBERODUNG (RED CROSS) is the main national counselling and prevention centre for HIV and AIDS.
Prevention campaigns are conceptualised by the AIDSBERODUNG team in collaboration with the Ministry
of Health and an important network of volunteers. AIDSBERODUNG is part of the RELIS network. Testing is
provided by the CHL and the LNS and is free of charge. Furthermore, HAV, HBV, HCV and HIV testing and
vaccination for HAV and HBV is proposed to each person entering prison.
A new project foreseen by the national HIV/Aids action plan 2006-2010 focuses on outreach measures in
order to better reach target populations and in particular vulnerable groups. DIMPS (Mobile intervention
facility for sexual health) aims to access difficult to reach sub-populations and provide prevention
counselling and infectious disease testing on site to various populations. The project provides free rapid
testing of HIV and hepatitis and outreach counselling and has started in May 2009 and targeted firstly
scenes of drug users, sex workers and asylum seekers. Given the recent start of DIMPS no reliable client
statistics are available yet, but the referred project has known a very high acceptance by users thus far.
Based on experience gathered trough the DIMPS project and also on the recommendations of the Origer
and Removille study (2007), discussions are currently held whether to extend the DIMPS offer to free
HBV/HAV vaccination (where appropriate) for clients of specialised drug agencies.
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Jointly with the Ministry of Health and the Infectious disease department of the CHL, Aidsberôdung works
on a decentralisation concept regarding free HIV and hepatitis testing in order to increase accessibility
especially at regional level.
Infectious diseases treatment
Treatment of HIV and hepatitis infections is covered by the national insurance scheme. Specialised
treatment is provided by a special unit in the CHL in collaboration with the counselling staff of the
AIDSBERODUNG/Red Cross. In case the patient has no or no valid health insurance, treatment costs can
be covered by state.
A new project within national prison aims at setting up a specialised medical department for transmittable
diseases (COMATEP). Given the fact that according to 2008 data 20.97% of inmates carry a transmittable
disease and that 33.5% of new admissions in national prisons are drug law offenders, the project is
considered to be pertinent and important also by the national drug coordination office.
Interventions related to psychiatric co-morbidity                                          
The above referred working group ‘Therapeutic Chain’ has performed a needs assessment in terms of care
for drug users presenting psychiatric co-morbidity. The group retained that current offers and services for
double diagnostic (DD) patients are incomplete. Although the 2005-2009 national action plan foresees the
creation of a specialised therapy centre for DD drug patients has not been realised.
The number of confirmed DD patients is estimated at 40-50 people (adults). These patients show explicit
psychiatric disorders, are often socially disintegrated and need individual follow up although they tend not
to be attracted by existing care offers. There is a need of small supervised housing units for the target group.
Furthermore, the staff of specialised associations must be specifically trained to take care of DD clients.
Instead of creating a specialised and centralised care infrastructure, a better follow-up of patients within
existing outpatient services is needed in the first place, knowing that the referred clients only integrate with
difficulties in structures with compulsory residential character. The ‘Therapeutic Chain’ expert group
recommended in this context to fine-tune the concept of supervised / accompanied housing in order to
move towards a case management approach in a private and individualised environment, knowing that DD
patients often have difficulties to adapt to community oriented settings and offers.
RESPONSES TO OTHER HEALTH CORRELATES AMONG DRUG USERS
Somatic co-morbidity and general health related treatment                                               
The vast majority of specialised out- and inpatient and low threshold drug care facilities include medical or
paramedical care in their service provision. If needed patients are referred to specialised treatment. Related
costs are covered by health insurance schemes or by the Ministry of Health in case the patient has no valid
insurance. 
In the framework of the new drugs action plan 2010–2014, it is envisaged to setup a medical service
providing free and on site medical care to drug users independently of the institutional setting they are in
(except hospitals).   
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Non-fatal emergencies and general health-related treatment
No reliable data on drug related emergencies are currently available at the national level. Roughly
estimated, 25% of emergencies are related to substance abuse (all substances included) (Rauchs 2006).
Figure 7.1 refers to RELIS data on previous non-fatal and medically assisted drug overdose self reported by
PDUs. The proportion of indexed drug users reporting at least one overdose (as defined) (51%) during
lifetime has slowly decreased during the last seven years, which may be partly due to the further
development of low threshold facilities such as the supervised drug injection room.
Non-fatal drug related emergencies
No reliable data on drug related emergencies are currently available at the national level. Roughly
estimated, 25% of emergencies are related to substance abuse (all substances included) (Rauchs 2006).
Figure 7.1 refers to RELIS data on previous non-fatal and medically assisted drug overdose self reported by
PDUs. The proportion of indexed drug users reporting at least one overdose (as defined) (57%) during
lifetime has been fairly stable over the last nine years.
Fig. 7.1 Non fatal, medically assisted drug overdoses in RELIS respondents (2000-2008) (valid %)  
SOURCE: RELIS 2008
Prevention and reduction of driving accidents related to drug use
The law of 18 September 2007 modifies the national traffic code and introduces testing of illicit drug use
in vehicle drivers. The homologation of respective road side saliva tests (Drugwipe II) has still to be regulated
by grand-ducal decree. For more details on the new legislation please refer to chapter 1 (laws).
Interventions concerning pregnancies and children born to drug users
In the context of the development of social paediatrics at national level, child care professionals and
paediatricians call for the implementation of specialised care structures for children at risk. The approach of
social paediatrics considers a child in his global context including physical, psychological, social and cultural
health, family and environmental context and promotes coordination and collaboration between different
social and medical services.
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Due to the improvement of, and the better access to drug related treatment and especially the spread of
substitution treatment, the birth rate in drug users has increased over recent years. According to data from
the national drug surveillance system, the proportion of drug users having children has progressively
increased from 50% to 63% over the last 10 years (RELIS 1999, 2009). This evolution has been leading to
the first parental project launched by JDH in 2003 with the aim to provide psycho-social aid to drug-
dependant parents and their children. The primary objective of the project is to ensure security and well-
being to children and to strengthen parents’ educative abilities. This long term project is based upon
contractual commitments, co-intervention, home visits and functions in close collaboration with involved
services. In 2008, 57 different family situations have been taken in charge, 66.7% of them being mono
parental situations involving all in all 94 children. Approximately 50% of concerned parents rely on
specialised housing offers. An essential part of the project constitutes the outreach work. Meetings and
interviews are held within the natural environment of the family (at home).
Initiatives currently under discussion for inclusion in the 2010-2014 drugs action plan are training
programmes and capacity building for drug using parents in order to empower them with regard to their
educational role.
In order to meet specific needs of children and parents at risk, especially children from drug addicted
parents, the Ministry of Family and Integration has implemented a project of ‘out-of-hospital nursery’
(Maison Françoise Dolto) targeting children aged 0 to 3 years whose parents are temporarily not able to
ensure child care and education. The centre aims to provide temporary admission to these children and
helps to compensate the lack of parents’ involvement in child care. Besides, the structure offers therapy
options, diagnostic testing and functions as a resource centre for parents. The project has a capacity for
approximately 20 children and started in spring 2007.
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8. SOCIAL CORRELATES AND SOCIAL
REINTEGRATIONS
Introduction
Social correlates of drug use typically involve Justice, Health and Educational competences. The Ministry of
Health and the Ministry of Family and of Integration both intervene by financing measures to reduce social
consequences ranging from early detection of drug use to social-professional rehabilitation interventions.
The reduction of drug related crime involves the Ministry of Justice, focuses on supply reduction activities
and the Ministry of Health implements measures targeting socio-professional re-integration aiming at
reducing daily expenses and depths of drug addicts and thus the prevalence of acquisition crimes. Social
reintegration programmes are mainly monitored by the involved Ministries and through associations’ activity
reports and activity programmes.
SOCIAL EXCLUSION AND DRUG USE
Social exclusion among drug users
The question whether substance abuse leads to social degradation and exclusion or social factors (e.g.
family situation, poverty, low education or job perspectives) lead individuals to substance use is an
unsolvable one, although it tends to raise competence discussions between ministries. Fact is that a vast
majority of homeless and socially excluded people also present to various extends licit and/or illicit
substance abuse. Taking care of the latter is not enough as the social situation of these people needs to be
improved before there is a chance to obtain sustained results in drug treatment. This said, the national
strategy of care for socially excluded people is based on the principle of progressive reintegration through
capacity building and the improvement of the social abilities and environment. Associations as ‘Stëmm vun
der Strooss’ (Street voice) and Centre Emmanuel asbl, financed by the Ministry of Health, try to implicate
the target population again in active life by providing a safe and common environment and respecting
individual capacities and resources by applying case management methodologies further described below.
Drug use among socially excluded groups
Homelessness
According to latest estimations around 700 persons are currently homeless in the Grand Duchy of
Luxembourg 47. The study reported a proportion of 54% males and 46% females and a relatively young age
of homeless population. Half of the population of homeless people is aged 18 to 34 years and only 9% are
aged more than 55 years.
More specifically, housing status of registered drug users has markedly improved during recent years and
tends to stabilise. Since 1995, the proportion of persons disposing of a stable accommodation has more
than doubled. Currently 77 percent (73%) of PDUs report a stable housing situation (RELIS 2008). This
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positive evolution may be linked to an increased awareness of the housing problem and the set up of new
housing networks for socially deprived people by the Ministry of Health and specialised agencies.
Fig. 8.1 Last known housing situation of problem drug users. 1995 - 2008     
Source: RELIS 2008
Youngsters aged less than 25 and living on the street are referred to as a quite new phenomenon. Societal
changes as the increase of mono parental families, an increased number of divorces, the decrease of married
couples and the necessity to work for economic reasons for the two partners of a parental couple are likely to
have a negative impact on youngster’s psychological development and education.
Unemployment
Recent data suggest that the employment status of respondents tends to plateau, as the rate of people with
a stable job (47%) has shown a fair stability over the last 3 years. The unemployment rate has increased from
2004 to 2008 (63%).  
Fig. 8.2 Unemployment rate in problem drug users (1996 - 2008)    
Source: RELIS 2008
Remark: STATEC: Statistical Department of State – Unemployment rate in active general population.
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Data on revenues confirm observed trends in occupational status:
- increase of social dependence associated to a stable financial autonomy. The Guaranteed Minimum
Income constitutes the primary source of revenue of PDUs (47% in 2008);
- illegal activities as main revenue have witnessed an ongoing downward trend since 1995 (3% in 2008);
- a high proportion of respondents reporting major debts (>2,500 EURO) (39% in 2008).
Fig. 8.3 Primary source of income of problem drug users (1995 - 2008)     
Source: RELIS 2008  
School drop out
The study of ‘School leave in Luxembourg’48 (2006) surveyed a population of 37,347 secondary school
students during 1st November 2004 and 30 April 2006. A total of 2.422 students left school without a
professional certification (temporary stay offs from school have also been taken into consideration). The
study refers to a proportion of 6.5% of ‘school leavers’. This proportion figures 3.6% if one is considering
the total number of students having been reached but did not reintegrated a school in Luxembourg.
Concerning this category of school leavers, composed of students attending courses abroad, being
employed, following professional insertion measures and those without occupation (N=1,357), the situation
was as follows: 41.2% of students who dropped school have integrated the job market (work or professional
insertion measure), 39.8% didn’t work nor went to school and 19% attended school courses abroad. In
general boys, youngsters from abroad and aged more than 15 years (age of school obligation in 2006) are
more vulnerable to the risk of early school leave.
Fig. 8.4 Educational level of RELIS respondents (2008)     
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Regarding PDUs, the educational level of the latter, low and mostly incomplete, has been showing a creeping
deterioration since 1999 according to baseline data from RELIS. However, an increasing proportion of
respondents start secondary school without bringing their studies to term. The average age at the end of
studies shows a global decreasing tendency and currently situates at 16 years and 8 months. Lower levels are
particularly observed as regards acquired secondary and high school diploma. Post primary school is a special
educational setting for primary school pupils with learning difficulties.
Financial problems
39% of the population of PDUs have major debts (1997: 54%). Over the last ten years, after a peek in 1997,
the percentages stayed relatively stable (around 40% since 1998) representing less than half of the PDU
population. The RMG (Guaranteed Minimum Income) (47%) and the proper salary (17%) represent the main
income sources of the PDUs. Between 1997 and 2008, strong variations were observed in relation with these
two revenues. RMG as a primary source of revenue has known a remarkable increase from 1997 onwards in
contrast to the proper salary, which decreased during the last years. Money provided by parents as first source
of income has also decreased (18% in 1997 to 8% in 2008).
Concerning secondary income sources, 35% of respondents reported no secondary income, 34% referred to
‘illegal activities’49 and 23% were provided money by parents. 
Overall, the social dependence shows an increasing tendency over the last years (74% in 2008 – 42% in
1995). Consequently, autonomy shows a decreasing tendency (23% in 2008 – 35% in 1995).
Drug use in Family
According to RELIS data, drug use in the family of origin is high and stable. Drug use in this context is defined
as the use of illegal drugs or abuse of alcohol or psychotropic pharmaceuticals.
Fig. 8.5 Drug use in family of origin. 1994 - 2008     
Source: RELIS 2008  
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49 mainly selling of drugs
SOCIAL REINTEGRATION
Housing
Social reintegration measures, and in particular improvement and diversification of housing offers for drug
addicts, have been one of the priorities of the 2000-2004 national drugs action plan. The 2005-2009 drugs
action plan has foreseen the expansion of existing projects and the implementation of new decentralised
reintegration measures based on the previously described principle of progressive reintegration through
capacity building and the improvement of the social abilities and environment. 
In the framework of the 2000-2004 action plan, the Ministry of Health, jointly with the City of Luxembourg
opened a night shelter (called ‘Nuetseil’) for drug addicts in December 2003 which has evolved in an
integrated low threshold care centre for drug addicts (TOX-IN) including day and night shelter offers,
accommodation and a supervised drug injection facility. 
A project called ‘Les Niches’ functions as a kind of social real estate agency for drug addicts. Approximately
35 flats and apartments are rented by a drug-counselling centre and provided to drug addicts in need by
means of tailor made renting contracts. One of the medium term aims of the project is to allow demanding
drug addicts to take over the renting contract on basis of their own financial means and thus dispose
autonomously of a stable accommodation. The project is jointly financed by the Ministry of Health, National
Fund against drug trafficking, and the city of Luxembourg (VDL). 
A network of supervised housing facilities for specific target groups as for instance pregnant women, drug
addicted couples, treatment demanders on methadone are operational since September 2002 and are
situated in the vicinity of the main centre in order to take advantage of training and social reintegration
facilities offered by the CTM. The CTM also offers educational aid in several domains as well as professional
training opportunities.
Education, training
Aiming professional reintegration, a series of residential drug care centres offer oral and written language
courses in order to provide clients with basic language skills (if necessary) or to improve their writing skills. 
‘D’Stëmm vun der Strooss’ association (‘Street voice’ association) primarily takes care of homeless people
providing them with low threshold facilities and offering social and professional reintegration activities such
as literacy courses (provided by volunteers) and workshops (in journalism and radio broadcasting) held by
professionals. ‘The voice’ (‘d’Stëmm’) monthly broadcasts a one and a half-hour programme on a local radio.
Providing clients with the opportunity to widen their knowledge and introducing them to different or less
common professions has lead to a fair success in terms of interest of participants and retention rates.
Employment
Another reintegration project run by the referred association is the therapeutic redaction board, where
homeless people are given the opportunity toediting, printing, publishing and distributing an in house
magazine. This activity is supervised by professionals (one educator and one pedagogue). Addressing social
matters is supposed to help clients to regain a sense of responsibility and to increase the level of
acceptability in the general public (therapeutic aim). Another aim is sensitizing a wider public and helping
homeless people familiarize with new technologies. PDUs constitute a significant fraction of their clients.
Additionally clients are offered task and job opportunities in the laundry service called ‘Schweessdrëps’
(Drop of sweat) which covers the south of the country and is specialised in washing sports teams’ uniforms.
In 2008, 1 social worker and 18 clients have been working for 25 sports teams, washing, drying etc. 1,000
to 1,500 uniforms weekly. Besides these two main work-opportunities, the service also offers a therapeutic
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workshop called ‘Dressed for success’. In 2008, the service has been managed by 2 clients (offering them a
job opportunity and responsibility). Their main task was to organise (collect, wash, store, etc) clothes offered
by donors.
A new occupational project foreseen for 2009-2010 and run by the ‘Street voice’ (‘Stëmm vun der Strooss’)
association will further fill the gap in occupational offers for drug addicts at the national level. The detailed
concept of the residential centre offering temporary accommodation and day jobs will be described in the
2010 report.
Co-financed by the Ministry of Labour and Employment and the European Social Fund, the Centre
Emmanuel association launched the project ‘START’ in 2007, targeting progressive re-integration of drug
users into the first job market (G. Lambrette, 2009)50. The applied methodology combined case oriented
follow-up and job coaching and aimed at helping beneficiaries to find a work or professional training place
(e.g. establishing contact with companies, preparing job interviews, editing of resumes, etc.) and to assist
them in their daily work routine (definition of tasks, conflict management, mediation between employee
and employer, motivational follow-up, etc.). Intermediate feedback and final evaluation contributed to
improve autonomy of clients and are ideally leading to a permanent work contract. As one of the main
impediments regarding access to jobs by vulnerable groups, is the initially or even permanently reduced
work performances, the main objective of a job coaching project is the mobilisation of individual resources
and capacities of the beneficiary in tune with the need of the company he or she is given the opportunity
to work for.
Between 2007 and 2008, 230 demands have been treated in the framework of the START project. 23% of
demanders were female, a majority was aged 31 to 50 years and 76% presented a low professional
qualification profile. By the end of the project 27 beneficiaries had signed a work contract through START
and 21 persons more found a stable job indirectly due to their participation in START. 
110
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9. DRUG RELATED CRIME, PREVENTION OF DRUG
RELATED CRIME AND PRISON
Introduction
The main source of Information of this part of the report is the Judicial Police Service (SPJ) in Luxembourg. 
Due to obvious disparities at the European level in terms of concept definitions in the field of law
enforcement data, the respective national terminology should be clarified: 
- Interpellation’ (Eng. Interpellation/peremptory questioning, to call on): 
Intervention of law enforcement agents based on reasonable suspicion. The ‘interpellated’ person is heard
and a police record occurs. At this level, however, there is no notification to the Public Prosecutor and no
mention in the judicial record.
- The term ‘prévenus‘ (interpellated/indicted person):
Refers to persons who have been apprehended by legal enforcement agents for alleged offences against
the national drug law (or against law in general).
- ‘Arrestation’ (Eng. Arrest) : 
Interpellation followed by a deprivation of liberty and notification to the attorney at law. The preliminary
examination (instruction) refers to the subsequent judicial procedure that leads to public audience, which
claims the sentence.
- ‘Condamnation’ (Eng. Conviction) :
Judgement by which the accused person is found guilty.
- ‘Détention’ (Eng. Imprisonment) :
Deprivation of liberty. Distinction is made between protective custody (prior to the judgement) and regular
detention (following conviction).
DRUG-RELATED CRIME
The NFP collects and re-formats nation-wide data on drug-related offences provided by the SPJ. A staff
member of the NFP actively collaborates with the SPJ team in order to adapt law enforcement data to
standards required for the editing of the national report on drugs and the EMCDDA annual report.
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Drug law offences
As can be seen in tables 9.1, the total number of arrests (188) has increased discontinuously during the last
10 years. Traditionally heroin was the most frequent substance involved in drug-related arrests. In 2004
cocaine has turned to be the main substance involved in those arrests (confirmed by 2005 data), followed
by heroin and cannabis. Recently, cannabis offences have been increasing (2006 and 2008 data), followed
by heroin and cocaine offences.
Tab. 9.1 Arrests broken down by type of reporting institution (1995-2008)
ARRESTS
Year 1995 1997 1999 2001 2003 2004 2005 2006 2007 2008
S.P.J. 27 25 27 7 25 38 26 39 49 32
Gendarmerie 8 15 15
Police 32 32 32
Customs 61 82 34 40 28 37 35 62 41 54
Total 128 154 108 92 135 178 155 225 226 188
Tab. 9.2 Arrests broken down by type of offence and substances involved (1995-2008)
Substance Offence 1995 1997 1999 2001 2003 2004 2005 2006 2008
Heroin Use & Traffic 68 57 48 41 21 32 28 40 43
Traffic/Deal 21 53 18 8 22 19 14 29 30
Use 24 7 27 8 4 20 20 26 14
Total 113 117 93 57 47 71 62 95 87
Cocaine Use & Traffic 20 27 21 27 19 21 21 26 26
Traffic/Deal 7 23 9 9 30 64 42 38 21
Use 10 6 12 4 3 9 15 21 3
Total 37 56 42 40 52 94 78 85 50
Cannabis Use & Traffic 25 18 32 23 52 16 17 42 61
Traffic/Deal 1 11 8 1 17 20 27 36 11
Use 4 4 3 15 9 14 25 15 18
Total 30 33 43 39 79 50 69 93 90
Amphetamines Use & Traffic 2 1 2 2 0 0 0 3
Traffic/Deal 0 0 0 1 0 2
Use 2 0 0 0 0 2 0
Total 2 2 1 2 2 0 1 2 5
Ecstasy Use & Traffic 3 3 3 1 1 1 3 4 2
(MDMA, etc.) Traffic/Deal 1 3 0 0 1 6 1 0
Use 1 0 1 1 3 2 1
Total 5 6 3 1 2 3 12 7 3
LSD Use & Traffic 1 1 0 0 0 0 0 1
Traffic/Deal 0 0 0 0 0 0
Use 0 0 0 0 0 0
Total 1 1 0 0 0 0 0 1
Total number Use & Traffic 59 57 48 46 85 103
of arrest motives Traffic/Deal 13 61 93 63 87 53
independently of Use 20 15 35 45 47 31
involved substances Total 128 154 108 92 133 178 154 219 187
Source: Specialised Drug Department of the Judicial Police (Data formatted by NFP) 2008
45 82 103 94 124 79 102
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51 The general activity report of the Government Grand-Duchy of Luxembourg can be downloaded from:
http://www.gouvernement.lu/publications/informations_gouvernementales/rapports_activite/index.html
52 A summary of the general activity report of the "Anti-Drugs and Sensible Products’’ division of Customs can be found in annex H.
The original report can be downloaded from :
http://www.gouvernement.lu/publications/informations_gouvernementales/rapports_activite/index.html
The number of police records for presumed offences against the modified 1973 drug law (code: DELIT-
STUP), stable between 1996 and 1998, showed an important increase from 1998 to 2003 (825 to 1,660)
and has been stabilising since then (2008: 1,219 rec.).
The number of drug law offenders (‘prévenus’) has declined from 1,368 in 1996 to 1,170 in 1998 followed
by a subsequent increase. From 2003 onwards, one observes a significant decrease (1,487 in 2008) in drug
law offenders. The number of arrests on the same charge has decreased from 154 in 1997 to 135 in 2003
to increase and stabilise again in recent years (2008: 188 arrests).
Table 9.3 records the total number of law enforcement interventions and number of ‘prévenus’ at the
national level ensured by respective law enforcement actors that are the Specialised Drug Department of
the Judicial Police (SPJ), Police and Board of Customs from 1995 to 2008.
Tab. 9.3 Number of national law enforcement interventions (1995-2008)
DRUG LAW ENFORCEMENT RECORDS PREVENUS (Offenders)
Année 95 97 99 2001 2003 2006 2007 2008 95 97 99 2001 2003 2006 2007 2008
S.P.J. 123 137 343 216 239 190 177 110 152 182 434 321 369 248 203 128
Gendarmerie 198 255 782 319 335 916
1,126 1,326 824 998 881 1,272 1,753 1,007 1,160 1,009
Police51 199 177 189 371 280 283
Customs52 244 236 173 113 95 186 197 228 421 408 306 182 148 320 324 350
Total 764 805 1,187 1,455 1,660 1,200 1,372 1,219 1,263 1,205 1,939 1,776 2,270 1,575 1,687 1,487
Source: Specialised Drug Department of the Judicial Police
The population of drug law offenders is composed of 85% males; a proportion that has been varying
between 79% and 89% during the past decade. Since 1997, non-natives (58.7% in 2008) have been
representing the majority of drug law offenders (52-68%). The spectacular increase in 2002-2003 of the
proportion of first drug law offenders is not confirmed by 2007/2008 data reporting a decrease from 808
in 2003 to 546 in 2008. Also the percentage of minors (< 18 years) among drug law offenders having
increased between 1994 (4.9%) and 2000 (8.7%) shows a clear decrease in 2004 (5.7%) and tended to
stabilize from there on (2008: 5.5%). Heroin and cocaine are the main drugs involved in first drug offences.
Tab. 9.4 Socio demographic data on ‘prévenus’ (1986-2008)  
Year 1986 1988 1990 1992 1994 1996 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
AGE
0-14 9 7 6 1 3 7 27 21 11 15 41 24 9 8 11 8
15-19 121 212 179 320 169 270 249 415 413 399 647 602 334 436 279 318 282
20-24 264 569 383 527 403 447 321 519 497 566 650 557 510 617 415 480 436
25-29 119 220 278 371 309 304 220 448 354 299 388 375 278 345 323 321 274
30-34 49 67 124 159 186 191 187 269 208 194 219 254 250 230 188 216 205
35-39 17 29 27 52 65 80 76 131 113 139 177 162 190 174 136 162 134
≥ 40 17 19 43 46 21 42 78 84 108 113 82 174 126 153 181 165 129
unknown 27 21 30 50 20 31 32 46 44 55 40 106 95 70 43 14 19
TOTAL 623 1,137 1,071 1,531 1,174 1,368 1,170 1,939 1,758 1,776 2,218 2,271 1,808 2,034 1,575 1,687 1,487
Male 503 970 851 1,248 938 1,138 958 1,658 1,415 1,546 1,905 1,935 1,581 1,751 1,319 1,484 1,263
Female 120 166 220 256 209 173 193 248 241 215 292 288 181 237 218 190 206
gender unknown 0 1 0 27 27 57 19 33 44 15 21 48 49 46 38 13 18
Source: Specialised Drug Department of the Judicial Police 2008
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Tab. 9.5 Distribution of ‘prévenus’ according to first offence and underage status (1992-2008)
1992 1994 1996 1998 2000 2002 2004 2005 2006 2007 2008
First offenders 697 382 508 422 608 828 585 657 471 533 546
Offenders underage 96 57 102 79 154 145 103 86 72 80 83
TOTAL (‘Prévenus’) 1,531 1,174 1,368 1,170 1,758 2,218 1,808 2,034 1,575 1,687 1,487
Source: Specialised Drug Department of the Judicial Police (Data formatted by NFP) 2008
Tab. 9.6 Distribution of first offenders (use and use/traffic) according to substance involved ad minima 
(1992-2008)
1992 1994 1996 1998 2000 2002 2004 2005 2006 2007 2008
High risk substance involved ad minima
Heroin 162 154 121 109 133 114 103 110 84 83 88
Cocaine 64 39 34 30 37 64 125 86 52 37 48
Amphetamines 5 15 11 18 9 12 2 3 3 1 8
Type ‘ Ecstasy ‘ 1 9 20 26 11 34 8 17 4 4 9
Illicitly acquired medicaments 1 3 0 1 7 0 1 1 4 1 1
Substitution substances 0 1 0 0 0 1 0 1 1 0 0
TOTAL  (substances HRC) 233 221 186 184 197 225 239 218 148 126 154
Source: Specialised Drug Department of the Judicial Police (Data formatted by NFP) 2008
Other drug-related crime
The routine data protocol of the national drug monitoring system (RELIS) includes a series of drug-related
offences’ items: The following results summarise the situation observed in 2008:
- 92% of drug users indexed53 by specialised health care institutions have already been in conflict with law
enforcement agencies during lifetime.
- 79% of the total PDU population show multiple law enforcement contacts (stable).
- The proportion of ‘interpellations’ for other reasons than presumed offences against the drug law (e.g.
petty crime such as criminality linked to drug supply or fights) has been decreasing since 1997 (38%)
and has been fairly stable in recent years (2006: 34% and 39% in 2008).
- 62% (63%) of indexed PDUs have already served at least one prison sentence during lifetime. The
proportion of PDUs having served more than one prison sentence at the time of reporting (31% stable)
has stabilised during the last years.
PREVENTION OF DRUG-RELATED CRIME
In recent years, involvement of major cities in the management of drug-related problems and nuisances has
developed. So-called municipal ‘prevention committees’ that include local authorities, police forces and
specialised NGOs are in place. The setup of the first national drug injection room in Luxembourg City
obviously enhanced the involvement of municipal authorities. The Ministry of Health chairs a management
group that is mandated to follow up developments with regard to the injection room and to react
precociously to emerging problems. The national action plan clearly emphasises the importance of a visible
involvement of major cities in the management of public safety and order, urban nuisance and hygiene
problems related to drugs to guarantee the necessary decentralisation of demand reduction offers and
supply reduction interventions.
As far as preventive measures targeting youngsters are concerned, a mechanism has been put in place in
1996 aiming at underage and juvenile drug use offenders and in order to prevent recidivism. The Youth
Solidarity (Jongenheem asbl) project is financed by the Ministry of Health and intervenes in case a minor
of age has been running in conflict with law enforcement forces with respect to a drug-related offence. In
this respect the Youth Solidarity team may be considered as a crisis situation manager, offering their services
to drug offenders referred by judicial and penal institutions. The available services are free of charge. 
The intervention team, in direct collaboration with Youth magistrates and competent law enforcement
actors, offers a large variety of services with the primary aim to prevent minor aged drug offenders to enter
in the criminal justice system. Interventions are based on a holistic approach of the problem, including the
involved person him/herself and his/her family. Youth Solidarity directly reports on intervention progress to
the demanding authority. Client statistics show an increasing demand for this kind of intervention from both
the criminal justice system and the social oriented institutions.
Tab. 9.7 Clients’ core statistics SOLIDARITE-JEUNES 1997 – 2008  
YEAR 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Number of episodes 46 99 132 195 208 231 267 249 322 352 357
Referral from the criminal 
Justice system 26.1% 26.3% 41.4% 44.1% 44.2% 37.2% 46.2% 44.4% 43.4%
Gender distribution Female 28% 26.3% 34.1% 32.3% 34.1% 31.6% 31.9% 31.3% 30.1% 24.4% 30.5%
Male 72% 73.7% 65.9% 67.7% 65.9% 68.4% 68.1% 68.7% 69.9% 75.6% 69.5%
Age distribution < 14 9.5% 4.9% 2.0% 4.7% 4.6% 5.9%
14-15 38.1% 30.0% 22,9 27.9% 25.6% 24.9%
16-17 39.8% 46.4% 43.4% 46.9% 46.6% 50.4%
> 17 12.6% 18.7% 20.5% 16.5% 18.5% 15.9%
unknown 11.2% 4.0% 4.7% 2.9%
Main substance involved Cannabis 83.1% 72.4% 71.5% 73.3% 67.7% 69.4%
Heroin 3.5% 4.5% 5.6% 3.7% 2.5% 1.7%
XTC/Cocaine 1.3% 2.2% 0.4% 1.6% 1.1% 0.6%
Legal drugs 2.6% 3.0% 2.4% 3.1% 5.1% 7.8%
Polydrugs d.m. 1.9% 3.2% 3.7% 5.4% 4.5%
Other 1.3% 3.3% 2.0% 2.5% 2.5% 2.5%
None 8.2% 10.6% 10.4% 10.2% 9.6% 8.7%
Unknown 0.0% 2.2% 3.7% 2.5% 6.1% 4.8%
Source: Solidarité Jeunes (Jongenheem). 2008
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INTERVENTIONS IN THE CRIMINAL JUSTICE SYSTEM
Alternatives to prison
The Grand-Duchy of Luxembourg counts two state prisons at the national level; the CPL situated in the
vicinity of Luxembourg City and the CPG implemented in the East of the country.
The CPG, may be considered as an alternative to a strict penitentiary regime as it is defined as a semi-open
prison established in a fairly rural setting. During daytime, inmates follow a professional activity or
participate in one of the centre’s workshops (agriculture, animal breeding, kitchen, horticulture, woodwork,
locksmith’s and duties). After work they return to their individual cells for the night. Every block has its own
living room, kitchen, bathroom and laundry allowing inmates to live in more or less autonomy.
Part of inmates participates in the ‘DEFI’ programme (see below under ‘Reintegration of drug users after
release from prison’) working outside for a minimum loan (RMG - Guaranteed Minimum Income). Others live
under a semi-liberty regime (they live at CPG but have an individual and external work contract).
The ‘injonction thérapeutique’ is another alternative to prison (only possible in case of offences for personal
possession or use of illicit substances): the offender is proposed to undergo treatment instead of a prison
sentence. In other cases, community services (‘TIG: travaux d’intérêts généraux’) may also be an alternative
(depending on the gravity of the offence and the sentence). The sentence may be suspended if the ‘prévenu’
agrees to undergo treatment (‘sursis probatoire’). This said, these two alternatives are applicable in case of
drug possession or use only (not for cases of production, dealing or trafficking of illicit substances), as in the
Grand-Duchy of Luxembourg a drug addict is not considered a criminal but a person in need of psycho-social
and medical help.
A further, still experimental, alternative to prison available in Luxembourg is the electronic tag. In November
2006, the former Minister of Justice presented the introduction of the electronic tag as an alternative to
incarceration.
In an experimental phase, this system was exclusively meant for prisoners:
- whose sentence was less than one year
- who did not represent a predictable danger
- socially integrated and residing in Luxembourg
- who were working or undergoing training
DRUG USE AND PROBLEM DRUG USE IN PRISONS
In 1998, the Ministry of Justice commissioned the medical department of the state prison (CPL) to perform
an epidemiological study on HIV and HCV prevalence in prison population (Schlink 1999). The research
protocol relied on a self-administrated anonymous questionnaire on health behaviour and injecting drug
use prior and during prison sentence. 
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MAIN RESULT S :
Drug use in prison
- 32% of prisoners qualified themselves as injecting drug users;
- 28% reported current drug injection in prison;
- 9% have been initiated to injecting drug use in prison;
Risk behaviour
- 58% of current IVDU prisoners report life-time needle sharing in prison;
- 8%  of current IVDU prisoners report last month needle sharing in prison;
- 70% of IVDU prisoners only use water to clean up syringes, 22% do not clean syringes at all;
- 90% of prisoners reporting sexual intercourse in prison did not use condoms.
Miscellaneous
- IDUs have served more prison sentences than non drug users (control group);
- IDUs showed lower average age than non drug users;
- a majority of imprisoned IDUs were natives
Source: Schlink, 1999
The recent study ‘Prevalence of viral hepatitis A, B and C and HIV in problematic drug users of illicitly
acquired drugs’ (Origer & Removille, 2007) also addressed drug use and drug-related harm in prison
settings. Results are reported in standard table 12. Referred to the total study sample (N:246), 56.1% of
respondents who have had prison experience during the past ten years reported illicit drug use in prison;
30.5% reported intravenous drug use. 26.7% of lifetime IDUs inmates reported needle sharing in prison
which is sensibly lower than the rate observed in 1998 by Schlink (1999). Among all settings (inpatient,
outpatient treatment, low threshold, etc.) prevalence rates of HIV, HBV and HCV were highest in persons
recruited in prison settings.
RESPONSES TO DRUG-RELATED HEALTH ISSUES IN PRISONS 
Table 9.8 provides the number of general admissions and the number of admissions according to drug-related
convictions (DELIT ‘STUP’) in both national prisons from 1989 to 2008.
Tab. 9.8 General and DELIT ‘STUP’  admissions in both national prisons (1989 - 2008)
Year 1989 1990 1992 1994 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
New entries 
(Total) 685 858 796 859 767 641 794 1.141 1.078 1.341 1.043 1.030 990
New “STUP”
entries 163 244 157 288 292 309 167 139 161 119 101 143 92 247 243 212 332
42.6% 36% 21% 16% 21% 18.6% 12.7% 12.5% 8.5% 18.8% 23.3% 20.6% 33.5%
Source: Greffe CPL, CPG. 2008
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Drug treatment (including number of prisoners receiving opioid substitution treatment)
Following the law of 27 July 1997 concerning the modification of the penitentiary organisation54, a pilot
project named ‘Global Drug Care Programme in Prison’ (2000-2005 - TOX project) was set up by a group
of experts assigned by the Ministry of Justice in 1999. The concept was designed to implement, among
other objectives primary, prevention measures in regard to drug consumption and infectious diseases. The
overall aim of the project was to integrate drug dependant inmates into a medico-psycho-social drug care
network in order to reduce recidivism, risks and criminality after release from prison. The implementation of
the project had to be adapted to the two different prison settings. Joint financing by the Ministry of Justice,
the National Fund against drug trafficking and the EU (regarding evaluation) was ensured. 
The TOX programme (previously TOX project) takes care of the drug dependant inmates in the two state
prisons of Schrassig (CPL) and Givenich (CPG). This service is run by a multidisciplinary staff. The basic
principles of the TOX programme in the CPG are the voluntary participation, the cooperation, the
transparency, the quality of service, the determination of realisable objectives and the empowerment of
participants. 
Detoxification treatment is either provided in-house under the responsibility of the prison medical unit, or
by external detoxification units of general hospitals according to strict rules and procedures. CPL has signed
a convention with a major general hospital situated in Luxembourg City ensuring out-of-prison medical care
if required.
Psychosocial and therapeutic care is provided by both, in-house staff members and specialised external
agents from accredited drug agencies. Therapeutic in-house resources are deemed insufficient. An example
of good practice in this respect is the inclusion of clearly time on content defined service providing of
external specialised drug agencies contractually foreseen by state conventions (in the framework of the
global drug care programme). This mechanism also applies to external agents in the field of HIV and other
infectious diseases. One should also stress the role of the Central Probation Service (SCAS), which motivates
inmates to undergo treatment and enables contacts with external therapeutic agencies. Although the
psychosocial care strategy is similar in both national prisons, the CPG currently disposes of a more structured
intervention programme. 
Regarding substitution treatment in prison, three scenarios may occur:
- most frequently encountered situation applies to new prisoners who underwent substitution treatment
prior to their current incarceration. Medical prison staff inquires the accuracy of the information provided
by involved inmates by contacting the prescribing GP or the national substitution programme. In case of
confirmation, substitution treatment is continued and may be followed by maintenance, dose reduction
or detoxification treatment,
- increasingly substitution treatment is initiated within prison. It also includes inmates who have started
opiates use in prison,
- opiate using or already substituted prisoners may introduce an admission demand to the national
substitution programme 6 weeks before release. Continuity of care and re-socialisation measures are
ensured by the intervention of social workers from external field agencies (substitution, HIV, hepatitis,
etc.),
The main substitution opiates prescribed in prison are methadone (MEPHENON®), and to a lesser extend
buprenorphine (SUBUTEX®) and codeine. Prescription of benzodiazepines is widespread. 
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Official figures show that 20% of the inmates (of full age) who entered CPL in 2008 received drug
substitution treatment, representing a total of 216 people and 65% of persons entering prison due to drug-
related offences.
Tab. 9.9 Number of inmates receiving opioid substitution treatment (2008)
Year 2008
Methadone (Mephenon) 215
Subutex 1
(Total) 216
Source: Comité de Surveillance SIDA: Rapport d’activités 2008
The average dose of distributed methadone was 30mg per day (minimal dose 2.5mg and maximal dose
110mg). The average period of treatment was 123 days.
Prevention and reduction of drug-related harm
In 2008, the activities of the previously referred to TOX-programme in prison were centred on three pillars:
• Psychosocial prevention: psychosocial care of drug-addicted inmates, in order to prepare their future
after release from prison and to reduce risks of relapse and recidivism – intensive programme without
drugs to prepare post-release ambulatory therapy and/or individual preparation for release. 
• Prevention of the STDs: this health service is proposed in individual and collective settings
• Coordination of interventions: the drug-addicted platform was created in order to coordinate
interventions of involved professionals.
The TOX programme in the CPG has established psycho-educational activities. The group has focused on
two axes:
• Health development and
• specific psycho-educational practice for the drug-addicted inmates within a collective pavilion without
drugs (specific entourage of at least 4 months with an optional prolongation). 
• follow-up of the drug free section together with the « Program Charly » started in May 2007, as
preparation for multidisciplinary and intensive therapy: 25 (11) inmates.
As far as the CPL is concerned, in 2008, 192 (147) admission demands were addressed to the TOX
programme. 151 (92) demanders were provided with an individual psychosocial follow-up. 25 (28) clients
have benefited from an individual counselling in prevention of STD. Furthermore, a drug addiction platform
has been created and a new e-learning project started in 2008.
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The CPG reports for 2008, 7 withdrawal prevention modules, 5 tobacco prevention modules, 3 HIV/AIDS
prevention modules and 8 speaking groups. 70 clients were provided with an individual psychosocial follow-
up and 873 individual counselling sessions were held.
In 2007, the external evaluation report55 of the TOX project has been published and recommended the
continuation of the action. The programme is currently part of the RELIS routine data reporting network
(since 2009, first data expected in 2010).
PREVENTION, TREATMENT AND CARE OF INFECTIOUS DISEASES
New inmates are seen by medical staff in the framework of the admission procedure of both national
prisons. A HIV screening test is suggested during the medical counselling. If the inmate accepts, a
simultaneous screening of other infectious diseases like syphilis and hepatitis A, B and C is undertaken. 
In 2008, approximately 650 HIV tests have been carried out. 12 tests were positive (10 men and 2 women),
6 co-infections (HIV/HCV) were diagnosed in known drug-users. 2 of them were screened in prison (one of
them infected indoor). To prevent further contamination, vaccination against hepatitis B and A is
recommended to those who present a negative serology. 
A structured syringes distribution programme has officially been launched in 2005 in the framework of the
global drug care programme in prison. In order to enrol, inmates have to send a written request to the
prison’s doctor. After counselling, the inmate is handed a kit containing 2 syringes which may be exchanged
at the nursery. As the consumption and possession of drugs is illegal, those inmates in possession of a
syringe in its kit, are exempted from sanctions for detention of injection paraphernalia. In 2008, 36 kits have
been distributed and 178 syringes exchanged. The programme is under medical secrecy and is operational
although a series of changes are currently being discussed to increase the coverage and impact of the
programme.
Ascorbic acid, filters, sterile physiological water, antiseptic wipes and small plasters are available at the two
nurseries. Condoms are also available at different discrete spots of the prison (at the two nurseries, TOX-
programme and at the psychiatric ward).
In order to meet specific needs in terms of infectious diseases in prison settings, the creation of a specialised
transmittable disease counselling offer (COMATEP) involving prison administration and CHL is currently
under discussion.
Prevention of overdose-risk upon prison release
Overdose incidents following prison release is a documented reality that has also been addressed by
national research. For instance, the Origer & Dellucci study in 2002 recommended the following measures
to prevent overdose risk following an in-depth longitudinal analysis of drug-related death nationwide:
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- opening of supervised injection rooms according to the national drugs action plan (1)
- medical controlled heroin distribution programme (foreseen by the national drugs action plan) (2)
- first aid training courses provided to users and their relatives and partners (3)
- gender and ethnic specific interventions (4)
- provision of morphine receptor antagonists to users and selected persons (5)
- creation of ‘transition centres’ for ex or current PDUs leaving institutional settings (6)
- development of reintegration programmes for prisoners in the framework of the recent ‘Global care
programme for drug addicts in prison’ (7)
Besides, the law of 27 April 2001 introduced an important modification of the basic drug law with regard
to overdose prevention. Art.10-1 of the referred law exempts drug users who call for assistance in case
another user is in need of medical help, from prison sentences. This change is supposed to reduce drug-
related deaths occurring in consumer groups. A new flyer addressing among others measures to be
undertaken by witnesses of a drug-related overdose and the genuine legal situation was elaborated and will
be broadly distributed among PDUs in various settings in 2009. 
For persons (with drug careers) leaving prison, a series of measures such as; information and peer education,
banning multiple prescriptions of substitution drugs, considering interaction of substitution treatment and
concomitant/persistent street drug use and ensuring through-care after prison release need to be further
developed.
REINTEGRATION OF DRUG USERS AFTER RELEASE FROM PRISON
The CPL runs a proper psychosocial and educational department (SPSE). Jointly with the SCAS and the
prison guards’ association, it has set up a project called ‘DEFI’ (Challenge) that aims at the development of
therapeutic means, training facilities, socio-professional reinsertion measures and indebtedness
management, during prison journey and after the prison release phase.
The future development of synergies with external drug care agencies aiming at a comprehensive concept
of through care in terms of psychosocial measures, substitution treatment or economical start-up help are
some of the cornerstones of national after-prison reintegration strategies. 
The Centre Emmanuel (see above chapter on social reintegration) also contributes in various ways to
(re)insert drug users as far as (re)integration is possible.
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10. DRUG MARKETS
Introduction
Drug markets are of changing nature. They rely on factors such as supply mechanisms, on the economic
situation of the country they develop in and on the efficiency of law enforcement strategies. Availability and
supply indicators should be interpreted with caution as they rely on the interplay of all these factors. Law
enforcement authorities, the National Laboratory of Health and special surveys have provided data for the
present chapter.
Overall, the national drug market has become of a more aggressive nature in terms of selling techniques.
New distribution networks have developed in recent years and operate in an obviously professional way and
by doing so have significantly increased drug availability and in particular the supply of cocaine and
cannabis. Dealers increasingly tend to actively approach confirmed or potential clients. More recently ethnic
groups join to improve their drug distribution strategies whereas previously none of these criminal groups
actively searched contact with other groups. Moreover it has been noted that traffickers tend to delocalize
their selling points to locations or settings less visible to police as for instance private flats or bars.
Asylum demanders implicated in illicit cocaine trafficking mainly originate from West African countries,
particularly from the Ivory Cost. Their number tends to stabilise. In regard to heroin trafficking, no
predominant profile of nationality has been reported. A large number of drug traffickers come from North
Africa by transiting through Belgium. Numerous traffickers have changed from heroin to cocaine and
currently are also involved in cannabis traffic. 
Compared to the situation in 2003, purity of heroin and cocaine has remained fairly stable. Attention has
to be paid to the striking differences in maximum and minimum purities as well as to a historically high
maximum concentration of THC (over 30%) in herbal cannabis samples seized in Luxembourg in 2007.
Prices show broad ranges for heroin and cocaine, and a still ongoing decrease for ecstasy like products.
Cannabis and derivates however have known certain stability during the last 5 years as far as street prices
are concerned. 
In terms of quantity seizures of heroin have been fairly stable since 2000 and even decreasing as far as
cocaine and cannabis are concerned. The number of seizures did not show significant variations during the
same period, with the exception of cannabis going up. Also, the number of offenders involved in seizures
has been showing an overall decreasing trend. This may suggest that greater quantities of drugs are
trafficked by smaller groups of traffickers. A confirmed majority of offenders are involved in cannabis traffic
and are non-natives. 
The perceived illicit drug availability in general population is high and follows a weakly increasing trend.
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AVAILABILITY AND SUPPLY
Perceived availability of drugs
In addition to availability indicators from law enforcement sources, perceived availability of the general
public provides a complementary insight in the current situation. Both, the 2004 Flash Eurobarometer 158
survey “Young people and Drugs” and the 2002 Eurobarometer 57.2 survey inform about the level and the
evolution of illicit drugs availability in the G. D. of Luxembourg. 
Tab. 10.1 Ease of acquisition of drugs in Luxembourg (2002/2004)
QUESTION a: It is easy to get illicit drugs in Luxembourg ?
Near where I live In or near At parties In pubs/clubs
my school/college
2002 2004 2002 2004 2002 2004 2002 2004
Luxembourg 62.2 66% 60.5 63% 74.7 74% 73.2 70%
UE 61.9 63% 54.9 57% 76.0 79% 72.3 76%
In May 2008, the Directorate-General Justice, Liberty and Security of the European Commission published a
public opinion poll named “Young people and drugs among 15-24 years olds”(N°233) within the scope of
Eurobarometer surveys. Questions were included on the ease of access to illicit drugs, alcohol and tobacco:
The following figure presents the results of the question: “How difficult would it be for you to get hold of any of the
following substances if you wanted to?”: 
Ease of access to heroin (if desired)
very difficult fairly difficult fairly easy very easy dk/na
Luxembourg 44 33 14 9 2
EU27 42 30 16 7 5
Ease of access to cocaine (if desired)
very difficult fairly difficult fairly easy very easy dk/na
LU 37 30 22 9 3
EU27 35 26 22 11 5
Ease of access to ecstasy (if desired)
very difficult fairly difficult fairly easy very easy dk/na
LU 34 31 25 9 2
EU27 31 25 26 12 5
Ease of access to cannabis (if desired)
very difficult fairly difficult fairly easy very easy dk/na
LU 17 11 30 41 1
EU27 19 15 31 32 4
Ease of access to tobacco (if desired)
very difficult fairly difficult fairly easy very easy dk/na
LU 1 10 88
EU27 1 2 15 81
Ease of access to alcohol (if desired)
very difficult fairly difficult fairly easy very easy dk/na
LU 1 5 94
EU27 1 2 17 80
2
0
0
9
123
NATIONAL REPORT TO THE EMCDDA
“GRAND DUCHY OF LUXEMBOURG”
New Developments, Trends and in-depth
Information on selected issues
Concerning heroin, youngsters from Luxembourg considered it slightly more difficult (77%) to obtain or to
have access to heroin than the European average (72%). Similar to the EU average, only 23% of
interviewees thought that getting hold of heroin was easy.
Even if heroin was the substance considered to be most difficult to get hold of, also cocaine was quoted by
67% of young people from Luxembourg as more difficult to obtain than did the EU average (61%).  
Ecstasy was considered being more difficult to obtain in Luxembourg (65%) compared to the EU average
(56%). Only 34% of youngsters from Luxembourg considered the access to ecstasy as easy (EU average:
38%).
Concerning cannabis, less youngsters from Luxembourg (28%) declared the access to cannabis difficult
than the EU average (34%). Access to cannabis was perceived easier (71%) than the EU average (63%).
Four out of ten youngsters (41%) found it very easy to obtain cannabis (EU average: 32%, three out of ten).
Luxembourg’s youngsters considered the access to licit substances as tobacco and alcohol as easier than the
EU average. Concerning tobacco, 88% of youngsters from Luxembourg found the access very easy
compared to the EU average (81%). Also the access to alcohol was referred to as very easy (LU: 86%, EU:
80%).
In summary one may note that a majority of Luxembourg’s youngsters are of the opinion that licit drugs are
very easily available in contrast to illicit drugs seen as very difficult to obtain with however the exception
of cannabis.
Origins of drugs
The national production of illicit drugs appears to be irrelevant in terms of quantities and quality. In 2008
no clandestine drug-manufacturing laboratory has been dismantled at the national level. Law enforcement
sources56 indicate that currently the majority of illicit drugs consumed in the G. D. of Luxembourg originate
from the Netherlands (cannabis production and transit of other drugs), followed by Belgium (ecstasy and
ATS production) and Morocco (cannabis production). Till the beginning of the nineties, most of the persons
involved in illicit drug distribution were consumers who supplied themselves in the Netherlands or acquired
limited extra quantities of drugs in order to sell them within restricted local networks. Since the opening of
EU borders, more organised distribution networks tend to develop within the national drug market. 
Drug Trafficking patterns
The expansion of more structured distribution networks by organised criminal associations has been
reported earlier. More recently different ethnic groups started to create synergies in drug distribution and
traffic, whereas previously these groups have been operating separately. The proportion of non-natives
involved in drug trafficking has been increasing until 2005 and has been decreasing quite sensibly although
non-natives drug traffickers represent 74% (60% in 2007). Typically, involved dealers carry small quantities
of drugs hidden in their mouth ready to be swallowed promptly in case of police controls. Initially drugs of
high quality have been sold at low prices. Progressively however the quality and diversity of sold drugs have
been decreasing. The national drug market has been flooded by a high proportion of low quality injection
drugs, which has induced major changes in consume patterns of national drug users.
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56 Non published information from the Specialised Drug Unit of the judicial Police
Little, however, is known on the provision sources of the referred distribution networks. They seem to rely on
important stocks of cocaine. They are highly organised and have managed to significantly increase the
supply and availability of drugs at the national level. In 2005 it was estimated that 0.5 kg of cocaine are
sold daily to drug users within the Luxembourg City drugs scene.
SEIZURES
In terms of quantity seizures, have been fairly stable since 2000 for heroin and even decreasing as far as
cocaine and cannabis are concerned. The number of seizures did not show significant variations during the
same period, with the exception of cannabis going up after 2000. Also, the number of offenders involved
in seizures has been showing an overall decreasing trend. This may suggest that greater quantities of drugs
are trafficked by smaller groups of traffickers. A confirmed majority of offenders are involved in cannabis
traffic and are non-natives. 
Quantities and numbers of drug seizures
Striking variations have been observed as to the quantity of illicit substances seized since the beginning of
the nineties. A longitudinal data analysis indicates a general decreasing tendency of heroin, cocaine and
cannabis seizures until 200257. Since 2002 however, one observes a significant increase in the quantity of
drug seizures mainly concerning heroin and herbal cannabis. Cocaine seizures (quantity) are highly variable
since the beginning of the nineties. Compared to 2007 data, the quantity of seizures of nearly all listed
substances went up in 2008 (except for heroin). This observation particularly applies to cannabis and
cocaine.
Notwithstanding the quantities seized, the number of seizures has grown discontinuously since 1990. Since
2000 the number of cannabis seizures has clearly increased but likewise the number of heroin and cocaine
seizures tends to stabilise. Markedly, the number of cannabis seizures has risen from 167 to 580 between
1994 and 2008. The total number of persons involved in traffic has followed a constant upward trend until
2000 and stabilised afterwards (2008: 1487 (1072) persons). A confirmed majority of offenders are
involved in cannabis traffic and are non-natives. For detailed information, see standard table 13.
Crack (cocaine-base) seizures have not been reported to date by national authorities. It has, however,
appeared on the national market according to field agencies. The first national seizures of ecstasy type
substances (MDMA, MDA, etc.) were recorded in 1994. The availability of ecstasy appeared to soar between
1994 and 1996. Most recent seizure data indicate, however, stabilization at very low level.
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Fig. 10.1 Total quantity of seizures: heroin, cocaine, ecstasy type (1988 - 2008)   
Source: Specialised Drug Department of the Judicial Police 2008
Fig. 10.2 Total number of seizures: Cannabis,Heroin, Cocaine, MDMA (1988 - 2008) 
Source: Specialised Drug Department of the Judicial Police 2008
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Fig. 10.3 Number of offenders involved in seizures according to type of offence (1988-2008)
Source: Specialised Drug Department of the Judicial Police 2008
Number of illicit laboratories and other production sites dismantled___________________
The last time the dismantling of a synthetic drug manufacturing laboratory was reported by law
enforcement dates back to 2003. Since then no further laboratory seizure on the national territory was
reported. 
According to police records, single cannabis growing fields are found on a fairly irregular basis. Local
cultures of cannabis remain rather insignificant in terms of quantity and national production is limited to
small indoor cannabis cultivations (mostly for personal use and not primarily meant to procure economic
profit).
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PRICE/PURITY
Price of drugs at retail level
Average street prices of heroin (brown), cocaine and ecstasy type substances have fallen from 1998 to
2002/2003 but broader price ranges as well as higher maximum prices for cocaine and heroin have been
observed since 2004, which is due to a high variability of purity. Cannabis and derivates however have
known a fair stability during the last 7 years. Heroin is frequently sold as ‘boule’ containing 0.2-0.4 grams
for 12-25. - EUR. Typical street retail cannabis is sold in pieces of 2.5 to 3 grams for 25. – EUR. 
Table 10.2 Price per unit evolution at the street level (1994-2008)
1994 1998 2000 2002 2004 2005 2006 2007 2008
Cannabis
Haschisch 5-6 7.4 7.3 7.3 8 8-10
Marijuana 2.5-3 6.2 7.3 7.3 7.5 5-10
Cocaine 100-150 120-170 90 50 20-120 20-110 30-100 30-100 70-100
Héroine (brown) 65-150 90-150 74.4 50 82 80 50-90 50-90 60-80
STA 25-30 n.a. 25 n.a. n.a. 5 5 20
Ecstasy 9-13 10,7 7 10 10 5 5 5-15
LSD 11-13 1-13 n.a. n.a. 10 10 n.a. n.a. 5-15
Sources : Specialised Drug Department of the Judicial Police confirmed by Tox-In 2008
Price: expressed in EURO at street level.
For cannabis, cocaine, heroin and amphetamines, price per gram is indicated.
For heroin and cocaine, minimum prices refer to traffic units. Maximum and average prices refer to street retail quantities.
For ecstasy and LSD, price per pill or unit are indicated.     
Purity/potency of illicit drugs
Compared to the situation in 2003, purity of heroin and cocaine has remained fairly stable. Attention has
to be paid to the striking differences in maximum and minimum purities as well as to a historically high
maximum concentration of THC (over 30%) in herbal cannabis samples seized in Luxembourg in 2007. 
Attention has to be paid to the striking differences in maximum and minimum purities of all substances.
For instance heroin and cocaine show very high maximum purity rates. These values should however be
considered carefully, the sampling may contain intermediary seizures, not ready for street consumption and
to which cutting agents were supposed to be added.
Historically high maximum concentration of THC in cannabis samples seized in Luxembourg has been
observed in 2007. Herbal cannabis showed highest maximum levels of THC concentrations (31.05% in
2007, 25% in 2008). In 2008 the figures for THC concentration have been similar for herbal (25%) and
resin (22.45%) cannabis for the first time since reported. For more detailed information please refer to
standard table 14.
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Table 10.3 Purity of drugs at street level (1994-2008)
1996 1998 2000 2002 2004 2006 2007 2008
Pur. (%) Pur. (%) Pur. (%) Pur. (%) Pur. (%) Pur. (%) Pur. (%) Pur. (%)
Average AVRG. AVRG. AVRG. AVRG. MIN. MAX. AVRG. MIN. MAX. AVRG. MIN. MAX. AVRG.
Cannabis (THC) 8.03 7.96 6.94 0.15 25.85 7.36 2.2 31.05 9.61 1.60 25 9.82
Marihuana 3.5 31.05 10.21 1.60 25 9.75
Hashish 2.2 18.02 8.52 2.25 22.45 10.3
Cocaïne 60-90 60-90 60.25 62.99 62.37 11.7 100 61.78 4.25 97.11 54.65 9.20 99.20 52.13
Héroïne (brown) 15-23 20-25 17.59 9.97 17.07 3.6 40.9 14.48 3.85 22.75 14.95 0.95 56.70 14.5
STA 15.09 9.44 3.6 15.35 7.1 2.7 33.25 13.81 0.50 43.65 18.2
Ecstasy 58
(MDMA) 35.5 71.11 29.77 1.2 43.98 26.44 0.20 39.29 20.52 4.83 68.28 23.52
(MDEA) 6.8 6.25 0.69 1.81 1.25 18 28.23 23.57
(MDA)
Psylocine 0.15 0.41 / / / / / / / / /
Sources : Specialised Drug Department of the Judicial Police / Laboratoire National de Santé. Division Toxicologie. 2008.
Purity: For cocaine, heroin and amphetamines, purity is expressed in percentages of pure active substance at the street level.
For cannabis, purity refers to percentage of THC.
Composition of illicit drug tablets
Information for this section was provided by the National Laboratory of Health (LNS) and formatted by the
NFP.
A total of 64.5 tablets have been analysed for 2008, provided from 49 different samples.
18 samples contained exclusively MDMA as active substance and 8 samples MDMA and ATS traces and 2
samples MDMA and mcPP. Two samples were exclusive: the first containing mcPP mixed with
metoclopramide and the second MDMA, MDA and MDE. A third group of analysed products were composed
of methadone.
The last category of pills or tablets analysed contained non-scheduled (schedule I or II) substances such as
Ibuprofen and paracetamol. Most common cutting agents found in MDMA, amphetamine or mcPP
containing products were sugar and caffeine.
For detailed information please refer to standard table 15. 
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PART B: 
SELECTED ISSUES
11. MARKET AND PRODUCTION OF CANNABIS 
MARKETS
History of cannabis domestic production
Cannabis is the most prevalent illicit drug in the Grand-Duchy of Luxembourg. In recent years potency of
cannabis (THC levels) has been increasing and so did risks associated to its use especially with regard to the
high and unpredictable variations in purity.
The number of persons in contact with the national specialised network for (preferential) cannabis use had
known a sensitive increase at the beginning of the 21st century but decreased again to stabilise between
2005 and 2008. Respectively 90% of current PDUs have tried cannabis while being minor of age.
The percentage of treatment demands related to cannabis use has passed from 4% in 1997 to 11% in 2002
and has decreased to 1% between 2006 and 2008. All indicators on cannabis use (problematic and
recreational) have been on the increase for several years but tend to stabilise more recently. Cannabis
showing high THC concentrations (max: around30%, mean: 9.61%) is increasingly found on the national
market. Marijuana shows the highest purity but also the most important variations in terms of quality. 
A more recent trend is the increase of treatment demands for cannabis use related problems associated to
alcohol abuse in youngsters as reported by the Medical Control Department in charge of referrals to
specialised treatment centres abroad. 
Local cultures of cannabis remain rather insignificant in terms of quantity. Generally spoken, Luxembourg is
not a cannabis producing country. If cultures of cannabis are detected, they are mostly attributed to single
cannabis users who grow cannabis plants only for their personal consumption. No plantations aiming at a
professional distribution of cannabis have been detected thus far on the national territory. Concerning the
type of cultivation of cannabis, cases of indoor (mainly) and outdoor cultivation have been detected as well
as some isolated cases of hydroponic cultures. One has to bear in mind that these plantations are of smaller
sizes and for personal use only. A single headshop is located in Luxembourg city. It mainly sells bongs of
different types and auxiliary tools. No genuine “Grow shop” does exist at national level.
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Legislation
The law of 27 April 2001, amending the law of 19 February 1973 concerning the sale of medicinal
substances and the fight against drug addiction, decriminalized cannabis consumption as well as the
possession for personal use. The law introduces a classification of substances into two categories: A (other
controlled substances) and B (cannabis).
The use of cannabis remains illicit but the use and possession for personal use does not imply prison
sentences anymore. A cannabis user may be sentenced to pay a fine ranging from 251 to 2,500 EUR. Prison
sentences from 8 days to 6 months and/or a fine ranging between 251 and 2,500 can be applied if
cannabis use occurs in presence of minors, in schools or at the workplace. Also, in case adults use cannabis
with minors, the sentence can increase up to two years of imprisonment (and/or a fine of 500 to 25,000
EUR) and up to 5 years (and/or a fine of 500 to 12,500 EUR) in case a medical doctor or pharmacist uses
cannabis in certain settings as prison, school, social services and their immediate vicinity (Art.7B1).
In case of cannabis production and trafficking prison sentences ranging from 1 to 5 years and/or a fine
ranging from 500 to 1,250,000 EUR are foreseen. These sanctions do also apply for the provision
(transportation, possession, distribution and fabrication) of equipments and materials used for the culture
and the production of cannabis. A minimum of 2 years of imprisonment and a minimum of 1,000 EUR are
requested in case this offence has been committed in prison, in schools or in a social service (or in the
immediate vicinity of those). The law does not explicitly foresee a distinction between small-scale and large-
scale drug trafficking. The respective sentences currently range from 1–5 years’ imprisonment and/or a fine,
while imprisonment of 5–10 years is foreseen if the distributed drug has caused severe damage to health
(e.g. incurable diseases). If the drugs had fatal consequences for the user, the punishment may increase to
15–20 years.
Consumer market shares of different cannabis products
At national level import and consumption of cannabis are estimated to a share of 90% relating to cannabis
herb and 10% to resin. Concerning sinsemilla or other types of cannabis herb with high THC concentration,
it is difficult to provide any estimation. The last ten years, cannabis showing high THC concentrations was
increasingly found on the national market with maximum THC concentration up to 30% (mean 10%).
Distribution of cannabis at national level
For some years the expansion of more structured distribution networks has been observed. “Drug
professionals” have joined the national illicit drug market and have developed structured commercial
distribution networks. Over the last 3 years the proportion of non-natives implicated in drug traffic can be
estimated up to 80%. A significant number of West and North African nationals as well as citizens
originating from Cap Verde appear in drug trafficking law offenders.
A considerable number of traffickers switched from the sale of heroin to the sale of cocaine and currently
are also implicated in the sale of cannabis. Overall, the national drug market has become of a more
aggressive nature in terms of selling techniques. More recently ethnic groups have joined and improved their
drug distribution strategies whereas previously none of these criminal groups actively searched contact to
other groups.
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Cannabis wholesale prices, 2008 (if possible 2004-2008)
Cannabis and derivates have known a fair stability over the last 7 years as far as street prices are concerned.
Typical street retail cannabis is sold in pieces (“grip” bag) of 2.5 to 3 grams for 25.- EUR.
Table 11.1 Price per unit evolution at the street level (1994-2008)
1994 1998 2000 2002 2004 2005 2006 2007 2008
Cannabis
Haschisch 5-6 7.4 7.3 7.3 8 8-10
Marijuana 2.5-3 6.2 7.3 7.3 7.5 5-10
Sources : Specialised Drug Department of the Judicial Police confirmed by TOX-IN 2008
Typology of retail outlets for cannabis sale
As referred to under point c), drug traffickers are mostly implicated in polydrug dealing.
The main retail outlets for cannabis sale are public spaces (often in the vicinity of train and bus stations),
locations where youngsters meet (bars, etc.) and areas close to schools. 
Cannabis sources and transaction sizes
Most of cannabis users buy their doses at the national illicit drug market. Some users grow cannabis plants
at home to share with other users. Different names for cannabis exist: grass, marihuana, weed, dope, pot,
joints, hashish or shit. Standard units for the purchase of cannabis resin go up to 4 grams and herbal
cannabis is mostly sold in bags (“grip”) containing 2.5 to 3 grams. Prepared joints are not or very rarely sold
on the national illicit drug market.
SEIZURES
Contextual info: supply reduction organisation and activities
The following units of the Grand-Ducal Police (Ministry of Justice) are involved in the fight against drugs:
- Specialised Drug Department of the Judicial Police (national and international investigation),
- Departments of search and criminal investigation (SREC) of the 6 regional sectors (national and regional
investigation),
- Intervention centres and commissariats of proximity (controls, selective investigations,...).
The anti-drugs division – “division anti-drogues et produits sensibles” (seizures, home visits, body visits) and
the tracking dogs brigade of the Administration of Customs (Ministry of Finance) are also involved in supply
reduction activities.
The fight against drug trafficking is one of the priorities of the Grand-ducal Police. The Grand-ducal Police
organises repression activities (investigations, controls) as well as prevention activities.
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Seizures of plants and/or plantations, 2006-2008
Table 11.2 Quantities of cannabis plants and products seized between 2006 and 2008 (Total)
  Quantities of drugs seized 2006-2008
Kilograms grams numbers of units type of unit Number
of seizure cases
06 07 08 06 07 08 06 07 08 06 07 08 06 07 08
Cannabis plant 105 45 3 25 plants plants plants 4 2 3
Cannabis herb (marijuana) 62 13 20 412 330 700 464 532 464
Cannabis résin (hashish) 4 0 8 584 460 80 117 111 113
Cannabis oil
Source: Specialized drug department of the Judicial Police 2008
As stated above, the Grand-Duchy of Luxembourg is not a producing country for cannabis (e.g. 3 plants
seized in 2007). If cultures of cannabis are detected, they mostly can be attributed to single cannabis users
who grow cannabis for personal use only. Police sources indicate that the type of material seized in relation
to the use and production of cannabis are mainly UV lamps and cannabis bags (“grips”).
Origin of cannabis products seized, 2006-2008 (if possible 2004-2008)
Law enforcement sources indicate that the majority of cannabis products consumed in the Grand-Duchy of
Luxembourg (herb and resin) originate from the Netherlands (99%). Cannabis resin, even if it mainly
originates from Morocco, is transported (hub) to the Netherlands and from there distributed to other
European countries. For several years one observes countries such as Albania and Afghanistan being
increasingly involved in the production of cannabis. The Balkan route still constitutes the main transport
land route.
Till the beginning of the nineties, most of the persons involved in illicit drug distribution were consumers
who supplied themselves in the Netherlands or acquired limited extra quantities of drugs in order to sell
them within restricted local networks. Since the opening of EU borders, more organised distribution
networks tend to develop within the national drug market. 
The road network is the main transport and transit route for cannabis.
Breakdown of cannabis seizures by product and by amount seized, 2008
Great variations have been observed as to the quantity of illicit substances seized since the beginning of the
nineties. A longitudinal data analysis indicates a general decreasing tendency of cannabis seizures until
2002. Since 2002 however, one observes a significant increase in the quantity of drug seizures mainly
concerning heroin and herbal cannabis. Compared to 2007 data, the quantity of seizures of nearly all listed
substances went up in 2008 (except for heroin). This observation particularly applies to cannabis.
Notwithstanding the quantities seized, the number of seizures has grown discontinuously since 1990. Since
2000 the number of cannabis seizures has clearly increased. Markedly, the number of cannabis seizures has
risen from 167 to 580 between 1994 and 2008. The total number of persons involved in traffic has followed
a constant upward trend until 2000 and stabilised afterwards (2008: 1487 (1,072) persons). A confirmed
majority of offenders are involved in cannabis traffic and are non-natives. This may suggest that greater
quantities of drugs are trafficked by smaller groups of traffickers. 
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Table 11.3 Breakdown of cannabis seizures by product and by seized amount in 2008
CANNABIS PRODUCT TYPE SEIZURES AMOUNT UNIT
HERBAL 464 20.733 KG
RESIN 113 8.084 KG
PLANTS 3 10559 KG
25 PLANTS
Source: Specialized drug department of the Judicial Police 2008
Table 11.4 Number of herbal cannabis cases and total amount seized for the following weight classes:
≤ 150 g 150 g - 1 kg 1 - 50 kg > 50 kg
CASES 451 10 3 0
AMOUNT SEIZED 3298 grams 4375 grams 13.063 kilograms 0
Source: Specialized drug department of the Judicial Police 2008
Table 11.5 Number of cannabis resin cases and total amount seized for the following weight classes:
≤ 150 g 150 g - 1 kg 1 - 50 kg > 50 kg
CASES 109 2 2 0
AMOUNT SEIZED 649 grams 975 grams 6.459 kilograms 0
Source: Specialized drug department of the Judicial Police 2008
Table 11.6 Largest single seizures
CANNABIS TYPE LARGEST SEIZURE 
HERBAL 8.973 kg
RESIN 5.332 kg
Source: Specialized drug department of the Judicial Police 2008
134 59 For one (the largest) seizure, plants have not been counted but weighted (therefore expressed in kg).
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OFFENCES
Cannabis supply-related offences reported by the police, 2006-2008
The following table shows the number of arrests broken down by type of offence and substance involved
(1995-2008):
Table 11.7 Number of arrests by involved substance and offence 1995 – 2008:
Substance Offence 1995 1997 1999 2001 2003 2004 2005 2006 2007 2008
Cannabis Use & Traffic 25 18 32 23 52 16 17 42 n.a. 61
Traffic/Deal 1 11 8 1 17 20 27 36 n.a. 11
Use 4 4 3 15 9 14 25 15 n.a. 18
Total 30 33 43 39 79 50 69 93 n.a. 90
Total number of arrest Use & Traffic 59 57 48 46 85 n.a. 103
motives independently Traffic/Deal 13 61 93 63 87 n.a. 53
of involved substances Use 20 15 35 45 47 n.a. 31
Total 128 154 108 92 133 178 154 219 226 187
Source: Specialized drug department of the Judicial Police 2008
Over the last 5 years, arrests related exclusively to cannabis traffic / deal have followed a decreasing
tendency in reference to the total number of arrest motives independently of involved substances (2003:
22%, 2004: 11.2%, 2005: 17.5%, 2006: 16.4%, 2007: n.a, 2008: 6%). 
The Specialised Drug Department of the Judicial Police reports the following number of offenders
(‘prévenus’) broken down by type of offence and substance involved (2004-2008):
Table 11.8 Number of drug law offenders by involved substance and offence 2004 - 2008:
Substance Offence 2004 2006 2008
N N N
Cannabis Use & Traffic 119 117 151
Traffic/Deal 93 105 35
Use 624 598 650
Total 836 820 836
Total number of Use & Traffic 296 280 278
accusation motives Traffic/Deal 502 239 141
independently Use 1.265 1.414 1.278
of involved substances Total 1.760 1.537 1.485
Total number of offenders 1.808 1.575 1.487
Offences exclusively related to cannabis traffic (and retail dealing) range between 2.4%% to 6.8% (5.2%:
2004, 6.8%: 2006, 2.4%: 2008) with regard to the total number of accusation motives independently of
involved substances. These figures do not suggest an upward trend in cannabis traffic offences the last 5
years.
Regarding the breakdown of the cannabis supply offences by production, it has to be stressed that
Luxembourg is not a producing country of cannabis and cases of cannabis cultivation are very rare.
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12. PROBLEM AMPHETAMINE AND
METHAMPHETAMINE USE, RELATED
CONSEQUENCES AND RESPONSES 
EPIDEMIOLOGY OF AMPHETAMINE AND METHAMPHETAMINE USE
History of (meth)amphetamine use
Epidemiological data of illicit drug use became available at national level in the course of the 70s. During
that period, heroin, cocaine and cannabis consumption started to spread. During the eighties the use of
cocaine, heroin and cannabis still remained important but a notable decrease of hallucinogenic substances
(mainly LSD) has been observed. 
Since 1988 an increasing consumption of pharmaceuticals diverted from their therapeutic use and
amphetamines appeared. Also in the mid nineties a growing tendency of amphetamine use was observed
as well as the first national seizures of MDMA. An increasing trend in the use of ecstasy-like substances
primarily in youngsters was observed subsequently. Since 1998 an increase of heroin and cocaine prevalence
occurred. The consumption of cannabis as well as the use of synthetic drugs had followed an increasing
tendency. To date, ecstasy-like substances and ATS remain popular even though seizure figures do suggest
an inverse and currently stable trend.
Scientific articles documenting exclusively the history of (meth)amphetamine use at national level do not exist.
Trends and patterns of (meth)amphetamine use
The study “Drugs and chronic alcohol abuse in drivers” (2005)60 assessed the proportion of medicinal drugs
(benzodiazepines, antidepressants, neuroleptics, etc.), illicit drugs (cannabinoids, opioids, amphetamine
derivates and cocaine metabolites) and chronic alcohol abuse in bloodspecimens from randomly selected
210 drivers (179 males, 31 females/mean age for both males and females: 39 years), apprehended in
Luxembourg from autumn 2001 to spring 2002 for whom blood alcohol concentration (BAC) were
determined. The study aimed at providing an indication of the extent of psychoactive substance use in
vehicle drivers by gender and age. Alcohol was detected in the majority of cases (88.1%), medicinal drugs
were detected in 22.9% and illicit drugs were detected in 10.5% of drivers investigated. Traces of illict drug
use not combined to alcohol use were reported for only nine drivers. Concerning the detection of
amphetamines, the detection threshold was 30 ng/mL. Amphetamine use had not been detected among
the population studied.
Concerning the study “Prevalence and spreading of viral hepatitis A, B, C and HIV in problem users of illicitly
acquired drugs” (2006)61 several questionnaire items of the study referred to drug use patterns. The study
analysed a total of 368 (validated) questionnaires which had been answered by PDU respondents from
national residential treatment centres, ambulatory treatment centres, low threshold services and national
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prisons. A total of 208 respondents (56.6%) out of 368 (84.2% ever injectors and 15.8% never injectors)
declared having consumed amphetamines. These respondents indicated a mean age of first consumption of
amphetamines at 18.69 years (min. age: 11 years and max. age: 37 years/ standard deviation: 4.8).
Concerning the item “frequency of consumption (or injection) of drugs in the last 2 months”, 17 persons
reported amphetamine use within the last 2 months (11.8% more than 4 times per day , 0% 2 to 4 times
per day, 5.85% 2 to 6 times per week, 5.85% 1 time per day, 0% once a week and 76.5% occasionally).
Concerning age, 13 respondents (N=17) having reported the use of amphetamines during the last two
months (11.2%), were aged less than 30 years whereas 4 respondents (4.3%) were aged more than 30
years.
Table 12.1 refers to amphetamine use history (first amphetamines use to last use):
Table 12.1 Amphetamine use history (first amphetamines use to last use):
Amphetamines
N %
200 100
0-2 years 105 52,5
3-5 years 37 17,5
6-9 years 27 13,5
>= 10 years 33 16,5
No data available 8
Source: Origer et Removille 2007 
The study revealed that hallucinogens, amphetamines and “other stimulants” (other than cocaine) are in
majority consumed for a two years period. In comparison, cannabis constitutes the drug which is consumed
for the longest period of time: more than 10 years. Concerning the item “last consumption of drugs”,
respondents declared that the consumption of hallucinogens (84.4%), amphetamines (76.3%) and “other
stimulants” (64.4%) dates back to more than 2 years.
The study also revealed a significant increase of the probability (p<0.05) to present a hepatitis B infection
in relation to the length of time of amphetamine consumption which however is not the case for the other
infections studied. Also the moment of the last use of amphetamines by ever injectors appeared to be a risk
factor for HCV infection.
Considering only the respondents from national prisons, a total of 142 questionnaires have been analysed.
In all, 13.5% of respondents were never injectors (19/141) and 86.5% were ever injectors (122/141).
Concerning questions on drug consumption habits, 46.1% (65/141) of drug dependant prison inmates
declared having consumed amphetamines during lifetime. Concerning the item “last consumption of drugs”,
“prison” 85.9% of respondents indexed as ever injectors (N=64) reported amphetamine use dating back to
more than two years. 
As also stated above, the study reveals a statistically significant relation between the “amphetamine career”
and a hepatitis B infection (p= 0.012) among ever injectors from prison centres. An ever injector from a
penitentiary institution has a 6.4 times higher chance to be infected with hepatitis B when having
consumed amphetamines for more than 6 years than respondents with no or shorter use of amphetamines.
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Prevalence estimates of problem (meth)amphetamine users
Table 12.2 presents preferential drug use (1 to 3) of PDUs registered by the national monitoring system
“RELIS”:
Table 12.2 Preferential drug reported by indexed current PDUs (2008)
Main Drug PREFERENCE 1 PREFERENCE 2 PREFERENCE 3
(valid %)
98 01 04 06 07 08 98 01 04 06 07 08 98 01 04 06 07 08
ALCOOL 1 2 4 4 4 6 4 8 10 7 12 21
CANNABIS 
AND DERIVATES 3 11 5 1 3 0 29 28 21 18 23 31 41 34 38 43 37 39
INHALANTS,  
VOLATILES SUBST.
HALLUCINOGENES
(LSD, PCP, etc.) 1 1 1 4 1 1 2 5 4 3 3 2 3
HYPNOTICS AND 
SEDATIVES 1 4 8 6 7 6 9 12 14 20 20 20 15
STIMULANTS CNS 1 1
MDMA (XTC) 6 3 2 2 2 2 7 4 4 1 4 2 10 7 6 6 2 7
Amphetamines 2 1 1 1 1 3 3 2 2 0 1 6 3 1 4 2 2
Crack (ex. cocaine freebase) 1 1 0 1 1
Cocaine (other 
administration routes) 4 7 9 7 7 13 18 14 20 19 16 13 7 7 6 4 7 4
Cocaine (i.v.) 3 2 7 10 8 4 15 12 22 25 21 16 7 5 5 5 4 3
OPIACES /OPIOIDS
(non specified) 2 1 2
Substitution products 
(illegal consumption) 2 2 2 3 3 1 1 3 2 3 2
Substitution 
products (prescribed) 1 6 3 1 1 7 5 6 6 4 5 4 4 6 5 3 4 3
Heroin and other opiates 36 22 23 20 30 31 4 9 4 3 3 8 3 3 3 1 2 2
Heroin and other 
opiates (i.v.) 41 47 48 57 47 41 7 8 7 12 11 6 3 6 1 1 1 0
OTHER PSYCHOACTIFS
SUBSTANCES 1 1 1 0
N 574 724 687 737 734 678 397 561 526 506 463 356 255 375 350 348 273 191
Source: RELIS 2008
Only 1% of PDU’s indexed by RELIS reported in 2008 amphetamine as main drug. The RELIS network
includes specialised drug agencies, psychiatric departments of a series of general hospitals, law enforcement
agencies and national prisons.
Amphetamines are also rarely cited (1%) as drug of first contact.
Table 12.3 shows the ages of first use of amphetamines and other drugs:
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Table 12.3 Age of onset of amphetamine use reported by indexed current PDUs (2008)
AGE 2008 (2007) 10-13 14-15 16-17 18-19 20-21 22-25 26-33 +33
ALCOOL 39(39) 39(43) 10(11) 8(5) 2(2) 0(2) 2(0)
CANNABIS AND DERIVATES 34(36) 33(32) 23(21) 6(9) 2(2) 1(0) 1(0)
INHALANTS 33(20) 33(60) 33(20)
HALLUCINOGENES (LSD, PCP, etc.) 9(13) 42(35) 26(30) 14(19) 7(3) 2(0)
HYPNOTICS AND SEDATIVES 4(7) 8(7) 27(21) 22(30) 12(16) 10(5) 12(9) 4(5)
STIMULANTS SNC 0(17) 50(33) 50(17) 0(17) 0(17)
MDMA (XTC) 10(8) 34(38) 28(26) 7(13) 9(6) 7(7) 3(2)
Amphetamines 11(8) 0 (16) 44(32) 22(36) 22(8)
Crack ( ex. cocaine freebase) 17(20) 50(20) 0(20) 0(20) 33(20)
Cocaine 5(6) 15(18) 14(21) 26(17) 16(17) 14(12) 9(6) 1(3)
Cocaine (i.v.) 5(6) 17(12) 20(21) 21(24) 15(14) 13(14) 8(8)
OPIOIDES 50(50) 50(50)
Substitution products (illegal cons.) 0(17) 50(17) 0(17) 0(17) 50(33)
Substitution products (prescribed) 20(15) 20(8) 30(38) 30(8) 0(23)
Heroin and other opiates 3(4) 22(20) 22(23) 17(19) 9(17) 16(7) 11(8) 1(2)
Heroin and other opiates (i.v.) 5(4) 16(15) 25(25) 19(25) 13(11) 16(17) 5(3) 1(0)
AUTRES PROD. PSYCHOACTIFS 14(0) 14(0) 14(10) 28(20) 0(20) 0(30) 14(10) 14(10)
N = 950
Source: RELIS 2008
One may note that in 2008 and regarding age group 18 to 19 years, the majority (36%) of current PDUs
report their first consumption of amphetamines followed by age group 16 to 17 years (32%). In 2008,
however, the majority of PDUs reported onset of amphetamines use between the age of 16 and 17 years
(44%).
Treatment demand for (meth)amphetamine use
Treatment demands related to ATS use are rare (1-2%) and have shown a fair stability over the last years.
Production sites and laboratories, origin of products and trafficking routes, precursors seizures
In 2003 one clandestine laboratory of amphetamines has been detected in the Grand-Duchy of
Luxembourg.
Table 12.4 shows the number and quantities of seizures of amphetamine and methamphetamine:
NATIONAL REPORT TO THE EMCDDA
“GRAND DUCHY OF LUXEMBOURG”
New Developments, Trends and in-depth
Information on selected issues
140
09Édition 
Table 12.4 Number and quantity of seizures of amphetamine 1995 - 2008  
1995 2000 2004 2005 2006 2007 2008
Substances Q N Q N Q N Q N Q N Q N Q N
Amphetamines 0.03 9 0.157 9 0,951 4 83.3 2 11.44 4 1.60 3 0.172 19
Methamphetamines
Source: RELIS 2008
As one may note the number of amphetamine seizures are relatively limited and situate between 2 and 9
seizures from 2000 to 2007. In 2008, however, the number of amphetamine seizures has risen to 19. To
date, no methamphetamine seizures have been registered. In 2005 the most important seizure of the last
years of amphetamine was registered and amounted 83.3 kg.
OVERVIEW OF HEALTH AND SOCIAL CORRELATES OF CHRONIC
AMPHETAMINE AND METHAMPHETAMINE USE
Health and social correlates of chronic (meth)amphetamine use
To date, no case of (meth)amphetamine related death has been registered at national level.
RESPONSES TO CHRONIC AMPHETAMINE AND
METHAMPHETAMINE USE
Health, social and legal responses addressing (meth)amphetamine use or chronic use
Services, interventions or programmes especially dedicated to (meth) amphetamine use do not exist at
national level. All specialised drug treatment centres at national level accept clients with all kind of
substance abuse.
Quality assurance and best practices
As stated above no specific guidelines especially dedicated to the treatment, harm reduction, rehabilitation
and social reintegration of (meth)amphetamine users exist at national level. As the majority of national
PDUs are polydrug consumers, the national treatment and care institutions are primarily specialising in
prevention, treatment and care for polydrug users and intravenous use.
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Relevant data bases and information systems
A. RELIS drug monitoring system
Relying on a multi-sectorial data network including specialised in- and outpatient treatment centres and
low threshold facilities, general hospitals as well as law enforcement agencies and national prisons, the
RELIS drug monitoring system, established in 1995 by the NFP in collaboration with the Ministry of Health
enables the assessment of new trends in the problem drug users population in general as well as in drug
treatment demanders in particular. PFN has opted for a holistic monitoring of the drug population, which
by definition, is heterogeneous and not limited to drug treatment demanders. RELIS data refer to HRC drug
users indexed by the national specialised treatment and law enforcement network and, as such, defined as
problem drug users.
The main objectives of RELIS are the following:
• present comprehensive information on the drug phenomenon in the Grand Duchy of Luxembourg
• estimate the drug prevalence at the national level (problem drug users)
• unfold emerging trends
• track any drug-related activities, be they in policy, demand reduction or research areas
• assess the impact of offer, demand and risk reduction activities on current drug consume behaviours
• serve as a data base for research activities. 
The RELIS data collection procedure is based on a standardised extensive data protocol including 23 core
items and over 60 sub-items. The standard protocol, including 95 per cent of the Pompidou protocol’s items,
has been last modified in 2000 in order to reach compatibility with the TDI (Treatment Demand Indicator)
standard. The RELIS standard protocol includes a series of internal consistency items that allow to assess
quality and consistency of provided data and to operate unreliable data extraction. 
A second protocol, namely the Actualisation Protocol is completed each time a previously known problem
drug user is re-indexed after a period of one year following the previous indexing. Finally, a third protocol
(Identification Protocol) including only the identification code, the name of the contacted institution and
the date and context of admission is applied if a previously known user is re-indexed in the course of the
year following his previous indexing. The registration system allows for highly updated, detailed and com-
parable data and for a follow-up of institutional careers of problem drug users by means of a routine and
cost-effective data collection procedure.
To avoid multiple counting and to allow for a follow-up of drug users’ careers, RELIS is based on a 9-digit
numerical code obtained by indating 3 core variables (attributers) namely: gender (i.e. 01/02), date of birth
(i.e., 10051967), and country of birth into a code - calculator developed by the NFP in collaboration with
the CRP-Henri Tudor. The solution found is time and cost effective because it relies on a simple HP calcula-
tor that runs an attributor-to-code transcription programme based on a multiple-step algorithm.
Each contact person from the participant field institutions disposes of such a calculator and produces the
code by him/herself. The reliability in terms of data protection was approved by national data protection
authorities, by German partner regions of the Mondorf Group and by the National Commission for
Informatics and Liberties (CNIL) of France. 
One of the main benefits of the described procedure is that no personal data can be inferred directly from
the identification code. The indating and encoding procedures are carried out at the very level of the field
institutions. Thus, NFP is provided with individualised data (reporting protocols) without any reference to
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identifying information or attributors on the indexed persons, which is undoubtedly one of the major preoc-
cupations of field institutions.  
RELIS data processing is based on ORACLE ® database software and allows for multiple variable break-
downs as well as separated data analysis for different treatment or law enforcement settings. Separate data
can be provided for participation regions and institutions.
In terms of data provision, RELIS further relies on following national registers:
• Register of drug law offenders - Special Drug Department of the Judicial Police,
• National Mortality Register - Ministry of Health,
• Special Overdose Register - Special Drug Department of the Judicial Police,
• AIDS and HIV Register - Laboratory of retrovirology - CRP-SANTE.
• Early warning system on new synthetic drugs
B. Register on drug law offenders (SPJ)
The register on drug law offenders is paper-based and maintained by SPJ. Research and queries on drug law
offenders are performed manually. Special authorisation has been reached by the NFP to access the refer-
red register and to manually include non-nominative data on offenders into the RELIS database. The NPF
thus has developed a standard data collection protocol relying on SPSS ® based data analysis. This proce-
dures has enabled the NFP to dispose of detailed anonymous data on all drug law offenders indexed by SPJ
and to operate breakdowns referring to use and traffic offences and to substances involved according to
types of drug law offences.
C. General Mortality Register (GMR)
GMR is run by the Health Statistics Department of the Directorate of Health. The main impediment towards
refined data provision on drug-related deaths and the application of the EMCDDA promoted DRD standard
has been the 3-digit ICD coding applied by GMR until 1997. In 1998, ICD-10 standard was first applied by
GMR. Currently, drug-related death data are extracted from GMR by means of a separate extraction routine.
Efforts are currently made to implement an integrated software based on the DRD ICD-10 standard and
relying on the RELIS identification code, thus allowing for cross validation of drug-related death data. 
D. Special Overdose Register (SR) of SPJ
The SR is a paper-based register on acute and indirect drug-related deaths run by the SPJ. Over the past
years, NFP has put major efforts in the development of a computer-based indexing procedure (SPSS ®) of
drug-related deaths by means of a comprehensive data form. NFP is currently maintaining a standardised
database on acute drug-related deaths from 1985 to 1999. Anonymous drug-related death data is enco-
ded at the SPJ and transmitted to the NFP according approved standards. Data on indirect drug deaths that
are still paper based is also provided to the NFP. 
E. AIDS and HIV register (CRP-SANTE)
Official statistics from the national Retrovirology Laboratory of the CRP-Santé provide the number and pro-
portion of IDUs in HIV infected patients. Breakdowns by limited core socio-demographic variables are avail-
able. Provided data has public status. 
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F. Early Warning System on Synthetic Drugs (NFP / SPJ)
In the framework of the Joint Action on Information Exchange, Risk Assessment and Control of New
Synthetic Drugs, the NFP has developed a nation wide cross-sectional data exchange network 
Decision has been made to adopt a centralised structure relying on a nation wide EWS partners’ network
(local contact persons) as well as centralised coordination of key data providers’ activities. The national coor-
dination unit of EWS is implemented within the NFP. The head of NFP has been appointed national EWS
coordinator.
The new mandate of the Inter-ministerial Group on Drugs (November 2000), which represents the top deci-
sion level in the field of drug policies, expressively includes the follow-up of the national EWS system.
Governmental delegates represented within the Inter-ministerial Group have disseminated information on
EWS within their respective administration and have undertaken the required steps towards an effective
inter-ministerial collaboration.
The implementation of EWS relies on a network of institutional key-informants. Currently all specialised drug
agencies (low/high threshold) at the national level are involved in the data providing process in terms of
routine data transmission on new trends. Recently two new agencies have joined the EWS network, namely
a counselling centre for drug users underage and a low threshold project. The first does provide relevant
data on new consume patterns and trends within youngster population and the second focuses on opiate
users. One has to stress that the key-informants network does mainly provide data on trends in drug use but
not on toxicological characteristics of substances since the referred agencies do not propose substance rela-
ted services.
Currently, drug seizures are still one of the most important and the most reliable data source as to subs-
tance profiling and detection of new drugs. Samples seized by Customs or Police are either analysed (rapid
tests) by the SPJ, or sent, via the Prosecutors office, to the National Laboratory of the Department of Health
(LNS) for toxicological profiling. Respective results are not systematically transmitted to the department of
Health or the NFP. However, effective bilateral co-operation between the NFP and the national Europol unit
(SPJ) allow for rapid data transmission in case a new trend or substances should be detected by the latter.
The active involvement of law enforcement agencies in the national monitoring system highly facilitates the
implementation of Joint Action-related activities.
Agreements have been made between the National Fund Against Drug Trafficking, the NFP and the
National Health Laboratory (LNS) on the funding of new technical equipment allocated the toxicology unit
of the latter. This achievement has largely contributed to the improvement of the quality of toxicological
analysis provided by LNS.
General practitioners have recently been involved in the EWS in terms of data provision on new substances
and new consume patterns. All GPs and psychiatrists registered in the Grand-Duchy of Luxembourg have
received a standardised data form allowing them to provide relevant information to the NFP in case they
were confronted with an unknown psychotropic substance or unusual consume patterns. The NFP, as a coun-
ter part, committed to provide GPs and psychiatrists with information on the detected trends or substances,
as far as there is any information available. 
Drug-related deaths have to be reported by emergency services to the Police and the SPJ. Non-fatal drug-
related emergencies requiring medical intervention have not to been reported systematically. Moreover,
emergency services do not index drug-related interventions separately, which means that no monitoring of
those cases can be performed. The referred situation is not likely to change and thus, the inclusion of emer-
gency services in the EWS appears to be unfeasible at the present stage.
National drug legislation does not foresee a legal framework for testing or profiling illicit drugs in night-
clubs, public events or rave parties. No such activities have been planned or carried out under the authority
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of public administrations. Taking into account that the first official seizure of ‘ecstasy’ has only been recor-
ded in 1994, harm reduction and close monitoring activities in this particular field were previously not vie-
wed as a priority. 
In October 1995, a new drug help line was created, under the responsibility of the CePT. Given its easy
access and the anonymity it guarantees, phone help lines often represent the first step with regard to fur-
ther orientation or treatment demand proceedings and as such are able to provide high quality data on
recent trends in drug use. The national Drug Help Line has been included in the EWS system in the course
of 1999. In 2008 the drug phone help line has been replaced by an drug help on-line service run by CePT
( Fro NO)
The drug issue is largely covered by various media supports. Press, Music, fashion and leisure industries are
often the mirror of life styles and current trends in substance use. Information could be collected by scree-
ning the media targeted at young people and sub cultural groups. Radio, television, newspaper, magazines,
fanzines, books, comics, announcement of events, opening of new clubs, etc., are to be viewed as comple-
mentary indicators towards the global monitoring of new drug trends. Since the resources of the NFP do not
allow for an overall monitoring of media supports, decision has been made to compile, in collaboration with
the information and press department of the State’s Ministry, a monthly national and international press
review on drugs. 
G. Documentation Centres (NFP / CePT)
The Centre Logistique de Documentation sur les Drogues et les Toxicomanies (CLDDT) is a logistic docu-
mentation service run by the NFP since 1995. CLDDT runs the only computer-based national documenta-
tion management base specifically focusing on licit and illicit drugs. The CLDDT indexes about 2,900 docu-
ments mainly in French, German and English language. Users of information services provided by the CDTL
are mainly researchers, journalists, policy makers, drug treatment and prevention specialists, and general
public. The majority of indexed documents are paper-based and abstracts are provided.
In addition to its function of documentation base, CLDDT also ensures the conceptualisation and execution
of drug documentation dissemination strategies as required by the NFP. Topic-specific mailing lists have
been developed and maintained by active contact making and demand response.
CLDDT is linked to the Centre de Documentation du Centre de Prévention des Toxicomanies run by CePT
since 1996. The CePT documentation centre mainly focuses on primary prevention, training and evaluation
in the fields of licit and illicit drugs. The current stock approaches 1,000 documents or media supports.
Queries are handled manually and no computer-based consultation facilities are provided.
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Alphabetic list of relevant Internet addresses 
http://www.ceps.lu/
http://www.cept.lu/
http://www.crp-sante.lu/
http://www.ecbap.net/
http://eddra.eu.int/
http://eldd.emcdda.eu.int/
http://www.emcdda.eu.int/
http://www.etat.lu/
http://www.etat.lu/MS/
http://www.gouvernement.lu/
http://www.ilres.com/
http://www.jdh.lu/
http://www.legilux.public.lu/
http://www.msr.lu
http://www.police.public.lu/PoliceGrandDucale
http://www.relis.lu/
http://www.statec.lu/
http://www.unodc.org/
http://www.who.int/
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